Festphasensynthesen und Untersuchungen von konformationell-eingeschränkten Analoga der Calcitonin-Gen-Peptid-Superfamilien-Polypeptide Calcitonin (Ct) und Islet Amyloid Polypeptid (IAPP) by Kazantzis, Athanasios
 Solid-phase syntheses and studies of conformationally constrained analogues 
of the calcitonin gene peptide superfamily polypeptides calcitonin (Ct) 
and islet amyloid polypeptide (IAPP) 
 
Festphasensynthesen und Untersuchungen von konformationell-eingeschränkten 
Analoga der Calcitonin-Gen-Peptid-Superfamilien-Polypeptide 
Calcitonin (Ct) und Islet Amyloid Polypeptid (IAPP) 
 
 
 
 
                                                           DISSERTATION 
 
 
 
                                          der Fakultät für Chemie und Pharmazie 
                                         der Eberhard-Karls-Universität Tübingen 
 
 
                                          zur Erlangung des Grades eines Doktors 
                                                       der Naturwissenschaften 
 
 
 
                                                                      2004 
 
                                                               vorgelegt von 
                                                        Athanasios Kazantzis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tag der mündlichen Prüfung: 17.02.2004 
 
 
Dekan:    Prof. Dr. H. Probst 
1. Berichterstatter:  Prof. Dr. Dr. h. c. mult. W. Voelter 
2. Berichterstatter:  Priv. Doz. Dr. A. Kapurniotu 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Die vorliegende Arbeit wurde unter Anleitung von Priv.Doz. Dr. A. Kapurniotu 
in der Zeit von Oktober 1999 bis Dezember 2003 an der Abteilung für Physikalische 
Biochemie des Physiologisch-chemischen Instituts der Eberhard-Karls-Universität Tübingen 
(1999-2002) und am Institut für Biochemie des Klinikums der RWTH Aachen (2002-2003) 
durchgeführt. 
 
 i 
 
Acknowledgments 
 
I would like to express my sincere gratitude and appreciation to my supervisor Priv. Doz. Dr. 
Aphrodite Kapurniotu for introducing me to the field of peptide synthesis and for supervising 
and guiding me throughout my PhD thesis which provided the motivation and encouragement 
for accomplishing this work. Valuable and thoughtful discussions during these years 
enlightened my perspectives and provided new insights into my studies. I would also like to 
thank her for the design of the peptide analogues and her assistance in the experimental 
planning.  
I am thankful to Prof. Dr. Dr. h. c. Wolfgang Voelter for the continuous support and interest 
in my PhD work.  
I am thankful to Prof. Dr. Jürgen Bernhagen for teaching me and supervising the performance 
of the bioactivity assays (RIA and ELISA) in his laboratory and also for his continuous 
support and interest in my work.  
I am thankful to Doris Finkelmeier for assisting me during the bioactivity assays. I would like 
to thank Kostas Tenidis, Andreas Buck, Anita Horn, Anke Schmauder, Michaela Waldner, 
Jürgen Beck, and Thomas Hirsch for their assistance in the syntheses and HPLC purifications 
and for the friendly atmosphere in the Tübingen lab. I would also like to thank Kostas Tenidis 
and Anke Schmauder for performing the cytotoxicity assays and FT-IR spectroscopy. I would 
also like to thank Gunnar Müllenweg for helpful discussions and Marco Müsken and Heidi 
Vasen for the friendly atmosphere in the Aachen laboratory. 
I am thankful to Miriam Fecker for helping me with various kind of administrative paperwork 
during my studies. 
I am also thankful to Gabriele Fahrbüchel for her help and assistance with regard to the 
several issues related to my stay in Germany. 
I would like to thank Dr. Roland Wacker and all the coworkers in the MALDI-MS lab that 
acquired the mass spectra of the peptide samples. Their continuous effort was an invaluable 
help to my data and results analysis. 
I wish to express my thanks to my coworkers in Aachen: Michael Thiele, Helge Fünfzig, 
Manfred Dewor, Marianna Tatarek-Nossol, Hannelore Didden, and Dr. Hongqi Lue for their 
friendship and lab assistance. 
I am also thankful to my friends in Tübingen: Marcus, Daniel, Florian, Marc, Tina, Florian, 
Ilka, Andreas, Celine, and Mafiu for their good friendship and optimism during these years.  
 ii 
Finally, I would like to thank my parents and my brother for their patience, support and 
encouragement. 
It should be mentioned that parts of this thesis have been published in: 
 
1.) A. Kazantzis, M. Waldner, J. W. Taylor, & A. Kapurniotu, Eur. J. Biochem., 269, 
780-791, 2002. 
List of Abbreviations iii
List of Abbreviations 
 
 
Ab Absorbance 
Ac Acetyl 
AC Adenylate cyclase 
ACN Acetonitrile 
AcOH Acetic acid 
Ac2O Acetic anhydride 
ACS American chemical society 
Adoc 1-(1´-adamantyl)-1-methyl-ethoxycarbonyl 
Boc t-Butoxycarbonyl 
Bom π-Benzyloxymethyl 
BOP 1-Benzotriazolyloxy-tris-dimethylamino-phosphonium hexafluorophosphate 
BSA Bovine serum albumin 
Bzl Benzyl 
cAMP cyclo-Adenosine monophosphate 
CD Circular dichroism 
CNS Central nervous system 
Ct Calcitonin 
∆G Gradient change over time 
DCC Dicyclohexylcarbodiimide 
DCM Dichloromethane 
DIC Diisopropylcarbodiimide 
DIEA Diisopropylethylamine 
DKP Diketopiperazine 
DMF Dimethylformamide 
DMS Dimethylsulfide 
DMSO Dimethylsulfoxide 
DTT 1,4-Dithio-DL-threitol 
DTAB Dodecyltrimethylammonium bromide 
DVB Divinylbenzene 
EC50 Effective concentration at half-maximal response 
EDT 1,2-ethanedithiol 
EIA Enzyme immuno assay 
List of Abbreviations iv 
Eq Equivalent 
Et Ethyl 
Et2O Diethylether 
FAB Fast atom bombardment 
Fmoc 9-Fluorenylmethoxycarbonyl 
FT-IR Fourier transform infrared spectroscopy 
Gdn HCl Guanidine hydrochloride 
GPCR G-protein coupled receptor 
HATU 2-(1H-9Azabenzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexaflurophosphate 
HBTU 2-(1-H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate 
HF Hydrogen fluoride 
HFIP 1,1,1,3,3,3-hexafluoro-2-propanol 
HPLC High performance liquid chromatography 
HOBt 1-Hydroxybenzotriazole 
hrs hours 
IAPP Islet amyloid polypeptide 
IC50 Inhibition concentartion at half-maximal response 
iPrOH Isopropyl alcohol 
MALDI Matrix assisted laser desorption ionization 
MBHA p-Methylbenzhydrylamine 
Me Methyl 
min minutes 
Mob 4-Methoxybenzyl 
MS Mass spectroscopy 
Mtt 4-Methyltrityl 
MTT 3-[4,5-dimethylthiazol-1-yl]-2,5-diphenyltetrazolium bromide 
NMP N-methyl pyrrolidinone 
NMR Nuclear magnetic resonance 
OBt 1-Benzotriazolyl ester 
Oc Hx Cyclohexyl ester 
OD Optical density 
OFm Formyl ester 
p.a pro analysi 
PBS Phosphate buffer saline 
List of Abbreviations v 
Pip 2-Phenyl isopropyl ester 
Pmc 2,2,5,7,8-Pentamethylchroman-6-sufonyl 
PyBOP 1-Benzotriazolyloxy-tris-pyrrolidinophosphonium hexafluorophosphate 
Rink MBHA 4-(2´, 4´-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxy acetamido-norleucyl 
RP Reversed phase 
RPMI Roswell Park Memorial Institute 
RT Room temperature 
SAR Structure-activity relationship 
SD Standard deviation 
SPPS Solid phase peptide synthesis 
TAS Thioanisole 
TBTU Benzotriazole-1-yl-1,1,3,3,-tetramethyluronium tetrafluoroborate 
tBu tert-Butyl 
TFA Trifluoroacetic acid 
TFE 2,2,2-Trifluoroethanol 
TIS Triisopropylsilane 
TMB 3,3´, 5, 5´-Tetramethylbenzidine 
TMD Trans membrane domain 
Trt Trityl 
UV Ultraviolet 
Z Benzyloxycarbonyl 
 
List of Abbreviations vi 
Amino-Acids Abbreviations 
 
 
[Ala, A] Alanine 
[Aib] 2-Aminoisobutyric acid 
[Arg, R] Arginine 
[Asn, N] Asparagine 
[Asp, D] Aspartic acid 
[Cys, C] Cysteine 
[Dab] 2,4-Diaminobutyric acid 
[Dap] 2,3-Diaminopropionic acid 
[Glu, E] Glutamic acid 
[Gln, Q] Glutamine 
[Gly, G] Glycine 
[His, H] Histidine 
[Ile, I] Isoleucine 
[Leu, L] Leucine 
[Lys, K] Lysine 
[Met, M] Methionine 
[Nle, B] Norleucine 
[Orn] Ornithine 
[Phe, F] Phenylalanine 
[Pro, P] Proline 
[Ser, S] Serine   
[Thr, T] Threonine 
[Trp, W] Tryptophan 
[Tyr, Y] Tyrosine 
[Val, V] Valine 
[Xaa] Unspecified 
 
Table of contents vii
Table of contents 
 
Acknowledgments...................................................................................................................... i 
List of Abbreviations...............................................................................................................iii 
Table of contents.....................................................................................................................vii 
1 Abstract .................................................................................................................................. 1 
2 Objective ................................................................................................................................ 5 
3 Introduction ........................................................................................................................... 8 
3.1 Solid Phase Peptide Synthesis (SPPS) ............................................................................. 8 
3.1.1 Diketopiperazine formation..................................................................................... 11 
3.1.2 Acidic hydrolysis of N-methylated peptides ........................................................... 12 
3.2 Constrained peptides...................................................................................................... 13 
3.2.1 Rational design of drugs: constrained peptides....................................................... 15 
3.3 Calcitonin gene peptide superfamily.............................................................................. 16 
3.3.1 Calcitonins............................................................................................................... 16 
3.3.2 Islet Amyloid Polypeptide (IAPP) .......................................................................... 19 
4 Materials and Methods ....................................................................................................... 23 
4.1 Materials ........................................................................................................................ 23 
4.2 Methods .......................................................................................................................... 24 
4.2.1 SPPS using the Boc-strategy ................................................................................... 24 
4.2.1.1 Cleavage of the Nα-Boc-group of glutamine ................................................... 24 
4.2.1.2 Cyclization strategy in synthesis by Boc-chemistry ........................................ 25 
4.2.2 SPPS using the Fmoc-strategy ................................................................................ 26 
4.2.2.1 Cyclization strategy in Fmoc-chemistry .......................................................... 27 
4.2.2.2 Coupling of Cys residues in Fmoc-SPPS......................................................... 28 
4.2.3 Coupling of N-methyl residues ............................................................................... 29 
4.2.4 Coupling on N-methyl residues............................................................................... 32 
4.2.5 Kaiser test ................................................................................................................ 36 
4.2.6 Attachment of the C-terminal amino acid to the resin ............................................ 37 
4.2.6.1 Attachment of the C-terminal amino acid for the synthesis of Ct analogues 
using Boc-strategy........................................................................................................ 37 
4.2.6.2 Attachment of the C-terminal amino acid for the synthesis of Ct analogues 
using Fmoc-strategy ..................................................................................................... 37 
4.2.6.3 Attachment of the C-terminal amino acid for the synthesis of IAPP analogues
...................................................................................................................................... 37 
4.2.6.4 Determination of the substitution level of resin in Fmoc-strategy................... 38 
4.2.7 Final deprotection of side-chains and cleavage from the resin ............................... 38 
4.2.7.1 Final deprotection of side chains and cleavage of full length sequences from 
the resin in Boc-chemistry............................................................................................ 38 
4.2.7.2 Final deprotection of side chains and cleavage of full length sequences from 
the resin in Fmoc-chemistry......................................................................................... 39 
4.2.7.3 Deprotection of side chains and cleavage of partial peptide sequences from the 
resin in Fmoc-chemistry............................................................................................... 40 
Table of contents viii
4.2.8 Disulfide bridge formation ...................................................................................... 40 
4.2.8.1 Disulfide bridge formation for the Ct analogues.............................................. 40 
4.2.8.2 Disulfide bridge formation for the IAPP analogues......................................... 40 
4.2.9 RP-HPLC purification of the products.................................................................... 41 
4.2.10 Characterization of the peptides............................................................................ 42 
4.2.10.1 Matrix Assisted Laser Desorption Ionisation Mass Spectroscopy (MALDI-
MS)............................................................................................................................... 42 
4.2.10.2 Fast Atom Bombardment Mass Spectroscopy (FAB-MS)............................. 42 
4.2.10.3 Amino acid analysis ....................................................................................... 42 
4.2.11 Concentration determination of Ct and IAPP solutions with UV spectroscopy ... 42 
4.2.11.1 Secondary structure of IAPP with FT-IR spectroscopy ................................. 43 
4.2.12 Biological Assays.................................................................................................. 44 
4.2.12.1 Cell culture ..................................................................................................... 44 
4.2.12.2 Calcitonin receptor binding assay .................................................................. 44 
4.2.12.3 Adenylate cyclase activation assay ................................................................ 45 
4.2.12.4 Cytotoxicity assay for IAPP and IAPP analogue [2] ..................................... 45 
5 Results .................................................................................................................................. 47 
5.1 Design of calcitonin analogues ...................................................................................... 47 
5.1.1 Peptide synthesis using Boc-SPPS for calcitonins.................................................. 54 
5.1.2 Peptide synthesis using Fmoc-SPPS for calcitonins ............................................... 59 
5.1.3 Binding to the calcitonin receptor ........................................................................... 64 
5.1.4 Activation of the adenylate cyclase (AC) ............................................................... 70 
5.2 Design of IAPP analogues ............................................................................................. 77 
5.2.1 Synthesis of IAPP.................................................................................................... 80 
5.2.2 Synthesis of [(N-Me) Phe23, (N-Me) Ala25] IAPP [1]............................................. 85 
5.2.3 Synthesis of [(N-Me) Gly24, (N-Me) Ile26] IAPP [2] .............................................. 93 
5.2.4 Synthesis of [(N-Me) Ala25, (N-Me) Leu27] IAPP [3] ............................................ 98 
5.2.5 Synthesis of [(N-Me) Ile26, (N-Me) Leu27] IAPP [4] ............................................ 107 
5.2.6 Synthesis of [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [5] .................... 116 
5.2.7 Synthesis of S20G-IAPP [6] ................................................................................. 122 
5.2.8 FT-IR and cytotoxicity studies of IAPP and the IAPP analogue [2] .................... 126 
6 Discussion........................................................................................................................... 128 
6.1 Discussion of the results of the bioactivity studies on the calcitonin analogues ......... 128 
6.2 Discussion of the syntheses and studies of the IAPP analogues .................................. 131 
7 Zusammenfassung............................................................................................................. 138 
8 References .......................................................................................................................... 144 
 
 
 
Abstract 1 
1 Abstract 
 
Conformationally constrained analogues of natively occuring bioactive polypeptides are 
valuable tools for the understanding of their structure-function-relationships and for the 
design and development of lead structures with therapeutic and diagnostic applications. 
The work described in this thesis focuses on the application of conformational constraints on 
two polypeptides from the calcitonin gene peptide “superfamily”: the calcium- and bone-
turnover-regulating hormone calcitonin (Ct) and the carbohydrate metabolism-regulating 
hormone islet amyloid polypeptide (IAPP). These two, 32 and 37, respectively, residue 
polypeptides have a common genetic origin and exhibit some primary sequence homology 
and overlapping biological activities and receptor cross-reactivities. 
Ct has been long therapeutically used for the treatment of osteoporosis. The low bioactivity of 
the human sequence (hCt), however, has been the reason for its limited therapeutic application 
as compared to the highly potent salmon peptide (sCt). Recent work has shown that 
introduction of an i, i+4 side chain lactam bridge between residues 17 and 21 in hCt may lead 
to analogues with strongly enhanced in vivo hypocalcemic activity (Kapurniotu et al., Eur. J. 
Biochem. (1999)). This work has led to the discovery of the hCt analogue cyclo17,21-[Asp17, 
Orn21]hCt which is the most potent hCt analogue reported todate with regard to in vivo 
hypocalcemic activity. This work has also suggested that a potential β-sheet/β-turn 
conformation between residues 17 and 21 of hCt might be associated with bioactivity. The 
first part of the work described here aimed at obtaining detailed information about the effect 
of the conformational restriction in region 17 to 21 on Ct receptor binding and adenylate 
cyclase activation and to, possibly, identify structural features that may be directly associated 
with bioactivity. The specific issues that were addressed included: the effect of the ring size of 
the lactam bridge and of different types of β-turn-stabilizing residues at positions 18 and 19 
on receptor binding and AC activation, a role for a putative “Asx-turn” in region 17 to 21, for 
the H-bonding ability of the amino group of Phe19, and for the side chain of residue 17 in 
receptor binding and adenylate cyclase (AC) activation, the importance of the integrity of the 
backbone in region 17 to 21 for bioactivity, and, finally, the effect on bioactivity of the 
introduction of hydrophobic residues that are present in the α-helical region of the sCt 
sequence into the respective region of the potent hCt analogue cyclo17,21-[Asp17, Orn21]hCt. 
Towards this goal, twenty five hCt analogues bearing a cyclic conformational constraint 
and/or several substitutes for residues in region 17 to 21 that was postulated to be important 
for bioactivity were designed. The analogues were synthesized in good yields and purity by 
solid phase (SPPS) synthetic protocols using the Boc- and/or the Fmoc- strategy in 
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combination with special side chain protection strategies for the side chain-to-side chain 
cyclization on the resin. Following purification by RP-HPLC and characterization by mass 
spectrometry, their binding affinities to the Ct-receptor and their AC activation potencies were 
investigated using the T47D cell line. The studies with the ring size analogues showed that the 
19-membered analogues cyclo17,21-[Asp17, Orn21]hCt and cyclo17,21-[Glu17, Dab21]hCt together 
with the 20-membered ring cyclo17,21-[Asp17, Lys21]hCt had the highest receptor binding 
affinities as compared to all other analogues. In the AC activation assay, cyclo17,21-[Asp17, 
Orn21]hCt was found to be the strongest hCt agonist, whereas cyclo17,21-[Asp17, Lys21]hCt was 
similarily potent to hCt and cyclo17,21-[Glu17, Dab21]hCt was less potent than hCt. Receptor 
binding affinities and AC activation potencies were significantly reduced in the 18-membered 
ring containing cyclo17,21-[Asp17, Dab21]hCt and very weak in the 17-membered ring analogue 
cyclo17,21-[Asp17, Dap21]hCt. No receptor binding and a very weak AC activation potential 
was found for [Asp17, Orn21]hCt which strongly suggested that the Asp17 to Orn21 bridge-
induced conformational restriction in cyclo17,21-[Asp17, Orn21]hCt is directly associated with 
both increased receptor binding affinity and stronger AC activation potential. The studies with 
a series of substitution analogues of cyclo17,21-[Asp17, Lys21]hCt and respective control 
peptides showed that inversing the chirality of residues at positions 18 and 19 or replacing 
Lys18 by a type I β-turn-stabilizing residue (Aib) was compatible with the receptor binding 
requirements of the cyclic analogue, while these substitutions led to reduction of AC 
activitation potency. In the hCt sequence, inversement of chirality of residues 18 and 19 led to 
a strong reduction of both receptor binding affinity and AC activation ability. Furthermore, 
the studies with a series of analogues of cyclo17,21-[Asp17, Orn21]hCt where residues 18 and 19 
have been replaced by the “Asx-turn”-inducing residues Pro and Ser showed that residues 
Lys18 and Phe19 are very important for both receptor binding and AC activation. In fact, it was 
shown that these substitutions led to analogues with strongly reduced receptor binding 
affinities and AC activation potencies. The studies with N-methylated Phe19 analogues of 
cyclo17,21-[Asp17, Orn21]hCt clearly suggested that the H-bonding ability of Phe19 is very 
important for receptor binding affinity and AC activation, while the studies with the βeta-
analogues of cyclo17,21-[Asp17, Orn21]hCt showed that the integrity of the backbone between 
residues 17 and 21 is a necessary requirement for receptor binding and AC activation. The 
results of the studies with hCt analogues bearing a Dab or a Dap residue instead of Asn17 
suggested an immediate association of both the carbonyl and the amino function of the Asn 
side chain with receptor binding affinity and AC activation potency. Finally, the studies on 
the effect of introducing hydrophobic residues from the potential helical region of sCt into 
Abstract 3 
cyclo17,21-[Asp17, Orn21]hCt or [Asp17, Orn21]hCt indicated that the presence of Nle8, 
Leu12,16,19 and Tyr22 results in a strong enhancement of AC potency. Importantly, these 
substitutes alone were able to strongly enhance the receptor binding affinity of [Asp17, 
Orn21]hCt, whereas they had no effect on the affinity of cyclo17,21-[Asp17, Orn21]hCt. Taken 
together, the results of the studies with all hCt analogues have demonstrated that region 17 to 
21 of hCt plays a very important role in bioactivity and that small structural variations in this 
region can strongly affect both the receptor binding affinity and the AC activation potential. 
This result suggested that rationally introduced structural variations in the region 17 to 21 of 
hCt may result in highly potent and thus therapeutically interesting hCt agonists.  
The second member of the calcitonin gene peptide family IAPP is believed to play a crucial 
role in the pathogenesis of type II diabetes. One reason for this is that IAPP amyloid 
aggregates are found in the pancreata of more than 95% of type II diabetes patients and that 
these aggregates are cytotoxic. Understanding the molecular mechanism underlying the strong 
β-sheet-forming and the related amyloidogenic and cytotoxic potentials of the human IAPP 
sequence is the basis for the understanding the molecular basis of this disease and the 
development of therapeutic strategies. Conformational restriction via a rational introduction of 
N-methyl rests in amide bonds of short, β-sheet-forming, amyloidogenic sequences has been 
very recently suggested to be a reasonable strategy to delineate the structure-
amyloidogenicity-cytotoxicity relationships of such sequences and convert amyloid-forming 
sequences into non-amyloidogenic and non-cytotoxic ones. The second part of the thesis 
describes in detail the SPPS of the (human) IAPP sequence, of the strongly amyloidogenic 
IAPP mutant S20G-IAPP, and of five IAPP analogues that have been conformationally 
constrained via N-methylation of amide bonds. In addition, first studies on the effect of the 
selective introduction of N-methyl rests on the β-sheet-forming potential and the cytotoxic 
properties of one representative N-methylated IAPP analogue as compared to the natively 
occuring IAPP sequence are presented.  
The SPPS of IAPP, S20G-IAPP, and the N-methylated analogues proved to be a demanding 
task. This was due to the presence of several sterically hindered and aggregation-prone 
residues in the IAPP sequence and also due to synthetic problems related to steric hindrance 
of couplings and peptide bond lability in sequences containing N-methylated residues. Due to 
the low yield of the synthesis of IAPP, an optimized synthetic protocol was applied to the 
synthesis of S20G-IAPP and resulted in a reasonable yield and HPLC profile for crude S20G-
IAPP. During the syntheses of the N-methylated analogues [(N-Me) Phe23, (N-Me) Ala25] 
IAPP [1], [(N-Me) Gly24, (N-Me) Ile26] IAPP [2], [(N-Me) Ala25, (N-Me) Leu27] IAPP [3], 
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and [(N-Me) Ile26, (N-Me) Leu27] IAPP [4] several couplings involving N-methyl residues 
were incomplete. Unreacted amino groups of the N-methyl residues were subsequently 
capped by acetylation which resulted in a number of TFA-mediated amide bond cleavages: 
these included cleavages between an Ac-(N-Me) Ile and Leu, or (N-Me) Leu, between Ac-(N-
Me) Phe and Gly, and between Ac-(N-Me) Leu and Ser. The byproducts of these syntheses 
were completely characterized and the side reactions were thus understood. Importantly, the 
studies showed that the above peptide bonds were susceptible to hydrolysis under the TFA 
peptide resin cleavage conditions only when the N-methylated residues were in an acetylated 
form. Thus, this side reaction occurred mainly in the capped, partial sequences and only at the 
final TFA deprotection step at the end of the synthesis, while the full sequence N-methylated 
IAPP analogues per se were stable under the conditions of the Fmoc-synthetic strategy. Due 
to the very low coupling yield of (N-Me) Ala25 on (N-Me) Ile26, the synthesis of the fifth 
IAPP analogue ([(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [5]) bearing three 
consequtive N-methylated residues was only performed up to residue 25. Although the overall 
yields of the syntheses of the full sequence containing, N-methylated IAPP analogues [1] to 
[4] were low due to the incomplete couplings, overall, less by-products as compared to the 
IAPP synthesis formed, which led to higher yields in the RP-HPLC purification process than 
in IAPP.  
Finally, analogue [(N-Me) Gly24, (N-Me) Ile26] IAPP [2] was selected as a first analogue to 
study the effect of the rational introduction of N-methyl rests on the β-sheet and cytotoxicity 
potential of IAPP. These studies clearly showed that the two N-methyl groups at Gly24 and 
Ile26 led to a strong reduction of the β-sheet-forming potential and an abolishment of 
cytotoxicity of IAPP towards the pancreatic β-cell line RIN5fm. These results suggested that 
there is a direct association of the conformational restriction induced by the rational N-
methylation of amide bonds with IAPP amyloidogenicity and cytotoxicity. 
Taken together, the results of this work showed that restriction of conformational flexibility of 
medium-sized bioactive polypeptides can yield valuable information about the structure-
activity-relationships and contribute to the design of potent agonists (hCt analogues) or 
analogues with an altered or completely different biophysical profile as compared to the 
natively occuring polypeptides (IAPP analogues). In addition, the results of this work suggest 
that the conformational restriction strategy may be applicable to other polypeptides sequences 
too, including longer sequences or other amyloidogenic ones. This work also showed that the 
SPPS of N-methylated and aggregation prone polypeptide sequences is still a formidable 
synthetic task. 
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2 Objective 
 
Restricting the conformational flexibility of medium-sized polypeptides has proven a valuable 
approach towards understanding the structural and conformational features of bioactivity. 
Thus, in the case of peptide hormones, a number of studies in the past 20 years have shown 
that this approach can lead to the discovery of analogues with potent agonistic or antagonistic 
properties. In the case of polypeptides with specific biophysical properties, such as for 
example a β-sheet, self-assembly and a with self-assembly related cytotoxic potential, 
conformational restriction may lead to the design of novel analogues that have an altered or 
completely different biophysical profile as compared to the natively occuring peptide 
sequence. The rationally designed conformationally constrained analogues are in both cases 
tools for the understanding of the structure-activity-relationships of the natively occuring 
polypeptides and lead structures for the development of novel compounds with therapeutic 
and diagnostic applications. 
The work described in this thesis focuses on the application of conformational constraints on 
one representative for each one of the above mentioned two “categories” of polypeptides, i.e. 
the two polypeptides calcitonin (Ct) and islet amyloid polypeptide (IAPP). These two 32 and 
37, respectively, residue polypeptides belong together with the 37 residue calcitonin gene-
related peptide (CGRP) and the 52 residue polypeptide adrenomedullin, to the so-called 
calcitonin gene peptide “superfamily”. These four polypeptides have a common genetic 
origin, exhibit some primary sequence homology, and also exhibit overlapping biological 
activities and cross-reactivities between receptors.  
The calcium- and bone-turnover-regulating hormone calcitonin, which has been discovered 40 
years ago, has been therapeutically used since many years for the treatment of osteoporosis 
and other bone disorder diseases. Thereby, the low bioactivity of the human sequence (hCt) 
has led to its limited therapeutic application as compared to the highly potent salmon Ct (sCt). 
Recent work, however, has shown that introduction of conformational constraints in form of i, 
i+4 side chain lactam bridges in the sequence of human Ct (hCt) can strongly affect 
conformation and bioactivity and lead to potent agonists of the in vivo hypocalcemic activity 
of hCt. Based on the above findings, the first part of the work described here aimed at 
obtaining information about the molecular mechanism of Ct bioactivity and thus at 
contributing to the development of novel Ct-based drugs via the design, synthesis, and study 
of receptor binding and adenylate cyclase activity of a series of conformationally constrained 
Ct analogues.  
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Other than in the case of Ct, the biological role of IAPP, which has been discovered as the 
major component of pancreatic amyloid deposits in type II diabetes in 1987, has been yet not 
well described. IAPP is secreted together with insulin from the β-cells of pancreas and is 
believed to play an important role in carbohydrate metabolism as an insulin counterregulatory 
hormone, while it also exhibits an overlapping hypocalcemic activity and bone-turnover effect 
with Ct. Most importantly, the IAPP molecule appears to play a crucial role in the 
pathogenesis of noninsulin-dependent or type II diabetes that is a progressive, pancreatic cell-
degenerative disease that affects more than 150 million people worldwide. An important role 
of IAPP on the pathogenesis of this disease has been suggested based on the findings that a) 
more than 95% of type II diabetes patients contain extracellular fibrillar IAPP amyloid 
aggregates in their pancreata which colocalize with degenerated cells, b) IAPP oligomeric and 
multimeric proto- and fibrillar aggregates are cytotoxic, c) the sequence of human (h) IAPP 
per se has an extremely strong intermolecular β-sheet-forming, aggregation and 
amyloidogenic potential whereas the sequence of animal species that do not develop amyloid 
deposits and type II diabetes (i.e. rats) is devoid of β-sheet and amyloidogenic properties. 
Both the molecular “rules” for the strong β-sheet and amyloidogenic potential of the IAPP 
sequence and the conformation and self-assembly state of the cytotoxicity-mediating IAPP 
“molecular forms” are yet unknown. Therefore, understanding the structural and 
conformational requirements that confer on the hIAPP sequence its β-sheet-forming, 
amyloidogenic, and cytotoxic properties is an important step in the process of understanding 
and developing ways to delay or inhibit the disease progress. Furthermore, to date there are 
more than 25 other than IAPP polypeptides/proteins that exhibit an amyloid-forming 
propensity that has been associated with the pathogenesis of various cell-degenerative and 
fatal diseases that are known as protein aggregation diseases.  The most prominent 
representatives of these polypeptide/protein sequences are the β-amyloid peptide of the 
Alzheimer’s disease and the prion protein of the spongiform encephalopathies. According to a 
number of studies that have been performed mainly in the past 10 years, a common molecular 
mechanism may underly the β-sheet-forming, amyloid formation and cytotoxicity potentials 
of all these various polypeptide sequences. Hence, understanding the structural and 
conformational “requirements” for amyloidogenicity and cytotoxicity of the IAPP sequence 
would also assist in elucidating the molecular mechanism of other protein aggregation 
diseases pathogenesis.  
One approach to understanding the molecular basis of the β-sheet and amyloid formation 
potential of polypeptides is via the selective introduction of N-methyl rests in amide bonds of 
Objective 7 
the native sequence that are believed, based on structural models, to be crucial for β-sheet 
formation. In fact, very recent work has demonstrated that N-methylation of the amide bonds 
at G24 and I26 in short sequences of the amyloid core of hIAPP, i.e. sequences between 
residues 23-27, 22-27, 20-27, and 20-29 that are capable of forming β-sheet and amyloid 
aggregates by themselves, could completely abolish their β-sheet- and amyloid forming 
potentials. Similar results have been recently found when short amyloid core sequences of β-
amyloid polypeptide were selectively N-methylated. The effect, however, of selective N-
methylation on the amyloidogenic and cytotoxic potential of the full sequence of an 
amyloidogenic polypeptide has not yet been investigated. This can be due to the difficulties 
that one often encounters during the solid phase peptide synthesis (SPPS) of an 
amyloidogenic and/or N-methylated peptide sequence. These are due to the presence of 
several hydrophobic and aggregation-prone residues in the amyloid sequences and also due to 
synthetic problems related to steric hindrance and peptide bond lability, which are often 
caused by the presence of N-methylated residues. Hence, the SPPS of both amyloid-forming 
sequences such as full sequence hIAPP and of their N-methylated analogues is a demanding 
task.  
The 2nd part of the thesis aimed at performing and investigating SPPS of full sequence 
(h)IAPP, of the strongly amyloidogenic (h)IAPP mutant S20G-IAPP, and of a series of 
specifically N-methylated analogues of full sequence (h)IAPP. The work should mainly focus 
on the investigation of side reactions and the optimization of synthetic protocols that should 
allow for obtaining mg amounts of the above polypeptides in pure form to be used for future 
structure-amyloidogenicity-cytotoxicity studies. Finally, the effect of the selective 
introduction of N-methyl rests on the β-sheet-forming potential and the cytotoxic properties 
of one representative N-methylated IAPP analogue as compared to the natively occuring 
IAPP sequence should be examined.  
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3 Introduction 
 
3.1 Solid Phase Peptide Synthesis (SPPS) 
 
Solid phase peptide synthesis (SPPS) is based on the sequential coupling of α-amino and side 
chain protected amino acid residues to an insoluble support (Scheme 1). The acid-labile tert-
butyloxycarbonyl (Boc) group or the base-labile 9-fluorenylmethoxycarbonyl (Fmoc) group 
can be used for protection of the α-amino group. Cleavage of the Boc-protecting group is 
achieved with trifluoroacetic acid (TFA), whereas the Fmoc protecting group is cleaved with 
piperidine. After removal of the Nα-protecting groups, the subsequent protected amino acid is 
added using either a coupling reagent or a pre-activated amino acid derivative. The resulting 
peptide, which is attached to the resin through its C-terminus via a linker can be cleaved to 
yield a peptide-acid or peptide-amide, depending on the linker used. Side chain protecting 
groups are chosen to be cleaved simultaneously with the detachment of the peptide from the 
resin. Final cleavage of the peptide from the resin and removal of the side chain protecting 
groups requires strong acid, such as hydrogen fluoride (HF) in Boc-chemistry, and TFA in 
Fmoc-chemistry (Figure 1). Dichloromethane (DCM) and N, N´-dimethylformamide (DMF) 
are solvents that are usually applied throughout the SPPS [1]. 
Solid phase peptide synthesis has several advantages over solution synthesis: 
a) reactions can be driven nearly to completion through the use of excess reagents 
b) excess reagents and soluble by-products can be simply removed by washing of the 
resin 
c) since the peptide assembly occurs on the polymer, there is no loss of peptide 
throughout the synthesis  
d) the synthetic process has been automatized. 
 
For the synthesis the use of small particle-sized resins of low cross-linking is preferred. Such 
resins allow for rapid diffusion of reagents inside the beads and their high swelling ability 
enables for them to better accommodate the growing peptide chain [2]. Polystyrene (PS) based 
supports are usually employed cross-linked with divinylbenzene (DVB) (1-2%). Effective 
solvation of the resin is one of the most crucial issues for efficient chain assembly during 
SPPS. Under proper solvation conditions the linear polystyrene chains are nearly as accessible 
to reagents as if they were free in solution [3]. When the support is well-solvated diffusion of 
reagents is not a rate-limiting factor of the coupling reaction. Obtaining proper solvation 
conditions of resins and peptide resins is not always straightforward. Peptide resins are 
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expected to have physicochemical properties that differ considerably from the initial resin 
because of the addition of the polar peptide backbone. The peptide backbone would require a 
polar solvent (such as DMF) to ensure optimum solvation and, hence, accessibility to the 
reagents [4]. 
In addition, the use of low-substitution resins (0.1-0.4 mmole / gr) may increase the α-amino 
group accessibility by decreasing steric interactions as well as aggregation of the peptide 
chains [5]. Activation of the carboxyl group is a requisite for the chemical formation of a 
peptide bond. Since the reactivity of the activated species strongly affects the coupling yield 
several activation procedures have been developed. One of the most common peptide bond 
formation procedures is the use of dicyclohexylcarbodiimide (DCC). DCC can be replaced by 
N,N´-diisopropylcarbodiimide (DIC) which results in the formation of diisopropylurea that is 
more readily soluble than the dicyclohexylurea formed with DCC use. Addition of 1-
hydroxybenzotriazole (HOBt) to DCC–mediated couplings improves coupling reactions [6]. 
The activation procedure takes place in situ. In situ activation of the carboxyl function is also 
achieved with the phosphonium 1-benzotriazolyloxy-tris-dimethylamino-phosphonium 
hexafluorophosphate (BOP), 1-benzotriazolyloxy-tris-pyrrolidinophosphonium 
hexafluorophosphate (PyBOP) and the uronium benzotriazole-1-yl-1,1,3,3,-
tetramethyluronium tetrafluoroborate (TBTU), and 2-(1-H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate (HBTU) type activators [7]. 
Despite the general utility and efficiency of SPPS, the synthesis of ‘difficult sequences’ is still 
a problem. Ideally, the coupling reaction of a deprotected amino group and an activated 
carboxyl group should proceed to nearly 100% completion. However, coupling yields of less 
than 99% are occasionally observed, which are not acceptable for the synthesis of long 
peptides [8]. This is due to ‘the arithmetic demon’[9] according to which the overall yield in a 
multistep process depends on the yield per step (Figure 2). Couplings are also sequence- and 
residue-dependent. Difficulties often arise as peptides are elongated through residues 12-20 of 
their sequences. It has been demonstrated that difficult sequences originate from secondary 
structure formation such as intermolecular β-sheet formation. The aggregation of the resin 
bound peptide chains makes the deprotected Nα-amino group of the growing peptide only 
partially accessible to the incoming activated amino acid [10]. 
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Scheme 1. General scheme of SPPS from synthesis notes [1]. 
 
 
 
Figure 1. Protecting group strategies in SPPS (Boc- and Fmoc-chemistry) from synthesis 
notes [1]. 
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Several attempts have been undertaken for the prediction of difficult couplings and 
improvement of their yields. Sequences that are difficult to synthesize by the one chemistry, 
are often difficult to be synthesized with another chemistry. The main reasons are the 
aggregation of the peptide on the resin and steric hindrance due to bulky side chain and/or 
protectings groups. In the case of N-methylated peptides, the presence of a methyl group in 
the Nα amino group introduces an additional steric interference that greatly reduces the 
accessibility of the peptide chain resulting in reduced coupling efficiencies [11].  
 
 
 
Figure 2. Effect of coupling yield per coupling step on the overall yield of a synthesis (the 
‘arithmetic demon’) from Andersson et al. [9]. 
 
3.1.1 Diketopiperazine formation 
 
Alkyl esters of dipeptides bearing a free amino group can undergo spontaneous cyclization 
and produce 2,5-diketopiperazines (DKP). The mechanism involved is the nucleophilic attack 
of a carbonyl group by an a amine group (Figure 3):  
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Figure 3. Mechanism of DKP formation adapted from Bodansky [12].  
 
DKP formation can be either acid- or base-catalysed and is strongly dependent on the nature 
and sequence of the amino acids. In DKP both amide bonds are cis, that is the carbonyl 
oxygen atom and the amide hydrogen are on the same side of the C-N partial double bond. 
Ring formation is particularly pronounced in glycine and proline containing peptides: in the 
former because of the absence of an interfering side-chain, in the latter because the cyclic 
side-chain lies in the plane of the DKP molecule and is out of the way during ring closure. 
Similarly, DKP are readily formed when one of the residues belongs to the L and the other to 
the D family of amino acids as well as with N-methylated amino acids [13]. 
The formation of DKPs leads to lower overall yield of the final peptide, but also results in the 
presence in the crude peptide of deletion sequences missing the two residues that formed the 
cyclic dipeptide and cleaved away from the resin [14].  
 
3.1.2 Acidic hydrolysis of N-methylated peptides 
 
Synthetic peptides containing an N-methylated amino acid residue that have the general 
structure R1- (N-Alkyl) X1-X2-R2 have been reported to undergo facile TFA catalyzed 
hydrolysis under standard TFA cleavage / deprotection conditions of SPPS. The peptide bond 
cleaved is the bond C-terminal to the N-alkylated amino acid. The N-terminal fragment is 
believed to undergo equilibration of the Cα-chiral center of the N-alkylated residue. The 
mechanism that explains this equilibration includes formation of the oxazolone-like 
intermediates α, α´ and b (Figure 4), which are formed via the cleavage of a species that is 
generated by protonation at the N-methyl residue and subsequent nucleophilic attack of an 
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adjacent carbonyl group. Direct hydrolysis of intermediates α and α´ to give an N-terminal 
fragment is found to be much slower than tautomerization to the enol b [15].  
 
 
 
Figure 4. Proposed mechanism of the acidic hydrolysis of N-methyl containing peptide 
sequences according to Urban et al. [15].  
 
3.2 Constrained peptides 
 
Knowledge of the active conformation of a bioactive polypeptide is a major step towards 
understanding the mechanism underlying its biological function. Although a variety of 
biophysical techniques exist to study polypeptide conformation, a major obstacle in the study 
of short peptide sequences is their intrinsic flexibility. In solution short linear peptides are 
usually adopting a large number of conformation states that are almost equivalent 
energetically and, although slightly preferred conformations may be more populated in some 
cases, overall peptide conformation is generally highly dependent on the environment. The 
number of conformational ‘possibilities’ in peptides and proteins can be reduced by 
introducing constraints. Indeed, nature uses several such constraints to reduce the flexibility 
of polypeptide chains, including the incorporation of cyclic amino acid residues (proline) and 
the formation of macrocycles through disulfide bonds. In these ways, particular conformations 
of peptides and proteins are stabilized [16].  
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Model constrained peptides are used to study in detail the conformational preferences of 
natural and modified amino acid residues and assist to gain insight into their tendencies to 
adopt particular secondary structure. Constrained analogues of biologically active peptides 
have been generated to induce specific structural features and to understand the 
conformational requirements for receptor binding and signal transduction, leading to the 
development of potent agonists and/or antagonists [17]. 
α-Helices, β-sheets, and turns are the three main classes of secondary structure in peptides 
and proteins that one may want to stabilize through the use of constraints. The constraints can 
be classified into two broad categories: local and global constraints. Various different 
chemical modifications of the peptide backbone or the side-chains have been used to 
modulate local conformational properties of peptides. These include peptide bond surrogates 
and cyclic as well as conformationally constrained amino acid residues. Perhaps the simplest 
way to modify the local stereochemical properties of the peptide backbone is to introduce D-
amino acids. Heterochiral (LD or DL) dyads have an increased tendency to form β-turns 
because of the stabilizing effect of a D-amino acid on a β-turn conformation. The amide bond 
surrogates (such as CO-O, CS-TH, CH2-NH ) are modifications that directly affect the 
conformation of the novel backbone. In addition, such modifications can result in improved 
enzymatic stability, novel solubility properties and can significantly affect the in vivo 
transport characteristics of the analogues [18]. 
One of the steric constraint that have been used to limit the conformational space available to 
a polypeptide chain are alkylations in the N and Cα positions [19]. N-methylation restricts the 
conformations of both the residue bearing the modification and the preceding residue and 
studies carried out on model peptides have shown the tendency of N-methylated residues to 
participate in different turn conformations, depending on the chirality of the sequence and the 
trans or cis conformation of the tertiary amide bond [20]. 
The most general way to introduce a global constraint into a peptide chain and to affect 
drastically its overall conformation is the formation of a covalent bond between distant parts 
in the sequence. These constraints affect all the degrees of freedom of the peptide sequence in 
the ring that has been generated that should thus be able to adopt a more rigid conformation 
than in the parent linear form. The increased rigidity of the ring structure can also induce 
‘preferred’ conformations in the previously linear parts of the molecule. Cyclization can be 
performed by linking the two backbone termini, or two side chains, or one of the termini and a 
side chain, etc and formation of amide or disulfide bonds is thus the simplest method to 
achieve this. Side chain-to-side chain cyclization between residues i, (i+4) has been applied 
Introduction 15 
for the stabilization of the α-helical conformation [21]. However, not only α-helices can be 
stabilized by i, (i+4) lactam bridges but also β-turn conformations, although there have been 
no reports of the effect of the chain length of this type of cyclic structure on β-turn 
stabilization [22]. In contrast, i, (i+3) lactam bridges model tetrapeptides have been 
demonstrated to stabilize β-turns [23].  
In general, changes in the overall direction of the peptide chain are necessarily introduced by 
cyclic constraints and, hence, cyclic peptides are ideal models to study reverse-turn 
preferences of different amino acid residues and interactions that stabilize turns in peptides 
and proteins [24]. 
 
3.2.1 Rational design of drugs: constrained peptides 
 
Many short linear peptides (usually up to 50 residues) are key factors in the regulation of a 
wide variety of biological processes acting as hormones, neurotransmitters, or inhibitors of 
protein interactions. Major efforts have thus been dedicated to the development of agonists or 
antagonists of these peptides that could be used as drugs with high specificity and low 
toxicity. Much of the research in the field of peptide drugs has been based on the synthesis of 
a large number of analogues with different substitutions / or deletions, on determining the 
steric and hydrophobicity / hydrophilicity characteristics of a particular peptide sequence, as 
well as the minimum number of residues that are necessary for biological activity [25]. 
Although such approaches are very informative, it is often difficult to find reasonable 
correlations between the experimentally obtained data. The reason for this is that various 
biological activities of the analogues can be due to changes in the conformational properties 
of the analogues, rather than due to changes in amino acid polarity and/or bulkiness which is 
what was intended to occur. However, different conformations may result in similar side-
chain orientations, and various binding modes to receptors may also exist. Moreover, the 
conformational analysis of the analogues and the native short or medium-sized peptide is 
usually hampered by their high flexibility. The synthesis and study of constrained analogues 
has thus emerged as a very powerful approach in peptide drug design [26]. Ideally, a 
conformational constraint that stabilizes the bioactive conformation of a peptide should result 
in an increased receptor binding affinity, as there is little conformational entropy lost upon 
binding to the receptor. Furthermore, several biologically active peptides are believed to 
interact with different receptors, and constraining particular features can lead to drugs with 
high receptor specificity and free from undesired side effects [27]. Structural features that may 
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be important for the biological activity of a given peptide sequence can be predicted / or 
suspected based on a conformational study of the peptide, from results obtained with deletion 
/ substitution studies, and from known conformational propensities of residues in the 
sequence. An iterative process can then be started by using conformational constraints to test 
and refine the structural conformational hypotheses. The conformational and topological 
requirements for agonist or antagonist activity and for receptor specificity can be studied by 
modifying the constraints and using various biological assays [28]. 
 
3.3 Calcitonin gene peptide superfamily 
 
The calcitonin gene peptide superfamily consists of calcitonin (Ct), calcitonin gene-related 
peptide (CGRP), islet amyloid polypeptide (IAPP) and adrenomedullin. Ct and CGRP derive 
from the Ct / CGRP gene, which is located on chromosome 11. Alternative splicing of the 
primary RNA transcipt leads to translation of CGRP and Ct peptides in tissue-specific manner 
[for example, in the central nervous system (CNS), splicing of the CT/CGRP gene produces 
CGRP, whereas in the C cells of the thyroid gland Ct is formed]. The gene encoding for IAPP 
is located on chromosome 12, which is believed to be derived from evolutionary duplication 
of chromosome 11. This peptide superfamily share common structural features that are 
responsible for the overlapping biological effects and also for the cross-reactivity between 
receptors [29].  
 
3.3.1 Calcitonins 
 
Calcitonin (Ct) is a polypeptide hormone secreted by the C-cells of the thyroid gland in 
mammals and the ultimobranchial body in birds, reptiles and fish. Calcitonin is mainly 
kwown for its hypocalcemic effect and the inhibition of bone resorption, and is used 
therapeutically for the treatment of osteoporosis, Paget’s disease and other hypercalcemia-
related diseases. The observed antinociceptive effect of calcitonin on animals and patients 
suffering from Paget’s disease are also suggestive of potential new applications in the 
treatment of pain [30].  
Calcitonins from at least ten different species have been isolated and their primary sequences 
were determined. All of them consist of 32 amino acid residues with a disulfide bond between 
Cys1 and Cys7 and a prolinamide at their C-terminal (Figure 5). The two Cys residues, the C-
terminal Pro and the following residues Leu4, Ser5, Thr6, Leu9, Gly28 are highly conserved 
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among these ten calcitonins. The salmon and eel calcitonins (sCt and eCt) differ in their 
sequence in only three positions (26,27 and 29), whereas sCt and human calcitonin (hCt) 
differ in 17 positions (~50% homology). The homology between hCt and rat calcitonin (rCt) 
is very high (they differ in only two positions: 16 and 26) [31].  
 
        
CSNLSTCVLG10 KLSQELHKLQ20 TYPRTNTGSG30 TP sCt 
        
CSNLSTCVLG10 KLSQELHKLQ20 TYPRTDVGAG30 TP eCt 
        
CGNLSTCMLG10 TYTQDFNKFH20 TFPQTAIGVG30 AP hCt 
        
CGNLSTCMLG10 TYTQDLNKFH20 TFPQTSIGVG30 AP rCt 
        
CSNLSTCVLS10 AYWRNLNNFH20 RFSGMGFGPE30 AP pCt 
        
CASLSTCVLG10 KLSQELHKLQ20 TYPRTDVGAG30 AP chCt 
 
 
Figure 5. Primary structures of Calcitonins (s: salmon, e: eel, h: human, r: rat, p: porcine, ch: 
chicken). 
 
sCt and eCt are about 50 times more potent than hCt and other mammalian calcitonins in vivo. 
Therefore, sCt is the mainly therapeutically used calcitonin. hCt is also used but to a lesser 
degree. It has been long proposed that the propensity of the Cts to form an α-helix in the 
region [8-22] might correlate with their bioactivities [32]. sCt and hCt have regurlarly spaced 
hydrophobic amino acids at each third or fourth residue in the region [8-22] of the polypeptide 
chain. This regular spacing of hydrophobic amino acids would allow the peptide to fold into 
an amphiphilic α-helix in which one face of the helix is hydrophobic and the other 
hydrophilic [33]. Nuclear magnetic resonance (NMR) studies in mixed solvents such as 
methanol-water, or trifluoroethanol (TFE)-water, suggested the presence of a central helix in 
sCt that extends from residue 8 to 22, and similar results have been reported for hCt in TFE 
solutions [34]. The higher biological potency of sCt compared to hCt has been associated with 
a higher helix forming propensity in the region [8-22] for the sCt. However, for hCt there is 
no direct link between helicity and bioactivity. In contrast, other factors such as a β-turn/β-
sheet conformation in the central region of hCt, overall conformationally flexibility, tertiary 
structure interactions and interactions of specific residues may be related to bioactivity [35]. 
NMR studies in non-helix-inducing media (such as in neat dimethylsulfoxide (DMSO) or 
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DMSO / water) indicated a type I β-turn centered around residues 18 and 19 connecting two 
short antiparallel β-sheets to be present in the central region of hCt [36, 37]. Interestingly, hCt 
has three aromatic residues in position 12, 16 and 19, whereas these positions are occupied by 
leucine residues in sCt [38].  
Receptors for several peptide hormones belong to the superfamily of seven trans-membrane 
domain G-protein-coupled receptors (7 TMD-GPCRs). Based on primary structure homology, 
this superfamily can be divided into several subfamilies. The most recently identified 
subfamily comprises receptors for the peptide hormones calcitonin, parathyroid hormone, 
glucagon, glucagon-like peptide, secretin and vasoactive intestinal peptide. The diversity of 
intracellular effects mediated by members of the 7 TMD-GPCR superfamily is generated by 
coupling of the receptors to various G-proteins. An additional source of diversity results from 
the existence of receptor subtypes (or isoforms) that recognize the same ligand. These 
subtypes may be discrete gene products or the result of alternative splicing of primary 
messenger RNA transcripts to yield different protein products [39].  
Ct receptors are localized in bone and kidney and also in the CNS, i.e. the brain. Human and 
rat Ct receptors are the best characterized in terms of their ligand interactions and these 
receptors are known to be expressed in multiple isoforms as a result of alternative gene 
splicing. The major isoforms of the human Ct receptor, hCTRI1- and hCTRI1+ differ in the 
absence and presence, respectively, of a 16-residue insert in the proposed first intracellular 
loop region [40]. The insert-negative isoform of the human receptor appears to be the dominant 
isoform in most tissues, including the CNS. Both hCTR isoforms bind sCt with identical 
affinities, but the insert-positive isoform exhibits impaired signal transduction via the 
adenylyl cyclase (AC) and phospholipase C second-messenger systems [41]. 
Structure-activity relationships studies (SAR) have indicated that region [1-7] of the Cts is 
important for AC activation, while binding to the Ct receptor is believed to be mediated by 
region [8-32] [42]. Salmon calcitonin binds to human calcitonin receptors with a higher affinity 
as compared to hCt.  
According to one hypothetical model [43] (Figure 6), the structural feature that is responsible 
for the hormone binding has been mapped to the amphiphilic α-helical region, which has been 
proposed to interact primarily with the extracellular N-terminal domain of the Ct receptor. 
Hormone binding to the Ct receptor has been proposed to occur via two possible pathways: in 
pathway 1 binding occurs through the amphiphilic helix to the N-terminal domain of the Ct 
receptor and in pathway 2 by direct interactions of the hormone ligand with binding sites in 
the transmembrane domain of the Ct receptor. Pathway 1 may be more prominent for sCt 
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binding than for hCt binding. A tight, ‘closed’ complex (3) is then postulated to be a 
prerequisite for efficient receptor activation and signal transduction.  
 
 
 
Figure 6. Hypothetical model for receptor binding by the Cts [43]. The structural domains of 
Ct are depicted: the N-terminal disulfide-bridge (N), the amphiphilic α-helix [8-17], a β-turn 
in region [17-21] and the C-teminal domain [21-32]. (A): in pathway 1 binding of the 
calcitonin to the Ct receptor occurs through binding of the amphiphilic α-helix of the 
hormone to the N-terminal domain of the receptor, where in pathway 2 binding of the 
calcitonin to the Ct receptor occurs through direct interactions of the hormone ligand with 
binding sites in the transmembrane domain of the Ct receptor. (B): a tight, ‘closed’ complex 
(3) between the receptor and the hormone ligand is required for efficient receptor activation 
and signal transduction. 
 
3.3.2 Islet Amyloid Polypeptide (IAPP) 
 
IAPP is expressed mainly in the islets of Langerhans of pancreas and is believed to be 
genetically, structurally and functionally related to both Ct and CGRP [29]. hCt and hCGRP 
exhibit a primary sequence homology of 15 and 46% respectively, to the hIAPP sequence. 
The conserved amino acids between hIAPP and hCGRP are located in the regions between 
residues 1 and 20 and between 29 and 37. More than 80% of the hIAPP sequence is broadly 
conserved in the mammalian species suggesting a significant biological function for this 
polypeptide [44].  
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hIAPP is expressed as a 89-residue containing pre-propeptide and is stored in form of the 67-
residue human ProIAPP (hProIAPP) in secretory vesicles of the β-cells together with insulin 
(and proinsulin). hIAPP is secreted together with insulin (in a ratio of insulin to hIAPP of 100 
to 1) following proteolytic processing of the pro-region in response to insulin secretagogues 
and the basal blood concentration of IAPP in humans has been reported to be between 1 and 
10 pM [45]. The most well-studied biological effects of IAPP include its effect on carbohydrate 
metabolism and on bone metabolism [46]. IAPP is believed to play a role as an insulin counter-
regulator in skeletal muscle by inhibiting glycogen synthesis and promoting glycolysis. IAPP 
has been also reported to inhibit insulin secretion by the β-cells [47]. In addition, IAPP excerts 
hCt-like effects on bone turnover that include the inhibition of bone resorption most likely by 
inhibition of the osteoclastic activity and the reduction of plasma calcium. The biological 
activities of IAPP are believed to be mediated by G-protein coupled receptors, while a 
specific IAPP receptor has not been yet identified and characterized [48]. It is possible that 
IAPP can interact with CGRP receptors in target tissues such as in the brain, lung, stomach, 
spleen and liver [49].  
Although more than 80% of the hIAPP sequence is conserved in the mammalian species 
besides humans and human primates, only a few animal species including cats, dogs, 
monkeys and raccoons develop IAPP-derived islet amyloid. There is a clear species- and 
sequence-specificity of the amyloidogenic potential of the IAPP sequence [50]. In vitro studies 
have shown that hIAPP easily forms amyloid fibrils, whereas synthetic rat IAPP (rIAPP) is 
not able to form amyloid [51]. The sequence of rIAPP differs from the one of the hIAPP in 6 
out of 37 amino acids with 5 out of these 6 amino acids located in the region between 20 and 
29 (Figure 7). Two to three of the five different amino acids in the rat sequence are proline, 
which is a known β-sheet-breaking residue [52]. The amino acid constitution of sequence IAPP 
[20-29] has been, therefore, suggested to define and modulate the amyloidogenic propensities 
of complete sequence IAPP from different species [53]. 
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             
KCNTATCATQ10 RLANFLVVHS20 NNFGAILSST30 NVGSNTY hIAPP 
             
KCNTATCATQ10 RLANFLVRSS20 NNLGPVLPPT30 NVGSNTY rIAPP 
             
KCNTATCATQ10 RLANFLVRSS20 NNFGTILSST30 NVGSDTY mIAPP 
             
KCNTATCATQ10 RLANFLVRTS20 NNLGAILSPT30 NVGSNTY dIAPP 
             
KCNTATCATQ10 RLANFLIRSS20 NNLGAILSPT30 NVGSNTY cIAPP 
 
Figure 7. Primary structures of IAPP (h: human, r: rat, m: monkey, d: dog, c: cat). 
 
Type II diabetes mellitus (NIDDM) is a cell degenerative disease that belongs to the family of 
protein aggregation diseases (such as Alzeimer’s, Huntington’s or Parkinson’s disease). More 
than 90% of patients with type II diabetes have amyloid deposits in the β-cells of the pancreas 
[54]. Pancreatic amyloid fibrils consists of IAPP and contain the polypeptide chains organized 
in a ‘cross-β-sheet’ structure [55]. In the past ten years evidence has been gathered that there is 
a common mechanism of amyloid formation for various polypeptides (such as IAPP, and the 
AD β-amyloid peptide) that include a conformational transition of mainly random coil or α-
helical polypeptides into β-sheet aggregates. In addition, there is increasing evidence that 
fibrillar / or protofibrillar species formed by ordered aggregation of these polypeptides are 
cytotoxic and that their formation process is directly associated with the pathologic onset of 
the corresponding disease [56].  
The conversion of monomeric and soluble polypeptides into insoluble amyloid fibrils is a 
multistep process, which has been yet not understood. This is also due to the fact that the 
detailed biophysical characterization of various different structural and assembly states of one 
polypeptide sequence is necessary, which in turn requires the complementary use of several 
independent biophysical methods for its elucidation [57].  
The mechanism speculated for the amyloidogenic pathway of hIAPP is consistent with a 
nucleation-dependent polymerisation mechanism [58]. In Figure 8, a proposed model of 
possible molecular events in the hIAPP amyloid formation pathway via a partially folded 
intermediate state (I) (2) is shown [59]. According to the model during folding [from the 
unfolded state (U) (3) to folded state (N) (1)] or unfolding, this partly folded state and its self-
associated forms [(2) and (4), respectively in Figure 8] are in a concentration-dependent 
equilibrium with native nonamyloidogenic hIAPP (1). The intermediate folded state (I) is not 
stable as a monomer but can be stabilized by self-association into an oligomeric species (x-
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mer). The monomer and the oligomer species of the intermediate state (I) are early, soluble, 
α-helix and β-sheet-containing precursors of amyloid fibrils, with the potential to further 
associate in an enviroment- and concentration-depedent manner into β-sheet-rich 
protofibrillar (5) and fibrillar assemblies (6). Question marks (?) indicate that the intermediate 
steps in the amyloid forming pathway have not yet been characterized. Also, the exact 
structure, the assembly state, and the biophysical properties of the partly folded states (2) and 
(4) have not yet been characterized.  
 
 
 
 
 
Figure 8. Model of possible molecular events in the hIAPP amyloid formation pathway via a 
partially folded intermediate state(s) [59]. [(N) or (1): native or folded state, (U) or (3): 
unfolded state, (I) or (2): intermediate folded state, (4): multimer formed through self-
association of intermediate folded state(s), (5): protofibril species rich in β-sheet structure, 
(6): amyloid fibril].  
Question marks (?) indicate that the intermediate steps in the amyloid forming pathway have 
not yet been characterized. 
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4 Materials and Methods 
 
4.1 Materials 
 
Resins for solid phase synthesis were purchased by Bachem (Heidelberg, Germany) and 
Novabiochem (Laüfelfingen, Switzerland). Boc-protected amino acids were supplied by 
Bachem (Heidelberg, Germany), and Fmoc-protected amino acids were purchased by Rapp 
Polymere (Tübingen, Germany), except for the following: Fmoc-Asp(OPip)-OH, Fmoc-
Dab(Adoc)-OH, Fmoc-Dap(Boc)-OH, Fmoc-Dap(Adoc)-OH, Fmoc-Glu(OPip)-OH, Fmoc-
Orn(Mtt)-OH which were supplied by Bachem. Fmoc N-methylated amino acids were 
purchased by Novabiochem. Solvents required for synthesis such as DMF (lab grade), DCM 
(p.a grade) which was distilled prior to use, and NMP (synthesis grade) were acquired by 
Merck (Darmstadt, Germany). Additional solvents such as: MeOH (p.a grade), EtOH (p.a 
grade), Et2O (p.a grade), AcOH (100%) and iPrOH (p.a grade) were also purchased by Merck 
(Darmstadt, Germany). Coupling reagents were obtained by the following sources: TBTU 
(synthesis grade) by Rapp Polymere, HOBt (purum ≥ 98%) by Fluka (Buchs, Switzerland), 
DIC (purum ≥ 99%) by Sigma-Aldrich (Steinheim, Germany), DIEA (≥ 98%) by Fluka 
(Buchs, Switzerland), piperidine (synthesis grade) by Merck-Schuchardt (Hohenbrunn, 
Germany). Additional chemicals used during the synthesis were the following: acetic 
anhydride by Sigma-Aldrich (Steinheim, Germany), ninhydrin (~99%) by Fluka, 
triisopropylsilane (TIS) (99%) by Sigma-Aldrich, 4 M HCl in dioxane (synthesis grade) by 
Sigma-Aldrich. Reagents used for cleavage of the peptides from the resin were: TFA (peptide 
synthesis grade) by Biosolve (Valkenswaard, Netherland), phenol (99%) by Sigma-Aldrich, 
where the scavengers thioanisole (TAS) (≥ 99%), 1,2-ethanedithiol (EDT) (≥ 98%), 
dimethylsulfide (DMS) (≥ 99%) were supplied by Fluka. Solvents for the HPLC purifications 
were: acetonitrile (ACN) (liquid chromatography grade) by Merck and TFA (protein 
sequencing grade) by Fluka. NH4HCO3 (≥ 99%) was from Fluka, and HCl (37%), guanidine 
hydrochloride (Gdn HCl) (99%) and urea (99%) were provided by Sigma-Aldrich. Synthetic 
analogues (hCt and sCt) for the bioactivity assays were from Novabiochem. Medium (RPMI 
1640), fetal bovine serum and cell culture antibiotics and hormones (hydrocortisone, insulin) 
were from Invitrogen (Karlsruhe, Germany). Salmon 125I- labelled Ct and the EIA kit for 
cAMP determination (Biotrak) were both from Amersham Pharmacia Biotech (Freiburg, 
Germany). For the in vitro toxicity assays of IAPP and IAPP analogue [2], 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP) and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium 
bromide (MTT) were from Sigma-Aldrich. 
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4.2 Methods 
 
4.2.1 SPPS using the Boc-strategy 
 
Boc-chemistry SPPS was performed using Boc-protected amino acids on p-methyl-
benzhydrylamine (MBHA) polystyrene resin (crosslinked with 1% DVB). Peptide assembly 
was carried out manually using a glass reaction vessel equipped with filter unit. Removal of 
the Nα-Boc group (except for Gln) was performed by 50% TFA in DCM, followed by 
neutralization of the resin with 5% DIEA in DCM and subsequent washings with DCM, 
iPrOH and DMF. Thereafter, a solution of the Boc-amino acid, TBTU, DIEA (in a molar ratio 
of 4/4/6) was added. Couplings were performed for 60 to 90 min and their completeness was 
checked by Kaiser test (see 4.2.5). When not satisfactory, either a second coupling or capping 
of the peptide resin with Ac2O (10-fold molar excess) in the presence of DIEA (10-fold molar 
excess) in DMF for 45 min was carried out. In the calcitonin analogues after the coupling of 
Met8 the subsequent cleavages of the Boc-group were achieved with 50% TFA in DCM plus 
1% DMS as scavenger of the tert-butyl. The above steps were repeated for each amino acid 
and are summarized in table 1. 
All Boc-amino acids were of L-configuration unless otherwise specified and the side chain 
protecting groups were the following: Asp(OcHx), Cys(Mob), His(π-Bom), Lys(2-Cl-Z), 
Ser(Bzl), Thr(Bzl), Tyr(2-Br-Z). 
 
4.2.1.1 Cleavage of the Nα-Boc-group of glutamine 
 
The calcitonin sequence has two glutamine residues that may form pyroglutamine during 
TFA-mediated Boc-cleavage [60]. Therefore, a special protocol was applied for the cleavage of 
the Boc-group of Gln. According to it, 4 M HCl in dioxane was used and short washing steps 
were applied. After cleavage of the Boc-group and neutralization a positive Kaiser test 
indicated the presence of free amino groups. The next amino acid was then coupled using 6-
fold molar excess instead of 4-fold molar excess that was applied in the standard coupling 
protocol. 
The procedure is shown in table 2. 
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Table 1. Protocol for SPPS using Boc-chemistry.  
 
Synthesis cycle: Reagent: Time: 
Wash DMF 2 x 1 min 
Wash DCM 2 x 1 min 
Deprotect 50% TFA / DCM § 1 x 2 min 
Deprotect 50% TFA / DCM §  1 x 28 min 
Wash DCM 2 x 1 min 
Neutralize 5% DIEA / DCM 2 x 2 min 
Wash DCM 2 x 1 min 
Wash iPrOH 1 x 1 min 
Wash DCM 1 x 1 min 
Wash DMF 2 x 1 min 
Coupling Boc-AA / TBTU / DIEA (Eq: 4 / 4 / 6)  60-90 min 
Wash DMF 3 x 1 min 
Acetylation Ac2O / DIEA (Eq: 10 / 10) 45 min 
Wash DMF 3 x 1 min 
 
§: after Met8 in Ct analogues plus 1% DMS as scavenger. 
 
Table 2. Cleavage of the Nα-Boc-group of Gln. 
 
 
Synthesis cycle: Reagent: Time: 
Wash dioxane 1 x 10 sec 
Deprotect 4 M HCl / dioxane 1 x 2 min 
Deprotect 4 M HCl / dioxane  1 x 28 min 
Wash dioxane  1 x 10 sec 
Wash DCM  2 x 10 sec 
Neutralize 5% DIEA / DCM 2 x 1 min 
Wash DCM 1 x 1 min 
Wash DMF 1 x 1 min 
 
 
4.2.1.2 Cyclization strategy in synthesis by Boc-chemistry 
 
The synthesis of the side chain-to-side chain lactam bridged analogues of calcitonin was 
accomplished using a previously established side chain-to-side chain cyclization strategy on 
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the resin [21]. The use of Asp & Orn / Lys amino acids derivatives at positions 17 & 21 that 
beared base labile side chain protecting groups (Fmoc- and OFm respectively) enabled for the 
selective cleavage of these groups in the presence of Boc- and Bzl- based groups. After 
incorporation of the residue at position 17, the peptide resin was treated with piperidine in 
DMF (25% v/v) to remove the side-chain groups of residues 17 & 21. A small aliquot of resin 
was tested with Kaiser test and following washes of the resin, BOP (4-fold molar excess) and 
DIEA (4-fold molar excess) in DMF were added. Completeness of the cyclization was 
checked with the Kaiser test (after 4 hrs reaction time) and in most of the cyclizations a 
second coupling was performed overnight (16-18 hrs). Finally, unreacted groups were 
acetylated by Ac2O and DIEA in DMF (10-fold molar excess each) for 45 min. The protocol 
is summarized in table 3. 
 
Table 3. Cleavage of Fmoc- and OFm- side chain protecting groups and side chain-to-side 
chain cyclization protocol in Boc-SPPS. 
 
Synthesis cycle: Reagent: Time: 
Wash DMF 2 x 1 min 
Deprotect 25% piperidine / DMF 1 x 2 min 
Deprotect 25% piperidine / DMF   1 x 28 min 
Wash DMF 3 x 1 min 
Wash 10% DIEA / DMF 1 x 1 min 
Wash 10% DIEA / DMF 1 x 3 min 
Wash DMF 3 x 1 min 
Cyclization BOP / DIEA (Eq: 4 / 4) 
1 x 4 hrs 
  1 x 16 hrs 
Wash DMF  3 x 1 min 
Acetylation Ac2O / DIEA (Eq: 10 / 10)  45 min 
Wash DMF  3 x 1 min 
 
4.2.2 SPPS using the Fmoc-strategy 
 
For the Fmoc-strategy an orthogonal protection scheme was applied with the Fmoc- group as 
a temporary protection of the Nα group and tBu- and Trt-based side chain protecting groups. 
The 4-(2´, 4´-dimethoxyphenyl-Fmoc-aminomethyl)-phenoxy acetamido-norleucyl resin 
(Rink amide MBHA) was used in the case of peptide amides (such as Ct and IAPP 
analogues). Fmoc-cleavage was achieved by 25% piperidine in DMF. Couplings were 
performed using Fmoc-AA and TBTU (4-fold molar excess) in the presence of DIEA (6-fold 
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molar excess). Couplings of N-methylated amino acids, as well as couplings on N-methylated 
amino acids were performed as described under sections 4.2.3 and 4.2.4. The following 
Fmoc-protected amino acid derivatives were applied: Asp(OtBu), Glu(OtBu), Gln(Trt), 
Cys(Trt), His(Trt), Lys(Boc), Thr(tBu), Ser(tBu), Arg(Pmc), and Tyr(tBu). The side chain 
protecting groups of the residues that were to be covalently linked via side chain-to-side chain 
were: 2-phenyl-isopropyl ester (OPip) for Asp17, 4-methyl-trityl (Mtt) for Orn21 & Lys21and 
adamantyl-1-methyl-ethoxy-carbonyl (Adoc) for Dap21 & Dab21. Coupling efficiencies were 
checked by the Kaiser test and/or reversed-phase high performance liquid chromatography 
(RP-HPLC) and mass spectroscopic (MS) analysis of a small sample of peptide resin 
following treatment with TFA to cleave the peptide from the resin (see 4.2.7.3). The protocol 
is summarized in table 4. 
 
Table 4. Protocol for SPPS using Fmoc-chemistry. 
 
Synthesis cycle: Reagent: Time: 
Wash DMF 2 x 1 min 
Deprotect 25% piperidine / DMF 1 x 5 min 
Deprotect 25% piperidine / DMF   1 x 20 min 
Wash DMF 4 x 1 min 
Coupling Fmoc-AA / TBTU / DIEA (Eq: 4 / 4 / 6)   60-90 min 
Wash DMF 3 x 1 min 
Acetylation Ac2O / DIEA (Eq: 10 / 10) 45 min 
Wash DMF 3 x 1 min 
 
4.2.2.1 Cyclization strategy in Fmoc-chemistry 
 
Cyclizations in calcitonins were performed between the side chains of residues 17 and 21. 
After incorporation of residue 17, the peptide resin was washed with distilled DCM. A 
mixture of triisopropylsilane (TIS) (5%) (v/v) and TFA (1%) (v/v) in distilled DCM was 
added to cleave the side chain groups OPip, Mtt and / or Adoc. At this point, the positive 
Kaiser test indicated the presence of free side chain amino groups. The peptide resin was 
further washed with distilled DCM and with DMF and was then neutralized with 1% DIEA in 
DMF and finally washed with DMF. The cyclization reaction was performed by the addition 
of BOP (4-fold molar excess) and DIEA (4-fold molar excess) in DMF. The progress of the 
reaction (after 4-5 hrs) was checked by Kaiser test. Thereafter, the cyclization reaction was 
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repeated for another 16-20 hrs. Upon completeness of the 2nd cyclization reaction, capping of 
the peptide resin was carried out with acetic anhydride and DIEA in DMF (10-fold molar 
excess each) for 45 min. The protocol is summarized in table 5. 
 
Table 5. Cleavage protocol of special side chains groups and side chain-to-side chain 
cyclization protocol in Fmoc-SPPS. 
 
Synthesis cycle: Reagent: Time: 
Wash DCM 3 x 1 min 
Deprotect TIS / TFA (5% / 1%) in DCM 2 x 2 min 
Deprotect TIS / TFA (5% / 1%) in DCM   6 x 10 min 
Wash DCM 3 x 1 min 
Wash DMF 3 x 1 min 
Neutralize 1% DIEA / DMF 2 x 2 min 
Wash DMF 3 x 1 min 
Cyclization BOP / DIEA (Eq: 4 / 4) 
1 x 4 hrs 
  1 x 16 hrs 
Wash DMF  3 x 1 min 
Acetylation Ac2O / DIEA (Eq: 10 / 10) 45 min 
Wash DMF  3 x 1 min 
 
4.2.2.2 Coupling of Cys residues in Fmoc-SPPS 
 
Coupling of Fmoc-Cys(Trt)-OH was performed by a different method than the coupling of the 
other amino acids. This is due to the fact that the activation of Fmoc-Cys(Trt) when 
performed with TBTU in the presence of base as normally performed in Fmoc-strategy can 
cause significant racemization of Cys [61]. Therefore, Cys couplings were performed using an 
in situ activation protocol via 1-hydroxybenzotriazole (HOBt) and diisopropylcarbodiimide 
(DIC). For this activation no addition of base was necessary [62]. Specifically, equimolar 
amounts of Fmoc-Cys(Trt)-OH , HOBt, and DIC (4-fold molar excess each with regard to the 
amino groups) were dissolved in DMF (concentration 0.15 M each). Following stirring of the 
reaction mixture at 4 °C for 45 min, the solution containing the OBt-ester of Fmoc-Cys(Trt) 
was added to the Nα-deprotected peptide resin. Coupling was performed for 60-90 min. A 
second activation / coupling cycle was also performed using the same methodology. Coupling 
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efficiency was estimated by the Kaiser test and prior to proceeding with the synthesis a 
capping step (Ac2O / DIEA in DMF, 10-fold molar excess each) was usually performed.  
 
4.2.3 Coupling of N-methyl residues 
 
For the coupling of N-methyl (N-Me) residues the standard TBTU coupling as described 
under 4.2.1 and 4.2.2 was applied. In the Ct analogues (such as QCcyclo, QClinear), that were 
synthesized by both chemistries (Boc- and Fmoc-), the single N-methyl residue (N-Me) Phe19 
was coupled twice using 4-fold molar excess of protected amino acid in the presence of 4-fold 
molar excess TBTU and 6-fold molar excess DIEA. However, in the IAPP analogues, the N-
methylated residues (N-Me) Phe, (N-Me) Gly, (N-Me) Ala, (N-Me) Ile, (N-Me) Leu were 
coupled using up to 10-fold excess of the protected amino acid with the corresponding 
amounts of TBTU and DIEA. Coupling times were often longer than the ones used for non-N-
methylated amino acids, whereas use of mixture of solvents or coupling at elevated 
temperatures were usually employed. These procedures depending on the particular sequence 
to be synthesized are described (in detail) in the results part. The following tables (tables 6, 7, 
8, 9, 10) provide an overview of the conditions used for the coupling of N-methylated amino 
acids. 
 
Table 6. Coupling conditions for the TBTU-coupling of (N-Me) Phe23 residue in IAPP 
analogue [1].  
 
IAPP 
analogue 
Synthesis 
No. of 
Couplings 
AA & 
TBTU# 
Excess 
Time Temp Solvent 
Acetylation 
after 
coupling 
1 1st 2 6-fold 
 90 min 
15 hrs 
RT 
Magic 
mix1 
Yes 
 
# ratio of AA / TBTU / DIEA was: 1 / 1 / 1.5  
1 magic mix was DMF / DCM / NMP: 1 / 1 / 1 (v/v/v) with 1% Triton X100 
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Table 7. Coupling conditions for the TBTU-coupling of (N-Me) Gly24 residue in IAPP 
analogue [2].  
IAPP 
analogue Synthesis 
No. of 
Couplings 
AA & 
TBTU# 
Excess 
Time Temp Solvent 
Acetylation 
after 
coupling 
2 1st 2 4-fold 
90 min 
135 min 
RT DMF Yes 
 
# ratio of AA / TBTU / DIEA was: 1 / 1 / 1.5 
 
Table 8. Coupling conditions for the TBTU-coupling of (N-Me) Ile26 residue in IAPP 
analogues [2], [4], and [5].  
 
IAPP 
analogue 
Synthesis 
No. of 
Couplings 
AA & 
TBTU# 
Excess 
Time Temp Solvent 
Acetylation 
after 
coupling 
2 1st 3 4-fold 
90 min 
90 min 
110 min 
RT DMF Yes 
4 1st 2 6-fold 
17 hrs 
4/17 hrs 
RT 
50 °C/RT DMF Yes 
4 2nd 4 
5-fold 
5-fold 
5-fold 
7-fold 
100 min 
16 hrs 
3 hrs 
16/4/20 hrs 
RT 
RT 
RT 
RT/40 °C/RT 
DMF Yes 
5 1st 2 8-fold 
17 hrs 
4/17 hrs 
RT 
50 °C/RT DMF Yes 
5 2nd 4 
4-fold 
4-fold 
8-fold 
4-fold 
80 min 
85 min 
7/15 hrs 
4 hrs 
RT 
RT 
50 °C/RT 
60 °C 
DMF Yes 
 
# ratio of AA / TBTU / DIEA was: 1 / 1 / 1.5 
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Table 9. Coupling conditions for the TBTU-coupling of (N-Me) Leu27 residue in IAPP 
analogues [3], [4], and [5].  
IAPP 
analogue Synthesis 
No. of 
Couplings 
AA & 
TBTU# 
Excess 
Time Temp Solvent 
Acetylation 
after 
coupling 
3 1st 1 2-fold 90 min RT DMF No 
3 2nd 2 4-fold 
70 min  
75 min 
RT 
DMF 
   NMP 
Yes 
3 3rd 2 4-fold 
70 min 
75 min 
RT DMF No 
4 1st 2 4-fold 
75 min 
75 min 
RT DMF No 
4 2nd 2 4-fold 
75 min 
75 min 
RT DMF No 
5 1st 2 6-fold 
75 min 
75 min 
RT DMF No 
5 2nd 2 4-fold 
70 min 
90 min 
RT DMF No 
 
# ratio of AA / TBTU / DIEA was: 1 / 1 / 1.5 
 
Table 10. Coupling conditions for the TBTU-coupling of (N-Me) Ala25 residue in IAPP 
analogues [1], [3], and [5]. 
 
IAPP 
analogue 
Synthesis 
No. of 
Couplings 
AA & 
TBTU# 
Excess 
Time Temp Solvent 
Acetylation 
after 
coupling 
1 1st 2 5-fold 90 min RT DMF No 
3 1st 1 2-fold 110 min RT DMF No 
3 2nd 2 4-fold 
70 min 
60 min 
RT 
DMF 
NMP 
Yes 
5 1st 1 10-fold§ 24 hrs RT 
Magic 
mix1 
No 
5 2nd 2 
8-fold 
4-fold 
1.3/5 hrs 
18 hrs 
50 °C/ RT 
RT 
DMF No 
# ratio of AA / TBTU / DIEA was: 1 / 1 / 1.5  
§ no DIEA was used  
1 magic mix was DMF / DCM / NMP: 1 / 1 / 1 (v/v/v) with 1% Triton X100 
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4.2.4 Coupling on N-methyl residues 
 
Coupling of amino acids on N-methyl residues was as difficult as the coupling of N-methyl 
amino acids. The coupling efficiency could only be evaluated by a small-scale cleavage of 
peptide resin, chromatographic separation of peptides and characterization by mass 
spectroscopy, because the Kaiser test could not be applied (see 4.2.5). The following tables 
(tables 11, 12, 13, 14, 15, 16, 17, 18) provide a summary of the coupling conditions in the 
region [19-27] of the IAPP analogues.  
 
Table 11. Synthesis summary in region [19-27)] for IAPP analogue [1].  
 
AA residue Excess No. couplings Conditions Cleavage Acetylation 
Leu27 4-fold 2 DMF: 1 x 70 min DMF: 1 x 70 min   
Ile26 4-fold 2 DMF: 1 x 60 min DMF: 1 x 80 min x  
(N-Me) Ala25 5-fold 2 DMF: 1 x 90 min DMF: 1 x 90 min   
Gly24 5-fold 2 DMF: 1 x 75 min        DMF: 1 x 15 hrs x x 
(N-Me) Phe23 6-fold 2 DMF: 1 x 90 min Magic mix1: 1 x 15 hrs x x 
Asn22 
6-fold 
10-fold 
6-fold 
3 
DMF: 1 x 90 min 
       DMF: 1 x 14 hrs 
Magic mix1: 1 x 90 min 
x x 
Asn21 6-fold 10-fold 2 
 DMF: 1 x 145 min 
       DMF: 1 x 16 hrs  x 
Ser20 6-fold 2        DMF: 1 x 60 min        DMF: 1 x 55 min   
Ser19 6-fold 2        DMF: 1 x 65 min        DMF: 1 x 60 min x  
 
1 magic mix was DMF / DCM / NMP: 1 / 1 / 1 (v/v/v) with 1% Triton X100 
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Table 12. Synthesis summary in region [19-27] for IAPP analogue [2].  
 
AA residue Excess No. couplings Conditions Cleavage Acetylation 
Leu27 4-fold 2       DMF: 1 x 90 min       DMF: 1 x 90 min   
(N-Me) Ile26 4-fold 3 
      DMF: 1 x 90 min 
      DMF: 1 x 90 min 
DMF: 1 x 110 min 
x x 
Ala25 
4-fold 
4-fold 
6-fold 
6-fold 
6-fold 
5 
      DMF: 1 x 90 min 
DMF: 1 x 90 min 
      DMF: 1 x 90 min 
      DMF: 1 x 90 min 
      NMP: 1 x 150 min 
x x 
(N-Me) Gly24 4-fold 2       DMF: 1 x 90 min       DMF: 1x 135 min x x 
Phe23 6-fold 3       DMF: 1 x 90 min DMF: 1 x 150 min x x 
Asn22 6-fold 2       DMF: 1x 100 min DMF: 1 x 100 min   
Asn21 6-fold 2       DMF: 1 x 90 min DMF: 1 x 120 min   
Ser20 6-fold 2       DMF: 1 x 80 min       DMF: 1 x 60 min   
Ser19 6-fold 2       DMF: 1 x 90 min       DMF: 1 x 80 min x  
 
Table 13. Synthesis summary in region [19-27] for IAPP analogue [3] / (1st synthesis). 
A.A residue Excess No. couplings Conditions Cleavage Acetylation 
(N-Me) Leu27 2-fold 1 DMF: 1 x 90 min    
Ile26 2-fold 2 DMF: 1 x 75 min DMF: 1 x 75 min  x 
(N-Me) Ala25 2-fold 1   DMF: 1 x 110 min   
Gly24 2-fold 2 DMF: 1 x 80 min DMF: 1 x 95 min x x 
Phe23 2-fold 2 DMF: 1 x 60 min DMF: 1 x 60 min   
Asn22 2-fold 2 DMF: 1 x 80 min DMF: 1 x 90 min   
Asn21 2-fold 2 DMF: 1 x 75 min DMF: 1 x 80 min   
Ser20 2-fold 2 DMF: 1 x 60 min DMF: 1 x 60 min   
Ser19 2-fold 2 DMF: 1 x 70 min DMF: 1 x 80 min x  
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Table 14. Synthesis summary in region [19-27] for IAPP analogue [3] / (2nd synthesis). 
 
A.A residue Excess No. couplings Conditions Cleavage Acetylation 
(N-Me) Leu27 4-fold 2 DMF: 1 x 70 min NMP: 1 x 75 min  x 
Ile26 4-fold 2 DMF: 1 x 75 min NMP: 1 x 85 min  x 
(N-Me) Ala25 4-fold 2 DMF: 1 x 70 min NMP: 1 x 60 min  x 
Gly24 4-fold 2 DMF: 1 x 70 min NMP: 1 x 80 min x x 
Phe23 4-fold 2 DMF: 1 x 60 min DMF: 1 x 70 min   
Asn22 4-fold 2   DMF: 1 x 100 min DMF: 1 x 75 min   
Asn21 4-fold 2 DMF: 1 x 60 min DMF: 1 x 70 min   
Ser20 4-fold 2 DMF: 1 x 65 min DMF: 1 x 75 min   
Ser19 4-fold 2 DMF: 1 x 65 min DMF: 1 x 80 min x  
 
Table 15. Synthesis summary in region [19-27] for IAPP analogue [4] / (1st synthesis). 
 
A.A residue Excess No. couplings Conditions Cleavage Acetylation 
(N-Me) Leu27 4-fold 2 DMF: 1 x 75 min DMF: 1 x 75 min   
(N-Me) Ile26 6-fold 2 DMF: 1 x 17 hrs DMF: WB* 4 hrs/17 hrs x x 
Ala25 5-fold 3 
       DMF: 1 x 6 hrs 
       DMF: 1 x 18 hrs 
       DMF: 1 x 150 min 
x x 
Gly24 5-fold 2    DMF: 1 x 100 min        DMF: 1 x 3 hrs   
Phe23 5-fold 3 
   DMF: 1 x 100 min 
DMF: 1 x 11 hrs 
DMF: 1 x 18 hrs 
x x 
Asn22 5-fold 2    DMF: 1 x 120 min    DMF: 1 x 140 min   
Asn21 5-fold 2       DMF: 1 x 2 hrs       DMF: 1 x 18 hrs  x 
Ser20 5-fold 2 DMF: 1 x 70 min DMF: 1 x 80 min   
Ser19 5-fold 2 DMF: 1 x 70 min DMF: 1 x 80 min x  
 
* Water Bath 
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Table 16. Synthesis summary in region [19-27] for IAPP analogue [4] / (2nd synthesis).  
 
A.A residue Excess No. couplings Conditions Cleavage Acetylation 
(N-Me) Leu27 4-fold 2          DMF: 1 x 95 min  DMF: 1 x 150 min   
(N-Me) Ile26 
5-fold 
5-fold 
5-fold 
7-fold 
4 
 DMF: 1 x 100 min 
         DMF: 1 x 16 hrs 
         DMF: 1 x 3 hrs 
DMF: 16 hrs / WB* 4hrs 
/ 20 hrs 
x x 
Ala25 6-fold 3 
DMF: WB 2 hrs / 23hrs 
    DMF: WB 3hrs / 19hrs 
DMF: WB 3 hrs / 14hrs 
x x 
Gly24 5-fold  2 DMF: 1 x 75 min   DMF: 1 x 140 min   
Phe23 5-fold 2 DMF: 1 x 85 min DMF: 1 x 80 min   
Asn22 5-fold 2   DMF: 1 x 120 min DMF: 1 x 80 min   
Asn21 5-fold 2 DMF: 1 x 75 min DMF: 1 x 60 min   
Ser20 5-fold 2 DMF: 1 x 75 min DMF: 1 x 85 min   
Ser19 5-fold 2   DMF: 1 x 105 min   DMF: 1 x 110 min x  
 
* Water Bath 
 
Table 17. Synthesis summary in region [25-27] for IAPP analogue [5] / (1st synthesis)  
 
A.A residue Excess No. couplings Conditions Cleavage Acetylation 
(N-Me) Leu27 6-fold 2 DMF: 1 x 75 min DMF: 1 x 75 min x  
(N-Me) Ile26 8-fold 2 
      DMF: 1 x 17 hrs 
DMF: WB* 4 hrs / 17 
hrs 
x x 
(N-Me) Ala25 10-fold 1 Magic mix1 : 1 x 24 hrs x  
 
* Water Bath 
1 Magic mix was DMF / DCM / NMP: 1 / 1 / 1 (v/v/v) with 1% Triton X100 
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Table 18. Synthesis summary in region [25-27] for IAPP analogue [5] / (2nd synthesis)  
 
A.A residue Excess No. couplings Conditions Cleavage Acetylation 
(N-Me) Leu27 4-fold 2 DMF: 1 x 70 min DMF: 1 x 90 min   
(N-Me) Ile26 
4-fold 
4-fold 
8-fold 
4-fold 
4 
DMF: 1 x 80 min 
DMF: 1 x 85 min 
DMF: WB* 7 hrs / 15 hrs 
DMF: WB* 4 hrs 
x x 
(N-Me) Ala25 4-fold 8-fold 2 
       DMF: 1 x 18 hrs 
DMF: WB* 90 min / 5hrs x  
 
* Water Bath 
 
4.2.5 Kaiser test 
 
The most widely used test for the presence or absence of free amino groups on a peptide resin 
(deprotection / coupling steps) was devised by E.T.Kaiser [63]. The test is simple and quick. 
However some amino groups (such as in Ser, Asn) do no show the expected dark blue colour 
that is typical for more than 95% free primary amino groups. Additionally, the test could not 
be applied in the case of the imino-acid Pro or N-methylated amino acids because the test 
could detect only primary amino groups and not secondary. Occasionally, also false negative 
tests are observed (as in the case of a sterically hindered Nα amino group) [64]. 
For the Kaiser test the following three solutions are prepared: 
• Ninhydrin in ethanol (5 gr in 100 ml ethanol) 
• Phenol in ethanol (40 gr in 10 ml ethanol) 
• An aqueous solution of potassium cyanide in pyridine (2 ml of aqueous 0.001 M 
KCN in 100 ml pyridine) 
 
A small sample of resin is placed into a glass test tube and washed three times with ethanol. 
Two drops of each of the above solutions is then added to the resin and the mixture is mixed 
thoroughly and heated at 110 °C for 5 min. Blue beads and blue solution indicate the presence 
of more than 95% free amino groups while a yellow solution and yellow beads indicate that 
the coupling is more than 99% complete. 
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4.2.6 Attachment of the C-terminal amino acid to the resin 
 
There are several linkers and derivatized resins for Boc- and Fmoc-SPPS available. For the 
synthesis of peptide amides (as in the case of Ct, IAPP and analogues), resins with linkers 
containing a free amino group were selected (MBHA for Boc- and Rink Amide MBHA for 
Fmoc-chemistry).  
 
4.2.6.1 Attachment of the C-terminal amino acid for the synthesis of Ct analogues using 
Boc-strategy 
 
Attachment of the C-terminal residue (Boc-Pro) was achieved using the following synthetic 
protocol: in 1gr of resin, Boc-protected amino acid (10-fold molar excess with regard to the 
substitution level of the resin) was coupled using TBTU (10-fold excess) and DIEA (15-fold 
excess). After 2 hrs coupling time Kaiser test indicated the completeness of the reaction. The 
resin was acetylated (Ac2O / DIEA 10-fold molar excess each in DCM) for 1 hr before 
proceeding with the synthesis. 
 
4.2.6.2 Attachment of the C-terminal amino acid for the synthesis of Ct analogues using 
Fmoc-strategy  
 
Attachment of the C-terminal residue (Fmoc-Pro) was achieved using the following protocol: 
in 1gr of resin, Fmoc-protected amino acid (5-fold molar excess with regard to the 
substitution level of the resin) was coupled using TBTU (5-fold excess) and DIEA (7.5-fold 
excess). After 2 hrs coupling time, Kaiser test or determination of the substitution level of the 
resin was performed as follows. 
 
4.2.6.3 Attachment of the C-terminal amino acid for the synthesis of IAPP analogues 
 
The C-terminal residue [Fmoc-Tyr(tBu)] was attached to the resin taking into consideration 
the intended ‘dilution’ of the substitution level of the resin (substitution level of resin usually 
was 0.5-0.7 mmole / gr, the intended substitution level between 0.2-0.3 mmole / gr). The 
protected amino acid (80% with regard to the total amount of NH2 groups of the resin) was 
coupled using TBTU and DIEA (ratio of AA / TBTU / DIEA: 1 / 1 / 1.5). After 4 hrs coupling 
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time, determination of the substitution level was estimated as below (4.2.6.4). Depending on 
the determined substitution level, the coupling was repeated or capping of unreacted amino 
groups (Ac2O / DIEA in DMF, 10-fold molar excess each with regard to the total NH2-groups 
of the resin) for 1 hr was performed.  
 
4.2.6.4 Determination of the substitution level of resin in Fmoc-strategy 
 
Estimation of the substitution level of Fmoc-protected peptide resin was performed by 
measuring the absorbance of the piperidine-dibenzofulvene adduct that is generated after 
Fmoc-cleavage as follows: two aliquots of the dry peptide resin (3-4 mg) were weighted in a 
volumetric flask (10 ml), which was then filled with 25% piperidine in DMF and left to stand 
for 15 min. Thereafter, the absorbance at 290 nm was measured and the substitution level of 
the peptide resin was estimated by the formula: 
 
Substitution level:       (Ab290nm x 10) / (ε x w x 10-3) in mmole / gr                                 
        where    Ab290nm : absorbance of sample at 290 nm 
                            ε      : molecular coefficient of piperidine-dibenzofulvene at 290 nm = 5800  
                            w     : weight of peptide resin (in mg) 
 
The resin was acetylated (Ac2O / DIEA 10-fold molar excess each in DMF) for 1 hr before 
proceeding with the synthesis. 
 
4.2.7 Final deprotection of side-chains and cleavage from the resin 
 
4.2.7.1 Final deprotection of side chains and cleavage of full length sequences from the 
resin in Boc-chemistry 
 
The most popular reagent for cleavage of peptides synthesized by Boc-chemistry is anhydrous 
HF. This procedure appears to be the most versatile and least harmful to the peptides attached 
to the resin [65]. The major disadvantage of the procedure remains its highly toxic and reactive 
nature, which requires the use of an HF resistant cleavage apparatus. Before HF cleavage the 
N-terminal Boc-group was removed from the peptide resin, followed by proper washes 
(DCM, DMF, Et2O) and drying in dessicator. The HF cleavage was performed for 30 min at –
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20 °C, and 1 hr at 0 °C. The crude Ct peptides were obtained by treatment of the peptide resin 
(200 mg) with 10 ml of a mixture of (HF / TAS / DMS / p-thiocresol) (10 / 1 / 1 / 2, v/v/v/w). 
Cysteine (500 mg) was added to the cleavage mixture in order to suppress a possible N-
terminal thiazolidine formation, which is likely to occur during HF cleavage of peptides with 
N-terminal Cys and the Bom-group for the side chain protection of His [66]. Following 
accomplishment of the cleavage reaction, HF and DMS were evaporated and cold diethylether 
was added to the peptide resin. The precipitated crude peptide was filtered together with the 
resin and washed with cold diethylether (3 times) to remove the scavengers. Thereafter, 10% 
aqueous AcOH was used to extract (3 times) the product from the peptide resin mixture and 
the extracts were collected and lyophilised.  
 
4.2.7.2 Final deprotection of side chains and cleavage of full length sequences from the 
resin in Fmoc-chemistry 
 
The N-terminal Fmoc-group was first removed (with 25% piperidine in DMF) and the peptide 
resin was dried. Thereafter, the cleavage of side chain protecting groups and the peptide from 
the resin was carried out by treatment of the resin with TFA and scavengers. A widely used 
cleavage mixture is a slight modification of reagent K [TFA / water / TAS / EDT / phenol: 83 
/ 4.5 / 4.5 / 2 / 6 (v/v/v/v/w)] [67]. Cleavage of the peptide resins were carried out at a 
concentration of 50-100 mg resin per 12 ml reagent K for 3 hrs at room temperature. After 
filtering the reaction mixture through a fritted funnel and washing with TFA (three times), the 
filtrate was evaporated (at ~ 30-33 °C). The resulting crude peptide was dissolved in 10% 
AcOH and the AcOH solution was then extracted with cold diethylether (three times at 4 °C). 
Extraction was performed as follows: following addition of diethylether and mixing, the 
solution was centrifuged (2000g, 3 min) and the ether layer was discarded. Thereafter, the 
aqueous layer was lyophilised. 
In the case of the IAPP analogue [6] [S20G-IAPP], the post cleavage work up procedure was 
as follows: the TFA solution (after filtering out the resin) was evaporated in a rotary 
evaporator till a small volume (~2 ml) and was transferred to a centrifuge containing cold 
diethylether. The peptide was left to precipitate (~10-15 min), was centrifuged (2000g, 2 min) 
and the ether layer was removed. The precipitate was then washed with cold ether twice (as 
above) and after the final removal of the ether, the precipitated peptide was dissolved in10% 
AcOH (~5 ml) plus some drops of 50% AcOH, and lyophilised. 
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4.2.7.3 Deprotection of side chains and cleavage of partial peptide sequences from the 
resin in Fmoc-chemistry 
 
Partial peptide sequences (mostly in IAPP analogues) with 10 to 15 residues were cleaved 
from the resin after treatment of the resin with TFA / H O (95 / 5 v/v) for 2 hrs at RT. The 
absence of residues such as Cys, Arg, Met enabled the cleavage without the addition of 
scavengers in the cleavage mixture . Again, the N-terminal Fmoc-group was first removed 
(with 25% piperidine in DMF) and the peptide resin was dried. After 2 hrs treatment with 
TFA / H O the peptide / resin mixture was transferred with a pasteur pipette to a fritted 
eppendorf tube, washed with neat TFA and centrifuged (2000g, 2 min). The TFA / peptide 
solution was diluted 10-fold in H O and extracted with cold diethylether (as described under 
4.2.7.2). The aqueous layer was then analysed by RP-HPLC and eluting peptide peaks were 
collected and lyophilised. MALDI-MS of the peptide peaks provided valuable information 
concerning the difficulties (incomplete couplings, deletion sequences) encountered during the 
peptide chain assembly. 
2
[68]
2
2
 
4.2.8 Disulfide bridge formation 
 
4.2.8.1 Disulfide bridge formation for the Ct analogues 
 
Crude peptides in their reduced form were subjected to air oxidation (in the dark) for disulfide 
bridge formation (Cys1 to Cys7). This was achieved by dissolving crude material (~1 mg / ml) 
in aqueous 0.1 M NH HCO  containing 1.5 M Gdn HCl. Gdn HCl was included to improve 
solubilities of the peptides and oxidation yields. The completion of the oxidation was 
monitored by RP-HPLC and for Ct sequences 2 hrs were usually sufficient time for the 
oxidation to be accomplished. 
4 3
 
4.2.8.2 Disulfide bridge formation for the IAPP analogues 
 
The IAPP analogues were also subjected to air oxidation (in the dark) for disulfide bridge 
formation (Cys2 to Cys7). Oxidations (1 mg crude material / ml solution) were performed in 
aqueous 0.1 M NH4HCO3, containing 3 M Gdn HCl to improve solubilities of the peptides 
and oxidation yields [except for IAPP and S20G-IAPP in which 6 M Gdn HCl was used]. The 
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completion of the oxidation was monitored by RP-HPLC and for IAPP analogues 2-4 hrs 
were usually required for the oxidation to be accomplished. 
 
4.2.9 RP-HPLC purification of the products 
 
Purification of the products (Ct and IAPP analogues) was carried out by RP-HPLC on a C18 
Nucleosil column with a length of 25 cm, internal diameter of 8 mm and 7 µm particle size. 
The device consisted of a Biotronic (Maintal, Germany) BT-8100 HPLC pump, a Biotronic 
BT-8200 uv-vis detector and a Shimadzu (Kyoto, Japan) C-R6A integrator. The flow rate was 
2 ml / min and eluting buffers were: A, 0.058% (v/v) TFA in water and B, 0.05% (v/v) TFA 
in 90% ACN / water. Peptides were detected at 214 nm and the gradients that were applied 
are shown in the tables 19, 20 and 21. Eluates containing peptide peaks were immediately 
frozen in dry ice, and lyophilised. 
 
 
Table 19. HPLC gradient 1 [Change of gradient over time (∆G): 1% / min)]. 
 
Step Time (min) Buffer A (%) Buffer B (%) 
1 0 70 30 
2 7 70 30 
3 37 40 60 
 
 
Table 20. HPLC gradient 2 (∆G: 2.66% / min). 
 
Step Time (min) Buffer A (%) Buffer B (%) 
1 0 90 10 
2 1 90 10 
3 31 10 90 
 
 
Table 21. HPLC gradient 3 (∆G: 0.74% / min). 
 
Step Time (min) Buffer A (%) Buffer B (%) 
1 0 65 35 
2 7 65 35 
3 34 45 55 
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4.2.10 Characterization of the peptides 
 
4.2.10.1 Matrix Assisted Laser Desorption Ionisation Mass Spectroscopy (MALDI-MS) 
 
Characterization of the oxidized and HPLC purified peptides was performed by MALDI-MS 
with a Kompact MALDI Kratos Analytical system (Duisburg, Germany). Peptides were 
dissolved in a (1:1) mixture of 5% TFA and 70% ACN / 0.01% TFA. Thereafter, 1.5 µl of α-
cyano-4-hydroxycinnamic acid (matrix) was placed on the slide, air dried and then 1.5 µl of 
the peptide sample were added. The mass was recorded on the positive ion mode and average 
mass was determined as [M+H]+. The average expected mass of the peptides was calculated 
using the Peptide Companion software (WindowChem Software, North Fairfield, USA). 
 
4.2.10.2 Fast Atom Bombardment Mass Spectroscopy (FAB-MS) 
 
Partial sequences of peptides (Ct and IAPP sequences) with a mass smaller than 2000 Dalton, 
were also measured by FAB using a MAT 711A Finnigan mass system (Bremen, Germany). 
Peptides were dissolved in liquid matrix (glycerol). The mass was recorded on the positive ion 
mode and average mass was determined as [M+H]+. 
 
4.2.10.3 Amino acid analysis 
 
Peptides (0.5 mg) were hydrolysed for 24 hrs in 6 M HCl at 110 °C. Samples were loaded into 
an Eppendorf (Hamburg, Germany) LC3000 amino acid analyser equipped with a cation 
exchange resin column. Sample concentration was 100 µM and ninhydrin post column 
derivatisation with detection at 570 nm was used for the determination of the amino acids [69].  
 
4.2.11 Concentration determination of Ct and IAPP solutions with UV spectroscopy 
 
HPLC purified peptides were stored in lyophilised form at –20 °C. Peptide stock solutions 
were made by dissolving the peptide in 1 mM HCl to a final concentration of about 500 µM. 
An exact concentration determination was necessary and was performed using UV-
spectroscopy with a Kontron Uvicon (Watford, UK) spectrophotometer. UV absorbance of 
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the peptide solution was measured between 330 and 240 nm and the absorbance at 274.5 nm 
was used to determine the exact peptide concentration (a representative example is shown in 
Figure 9). At this wavelength, the extinction coefficient of the Tyr residue (ε=1370 M-1 cm-1) 
and the disulfide bridge of Cys1 and Cys7 (ε=70 M-1 cm-1) was 1440 M-1 cm-1. Peptide 
concentrations were calculated according to the formula:      
                                              [C] = Ab274.5nm / (ε x l)                                                                   
        where                 ε= molecular extinction coefficient of peptides at 274.5nm 
                                   l= the length of the cuvette (1 cm) 
 
 
Figure 9. UV spectrum of a 0.52 mM stock solution of GCcyclo (in 1 mM HCl). 
 
4.2.11.1 Secondary structure of IAPP with FT-IR spectroscopy 
 
Fibrillar IAPP was prepared under strong amyloidogenic conditions as follows: 10% acetic 
acid was added to peptide solutions to give a concentration of 2.14 mM. Following incubation 
at RT for 4 days, the solution was neutralized with 10% NH4OH. Insoluble aggregates were 
collected and dried over KOH platlets. They were resuspended in 2H2O at an apparent 
concentration of 5 mM, applied onto a CaF2 plate and air-dried. Spectra were measured in a 
Perkin-Elmer spectrophotometer (Spectrum 1000). 
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4.2.12 Biological Assays 
 
4.2.12.1 Cell culture 
 
The biological activity of the synthetic Ct analogues were tested using the human breast 
cancer cell line T47D that was obtained from the American Tissue Culture Collection. Cells 
were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine 
serum, 1% streptomycin / penicillin, 0.1 µM insulin and 0.1 µM hydrocortisone. Cells were 
grown at 37 °C in a humidified atmosphere containing 5% CO2. The hormones were removed 
from the medium when subculturing the cells 2-3 days prior to the binding assays. Cells were 
subcultured in 12-well plates for the receptor binding experiments or in 96-well plates for the 
EIA experiments and were used when reached a confluence of 90%.  
 
4.2.12.2 Calcitonin receptor binding assay 
 
The receptor binding assay was performed based on the following protocol: cells in the 12-
well plates (1ml / well or 0.2 x 106 cells / well) were washed with phosphate buffered saline 
(PBS) (1 x 1 ml) at ambient temperature and then prewarmed (at 37 °C) assay buffer that 
consisted of RPMI 1640 with 0.1% bovine serum albumin (BSA) (w/v) was added to each 
well (930µl). 125 Iodine-labelled sCt (5 µCi, specific activity 2000 Ci per mmole, labelled at 
Tyr22) in its lyophilised form was reconstituted in 0.1 M HCl (200 µl) and aliquoted in 
eppendorf tubes (15 µl each), that were kept at –20 °C). For each 12-well plate, one aliquot 
containing 0.38 µCi was thawed at RT, diluted with assay buffer (245 µl) and used 
immediately. Twenty microliters of this solution of the tracer (0.03 µCi) were added to each 
well at room temperature and the plate was mixed by gentle shaking. Thereafter, solutions (50 
µl) of different peptide concentrations in assay buffer were added to the cells and following 
gentle mixing, cells were incubated for 1 hr at RT. Peptide solutions were freshly made prior 
to each experiment by diluting peptide stocks (~500 µM in 1mM HCl) in assay buffer. 
Binding to the calcitonin receptor was terminated by aspiration of the medium and washings 
of the cells with PBS (3 x 3 ml each time). Cells were scraped from the wells by short 
treatment (1 min) with 0.5 M NaOH (2 x 0.5 ml each time) and placed into plastic vials. 
Bound radioactivity was then measured using a γ-counter LKB Wallac 1282 CompuGamma 
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(Stockholm, Sweden). Specific binding was calculated as the difference between total binding 
(tracer alone) and non-specific binding (100 nM unlabelled sCt). 
 
4.2.12.3 Adenylate cyclase activation assay 
 
T47D cells were subcultured in 96-well plates two days prior the experiment (as described 
under 4.2.12.1). At the day of the experiment (~104 cells per 100 µl culture medium) the 
medium was removed. The cells were washed with PBS (200 µl) and then assay medium that 
consisted of RPMI 1640 with 0.1% BSA (w/v) was added (100 µl). Peptide solutions of 
different concentrations (freshly made and kept on ice) were added (100 µl) to the cells and 
incubations were performed for 15 min at 37 °C. Thereafter, the medium was removed and 
200 µl of cell lysis buffer 1B that consisted of 0.25% dodecyltrimethylammonium bromide 
(DTAB) in 0.05 M acetate buffer pH 5.8 with 0.02% w/v BSA were added to each well. An 
aliquot of the cell lysate containing solution (20 µl) was then diluted 25-fold with lysis buffer 
1B and then a sample (100 µl) was transferred to the EIA plate. In each well of the plate, 
rabbit antiserum (reconstituted with 11 ml lysis buffer 2B) was added (100 µl) and the 
solution was incubated for 2 hrs at 4 °C. Thereafter, the cAMP horseradish peroxidase-
conjugate was reconstituted in 11 ml assay buffer and 50 µl were added to each well and the 
plate was incubated for 1 hr at 4 °C. The solution was then removed from the wells, and the 
plate was thoroughly washed with 0.01 M phosphate buffer (pH 7.5) containing 0.05 w/v 
Tween 20. Residual liquid was removed by blotting the plate on tissue paper. Immediately 
thereafter 150 µl of the solution containing the enzyme substrate (solution consisted of 3,3´, 
5,5´-tetramethylbenzidine (TMB) / hydrogen peroxide in 20% v/v DMF) was added to all 
wells (a blue colour started to develop). The plate was mixed using a Rocky shaker (LTF 
Labortechnik, Wasserburg, Germany) for 20 min at RT, and the reaction was stopped (at 20 
min) by adding 1 M H2SO4 to all wells (100 µl). Thereafter the plate was placed in the Biorad 
3550 EIA reader (München, Germany) and the optical density at 450 nm was measured.  
 
4.2.12.4 Cytotoxicity assay for IAPP and IAPP analogue [2] 
 
The HTB14 human glioblastoma/astrocytoma cell line (American Type Culture Collection) 
was cultured in Dulbecco’s modified Eagle’s medium containing 10% heat-inactivated fetal 
bovine serum, 2 mM glutamine, and 0.1 mg / ml penicillin / streptomycin. Exponentially 
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growing cells were plated at a density of 1 x 105 cells / ml (100 µl / well). Following 
incubation for 24 hrs (37 °C, humidified atmosphere with 5 % CO2), serial dilutions of the 
peptide were made in cell culture medium and 11 µl added to the culture wells. The original 
peptide solution were 5 µM IAPP in 10 mM sodium phosphate buffer (pH 7.4) containing 1% 
1,1,1,3,3,3-hexafluro-2-propanol (HFIP). These solutions were incubated for 1 day at RT. 
Final concentrations of peptide in the wells were 50 and 5 nM. Cell viability was assessed 24 
hrs later by measuring the cellular reduction of 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) by measuring the absorbance at 595 nm. 
Complete inhibition of cell function (0% viability) was defined as the absorbance value 
obtained in wells containing 0.1% Triton X-100; 100% MTT reduction was defined as the 
absorbance value obtained upon the addition of the vehicle alone. For the calculation of cell 
viability (% of control) the following formula was used: 
 
 
% MTT reduction = [(Absample- Ab0.1 % Triton) / (Abmedium- Ab0.1 %  Triton) x 100 
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5 Results 
 
5.1 Design of calcitonin analogues 
 
The calcitonins from different species (i.e. human, salmon, eel, porcine) have a number of 
common structural features. These include a N-terminal disulfide loop linking cysteine 
residues 1 and 7, a potential amphiphilic α-helix between 8 and 22, and a C-terminal amide. 
In 1995, Kapurniotu and Taylor [22] designed, synthesized and studied three hCt analogues 
with lactam bridges joining the side-chains of residues 17 and 21 or the side-chains of 
residues 10 and 14. For these syntheses, residues Asn17 and Thr21 were replaced by Lys17 and 
Asp21, Asp17 and Lys21 and residues Gly10 and Gln14 by Lys10 and Asp14 resulting in the 
analogues: cyclo17,21-[Lys17, Asp21]hCt (1), cyclo17,21-[Asp17, Lys21]hCt (2) and cyclo10,14-
[Lys10, Asp14]hCt (3). These types of lactam-bridged structures were chosen on the basis of 
their α-helix potential as previously found for several peptide hormones and model 
amphiphilic α-helical peptides [70]. The analogues incorporated the lactam bridge in positions 
corresponding to the hydrophilic face of the helix, leaving the hydrophobic face intact and 
charged residues were not selected for substitution in order to keep the overall charge of the 
molecule unchanged. Peptide 2 showed an 80-fold higher potency than hCt in the [125I] sCt 
radioreceptor binding assay in rat brain membranes and a 10-fold increase in potency in the in 
vivo hypocalcemic assay in mice whereas the other two peptides (1) and (3) showed no 
significant increase in potency compared to hCt in either of these assays. However, 
correlations of the bioactivities with the solution conformations of the analogues as 
determined by circular dichroism (CD) indicated that a non-helical conformation might be 
important for bioactivity. The results indicated that a β-sheet / β-turn conformation that had 
been previously suggested by Motta et al. [37] for hCt residues 17-20 might correspond to the 
bioactive conformation of hCt.  
To further study the role of a potential β-turn structure for hCt bioactivity, Kapurniotu et al. 
[71] have recently devised the following hCt analogues: cyclo17,21-[Asp17, Orn21]hCt 
(CCcyclo), [Asp17, Orn21]hCt (CClinear), cyclo17,21-[Asp17, Dab21]hCt (DCcyclo), cyclo17,21-
[Asp17, Dap21]hCt (FCcyclo) and cyclo17,21-[Glu17, Dab21]hCt (GCcyclo) (Scheme 2, group 1). 
These analogues were designed to study the effect of ring-size of the lactam-bridge of 
residues 17 and 21 on hCt conformation and bioactivity. These analogues contained shorter 
rings than the 20-membered ring of cyclo17,21-[Asp17, Lys21]hCt (analog 1). This was achieved 
by replacing residue 21 by α,ω-diamino acid residues bearing side chains of various lengths. 
The results of the hypocalcemic assays showed dramatic effects of the various bridges on in 
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vivo hypocalcemic activity: CCcyclo was found to be ~ 400 times more potent than hCt and 4 
times more potent than sCt. By contrast, no increased potency was found for the control 
peptide CClinear indicating that the enhanced in vivo bioactivity was due to the 
conformational restriction introduced by the lactam-bridge of the side-chains. The 18-
membered ring containing DCcyclo was 30 times more potent than hCt, while the 17-
membered ring containing FCcyclo showed a similar bioactivity to hCt. In spite of having the 
same ring size as CCcyclo, GCcyclo was 74 times less potent than CCcyclo. These findings 
would argue for local conformational feature that is strongly related to the position of the 
βCO of Asn17 and that may play an important role for hCt bioactivity, whereas the low 
activity of GCcyclo could be due to the incapability of the γCO of Glu17 to involve into the 
same hydrogen bonding as Asn or Asp in a so called ‘Asx turn’ [72]. These data together with 
the results of the conformational analyses indicated that a stabilized type I β-turn/antiparallel 
β-sheet conformation in region [17-21] might be associated with hCt bioactivity (Figure 10). 
 
 
Figure 10. Schematic representation of the postulated lactam bridge-stabilized bioactive 
conformation in hCt between residues 17 and 21. The hydrogen bond, which might form 
between the side chain carbonyl of Asp17 and the αNH of Phe19, is indicated by the dashed 
line. 
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To study the importance of the topological features of the region between residues 17 and 21 
for bioactivity, and to test the hypothesis that a type I β-turn/β-sheet conformation in this 
region might be stabilized by the lactam bridge, several analogues of cyclo17,21-[Asp17, Lys21] 
hCt having type I and type II β-turn-stabilizing substitutions for residues 18 and 19, as well as 
non-bridged control peptides were designed [73] (Scheme 3, group 2). Based on previously 
reported NMR data [37], this postulated β-turn might be centered at residues 18 and 19.  
To study the effect of substituting residues in region [18-19] with amino acids that favor 
‘Asx-turn’ (such as Pro at position (i+1) / Ser at position (i+2) of the turn) [74] the following 
analogues of cyclo17,21-[Asp17, Orn21]hCt were designed: cyclo17,21-[Asp17, Pro18, Ser19, Orn21] 
hCt (HCcyclo) and cyclo17,21-[Asp17, Pro18, Orn21]hCt (ICcyclo) as well as the linear control 
peptides [Asp17, Pro18, Ser19, Orn21]hCt (HClinear) and [Asp17, Pro18, Orn21]hCt (IClinear) 
(Scheme 4, group 3). 
To study the role of the hydrogen bond forming ability of the Nα-H of Phe19, analogues 
cyclo17,21-[Asp17, (N-Me) Phe19, Orn21]hCt (QCcyclo) and [Asp17, (N-Me) Phe19, Orn21]hCt 
(QClinear) were designed (Scheme 5, group 4). These analogues incorporated a Nα-Me 
substitution at residue 19, that should abolish the potential hydrogen bond formation between 
the Nα-H of Phe19 and the side chain CO of residue 17 which has been also proposed by 
Kapurniotu et al. [71] to be related to in vivo bioactivity (Figure 10). 
To study the effect of distorting the backbone on bioactivity the βeta-peptides: cyclo17,21-
[βeta-Asp17, Orn21]hCt (βeta-CCcyclo) and cyclo17,21-[βeta-Asp17, (N-Me) Phe19, Orn21]hCt 
(βeta-QCcyclo) as well as their linear control peptides [βeta-Asp17, Orn21]hCt (βeta-CClinear) 
and [βeta-Asp17, (N-Me) Phe19, Orn21] (βeta-QClinear) were designed (Scheme 6, group 5). 
Also, hCt analogues [Dap17]hCt and [Dab17]hCt having Dap and Dab at position 17, 
respectively, were designed to provide additional insight into the importance of the side chain 
CO at position 17 for hCt bioactivity (Scheme 7, group 6). 
Finally, two peptides were designed that combined the presence of substituents that have been 
previously found by others to be important for bioactivity and the Asp / Orn lactam bridge of 
CCcyclo. These peptides were cyclo17,21-[Nle8, Leu12,16,19, Asp17, Orn21, Tyr22]hCt (TCcyclo) 
and [Nle8, Leu12,16,19, Asp17, Orn21, Tyr22]hCt (TClinear) (Scheme 8, group 7) that carried a 
Nle8 for Met8 substitution, that eliminates the possibility of oxidation of Met8, a Tyr22 for 
Phe22 substitution (since Tyr22 is present in the sCt sequence it has been suggested to be 
important for bioactivity), and Leu substitutents for the residues 12,16, and 19 that might 
occupy the hydrophobic face of the potential amphiphilic helix of hCt (because Leu12,16,19 are 
also present in sCt and have been linked to bioactivity) [75]. 
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Scheme 2. Primary structures of sCt, hCt and analogues of group 1 to study the effect of ring 
size on Ct bioactivity. 
  
                            17                  21 
CSNLSTCVLGKLSQELHis KLQThr YPRTNTGSGTP                        sCt 
 
 
                             17                  21 
CGNLSTCMLGTYTQDFAsn KFHThr FPQTAIGVGAP                      hCt 
 
 
                                     
CGNLSTCMLGTYTQDFAsp KFHLys FPQTAIGVGAP            analog 1 (20-member ring) 
 
                                               
                                     
CGNLSTCMLGTYTQDFAsp KFHOrn FPQTAIGVGAP           CCcyclo (19-member ring) 
 
 
                                     
CGNLSTCMLGTYTQDFAsp KFHDab FPQTAIGVGAP            DCcyclo (18-member ring) 
 
 
                                     
CGNLSTCMLGTYTQDFAsp KFHDap FPQTAIGVGAP            FCcyclo (17-member ring) 
 
 
                                     
CGNLSTCMLGTYTQDFGlu KFHDab FPQTAIGVGAP            GCcyclo (19-member ring) 
 
 
                               17                    21                                   
CGNLSTCMLGTYTQDFAsp KFHOrn FPQTAIGVGAP            CClinear 
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Scheme 3. Primary structures of sCt, hCt, analog 1 and analogues of group 2 to study the 
importance of β-turn stabilizing residues at positions 18,19 (substituents are shown in bold). 
 
                            17                   21 
CSNLSTCVLGKLSQELHis KLQThr YPRTNTGSGTP                                  sCt 
 
 
                              17                    21 
CGNLSTCMLGTYTQDFAsn KFHThr FPQTAIGVGAP                                 hCt 
 
 
                                     
CGNLSTCMLGTYTQDFAsp KFHLys FPQTAIGVGAP                              analog 1 
 
 
                                -      
CGNLSTCMLGTYTQDFAspK(D-Phe)HLys FPQTAIGVGAP                    ACcyclo 
 
 
                                      
CGNLSTCMLGTYTQDFAsp(Aib)FHLys FPQTAIGVGAP                         BCcyclo 
 
 
                                     
CGNLSTCMLGTYTQDFAsp(D-Lys)FHLys FPQTAIGVGAP                     ECcyclo 
 
 
                               17                                  21 
CGNLSTCMLGTYTQDFAsnK(D-Phe)HThr FPQTAIGVGAP                   OClinear 
         
 
                               17                                21 
CGNLSTCMLGTYTQDFAsn(D-Lys)FHThr FPQTAIGVGAP                    NClinear 
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Scheme 4. Primary structures of hCt, CCcyclo, CClinear, and analogues of group 3 designed 
to study the importance of an ‘Asx-turn’ in region 17-21. 
 
                              17                    21 
CGNLSTCMLGTYTQDFAsn KFHThr FPQTAIGVGAP                                hCt 
 
 
                                     
CGNLSTCMLGTYTQDFAsp KFHOrn FPQTAIGVGAP                            CCcyclo 
 
 
                                    
CGNLSTCMLGTYTQDFAsp KFHOrn FPQTAIGVGAP                            CClinear 
 
 
                              --      
CGNLSTCMLGTYTQDFAspProSerHOrn FPQTAIGVGAP                       HCcyclo 
 
 
                                    
CGNLSTCMLGTYTQDFAspProSerHOrn FPQTAIGVGAP                       HClinear  
 
 
                                     
CGNLSTCMLGTYTQDFAspProFHOrn FPQTAIGVGAP                           ICcyclo   
 
 
                                   
CGNLSTCMLGTYTQDFAspProFHOrn FPQTAIGVGAP                           IClinear  
 
 
Scheme 5. Primary structures of hCt and analogues of group 4 designed to study the 
importance of the H-bonding ability of the NH of Phe19. 
 
                               17                  21 
CGNLSTCMLGTYTQDFAsn KFHThr FPQTAIGVGAP                                hCt 
 
 
                                       
CGNLSTCMLGTYTQDFAsp K(N-Me)PheHOrn FPQTAIGVGAP            QCcyclo  
 
 
                                
CGNLSTCMLGTYTQDFAsp K(N-Me)PheHOrn FPQTAIGVGAP            QClinear  
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Scheme 6. Primary structures of hCt and βeta-analogues of group 5 designed to study the 
effect of moving the side chain CO at position 17 / or distorting the backbone of CCcyclo on 
bioactivity. 
 
                               17                  21 
CGNLSTCMLGTYTQDFAsn KFHThr FPQTAIGVGAP                                    hCt 
 
                                          -      
CGNLSTCMLGTYTQDF(βeta)AspKFHOrn FPQTAIGVGAP                      βeta-CCcyclo 
 
                                           
CGNLSTCMLGTYTQDF(βeta)Asp KFHOrn FPQTAIGVGAP                     βeta-CClinear 
 
                                                 
CGNLSTCMLGTYTQDF(βeta)AspK(N-Me)PheHOrn FPQTAIGVGAP     βeta-QCcyclo  
 
                                
CGNLSTCMLGTYTQDF(βeta)AspK(N-Me)PheHOrn FPQTAIGVGAP     βeta-QClinear 
 
 
 
Scheme 7. Primary structures of hCt and hCt analogues of group 6 to study the importance of 
the presence of the side chain CO at residue17. 
 
                                17                  21 
CGNLSTCMLGTYTQDFAsn KFHThrFPQTAIGVGAP                                     hCt 
 
 
                                17                  21 
CGNLSTCMLGTYTQDFDap KFHThrFPQTAIGVGAP                                  Dap17 hCt  
 
 
                                17                  21 
CGNLSTCMLGTYTQDFDab KFHThrFPQTAIGVGAP                                  Dab17 hCt  
 
 
Scheme 8. Primary structures of analogues of group 7 that were designed to study the 
importance of combined substitutions in the hydrophobic face of the potential α-helix; Nle8 
for Met8, Leu12,16,19 for Y12, F16, F19 and Y22 for F22.  
 
                                               
CGNLSTCNleLGTLeuTQDLeuAsp KLeuHOrnTyrPQTAIGVGAP                  TCcyclo     
   
 
                                  
CGNLSTCNleLGTLeuTQDLeuAspKLeuHOrnTyrPQTAIGVGAP                   TClinear     
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5.1.1 Peptide synthesis using Boc-SPPS for calcitonins 
 
All peptides of Table 22 were synthesized using p-methylbenzhydrylamine (MBHA) resin 
having a substitution level 0.57 mmole / gr. Residues [23-32] of hCt were single coupled (4-
fold excess for the protected amino acid and TBTU, 6-fold excess for DIEA) for 80 min, and 
the completeness of each coupling was checked by the Kaiser test. Cleavage of the Nα-Boc 
group was performed with 50% TFA in DCM, with the exception of Gln24 and Gln14 where 4 
N HCl in dioxane was employed. Intramolecular cyclization of N-terminal Gln to 
pyroglutamate is a frequent cause of chain termination in SPPS [76]. This side reaction is 
catalysed by weak acids such as Boc- amino acids and the TFA that is used for deprotection in 
Boc-SPPS. Ring closure has been found to be suppressed by the use of 4 N HCl in dioxane 
[77]. Following coupling of Met8, the cleavage mixture for Boc-group (50% TFA in DCM) 
contained 1% dimethylsulfide (DMS) as scavenger to prevent attachment of the tert-butyl 
cations to Met8 [78]. 
The side-chain lactam bridge formation between residues 17 and 21 was performed by the 
side chain-to-side chain cyclization strategy on the resin based on the method of Felix et.al. 
[21]. The base-labile side-chain protecting groups Fmoc / OFm were selectively cleaved by 
25% piperidine in DMF and cyclization was performed using BOP with DIEA (4-fold 
excess). The completeness of the cyclization was checked by the Kaiser test and subsequent 
capping of unreacted functional groups with Ac2O (10-fold excess) with DIEA (10-fold 
excess) was performed. 
The coupling of (N-Me) Phe19 (in QCcyclo) was performed once, using 3-fold excess of 
amino acid and TBTU and 4.5-fold excess for DIEA, but extensive coupling time (100 min) 
was employed. Residues [1-22] of the Ct sequences were single coupled (4-fold excess for the 
protected amino acid and TBTU, 6-fold excess for DIEA) for 90 min with Kaiser test 
performed after each coupling.  
The final cleavage of the peptides from the resin was achieved with anhydrous HF and the 
following scavengers were used: thioanisole (TAS), dimethylsulfide (DMS) and p-thiocresol. 
Peptides were obtained in their reduced form and the crude material was dissolved in 10% 
AcOH and analysed by RP-HPLC. Some of HPLC profiles of the products appeared to be 
quite broad. The reason for this could be the high aggregation potential of the peptides, the 
heterogeneous nature of the mixture, or formation of intermolecular S-S bond formation 
leading to covalently linked multimers. The crude material was oxidized (in the dark) under 
dilute conditions (3 x 10-4 M) in 0.5 M Gdn HCl in aqueous 0.1 M NH4HCO3. Oxidations 
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were usually complete after 1-2 hrs as indicated by RP-HPLC. The two forms of the peptides 
(reduced / oxidized) were separated by RP-HPLC on the basis of their different retention 
times (a shift of 1-1.5 min towards longer times for the oxidized form). A representative 
example of the two forms (reduced / oxidized) of peptide CCcyclo is shown: In Figure 11, the 
peak at 23.1 min is the reduced form of the peptide, and in Figure 12, the peak at 24.4 min is 
the oxidized form. In the case of peptide βeta-CCcyclo the two forms (reduced / oxidized) are 
shown: In Figure 13, the peak at 21.7 min is the reduced form of the peptide, and in Figure 14, 
the peak at 23.1 min is the oxidized form. Pure oxidized peptide was obtained usually in a 
yield of 5-10% with respect to the crude reduced material.  
The only difficulty that was encountered in the Boc-syntheses was the one during the 
synthesis of βeta-QCcyclo: the RP-HPLC trace (Figure 15) of the crude material dissolved in 
10% AcOH revealed the presence of two peaks: a peak at 21.7 min and another at 24.5 min. 
Upon oxidation under dilute conditions, both peaks were shifted towards longer times: 22.9 
min and 25.7 min respectively (Figure 16). According to MALDI-MS, the peak at 22.9 min 
was the correct product (expected [M+H]+: 3429.9, found [M+H]+: 3429.1), whereas the other 
peak was a deletion sequence (found [M+H]+: 3300.2). The missing residue (-129) was most 
probably Lys18, due to incomplete coupling of this residue to (N-Me) Phe19 (expected: 
3301.8).  
 
 
Table 22. Peptides synthesized by Boc-chemistry (in their oxidized form) and their mass (as 
determined by MALDI-MS).  
 
Short Name                             Sequence [M+H]
+ 
expected: 
[M+H]+ 
found: 
CCcyclo cyclo17,21-[Asp17, Orn21]hCt 3414,9      3414,0 
ACcyclo cyclo17,21-[Asp17, D-Phe19, Lys21]hCt 3428,9      3448,2§ 
QCcyclo cyclo17,21-[Asp17, (N-Me) Phe19, Orn21]hCt 3429,9      3433,9 
βeta-QCcyclo cyclo17,21-[βeta-Asp17, (N-Me) Phe19, Orn21]hCt 3429,9      3429,1 
βeta-CCcyclo cyclo17,21-[βeta-Asp17, Orn21]hCt 3414,9      3420,3 
 
§: [M+Na]+ adduct 3450,9 
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Figure 11. RP-HPLC analysis of crude CCcyclo (in reduced form) using gradient 1 on a C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 0.5 mg crude peptide in 
600 µl aqueous 10 mM HCl solution. 
 
 
 
Figure 12. RP-HPLC analysis of crude CCcyclo (in oxidized form) using gradient 1 on a C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 0.3 mg crude peptide in 
400 µl 0.5 M Gdn HCl in aqueous 0.1 M NH4HCO3 solution. 
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Figure 13. RP-HPLC analysis of crude βeta-CCcyclo (in reduced form) using gradient 1 on a 
C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 1.1 mg crude peptide in 
1 ml aqueous 10% AcOH solution. 
 
 
Figure 14. RP-HPLC analysis of crude βeta-CCcyclo (in oxidized form) using gradient 1 on a 
C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 0.8 mg crude peptide in 
1.4 ml 0.5 M Gdn HCl in aqueous 0.1 M NH4HCO3 solution. 
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Figure 15. RP-HPLC analysis of crude βeta-QCcyclo (in reduced form) using gradient 1 on a 
C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 1 mg crude peptide in 1 
ml aqueous 10% AcOH solution. 
 
 
 
Figure 16. RP-HPLC analysis of crude βeta-QCcyclo (in oxidized form) using gradient 1 on a 
C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 0.2 mg crude peptide in 
300 µl 0.5 M Gdn HCl in aqueous 0.1 M NH4HCO3 solution. 
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5.1.2 Peptide synthesis using Fmoc-SPPS for calcitonins 
 
The peptides synthesized by Fmoc-chemistry are summarized in Table 23. Fmoc-SPPS was 
performed using the Rink amide MBHA resin (substitution level: 0.49 mmole / gr). Fmoc-
protected amino acids (4-fold excess) were coupled using 4-fold excess TBTU and 6-fold 
excess DIEA for 45 min with the exception for the C-terminal amino acid. Couplings were 
done twice. The side chain-to-side-chain cyclization between residues 17 and 21 was 
performed on the resin support [21]. The very acid labile side-chain protecting groups 4-
methyltrityl (Mtt) / 1-(1´-adamantyl)-1-methyl-ethoxycarbonyl (Adoc) were used for residue 
21 and 2-phenyl isopropyl ester (Opip) for residue 17 and were selectively cleaved with TFA 
(1% v/v) in DCM. Under these conditions the other side-chain protecting groups remained 
intact. 5% TIS was included in the mixture to quench the trityl cations. The cyclization was 
performed using 4-fold excess of BOP in the presence of 4-fold excess of DIEA in DMF. 
Cyclization reactions were complete according to Kaiser test after 1 x 4 hrs; 1 x 15 hrs and 
acetylation (10-fold excess for Ac2O / DIEA) of the unreacted amino groups was carried out 
as standard part of the methodology.  
Cys residues were coupled using a different coupling method from the method used for the 
other residues. The reason for this is that DIEA catalyzed coupling methods can lead to 
considerable amounts of racemization of Fmoc-Cys(Trt) residues during the activation / 
coupling process [61]. Therefore, the activation of Cys was carried out under neutral conditions 
in a medium free of base, using 4-fold excess of HOBt and 4-fold excess of DIC in DMF (45 
min at 4 °C). The solution was then added to the Nα-deprotected peptide resin and left to react 
for 1 hr (second coupling followed according to the same method). Acetylation after 
incorporation of Cys7 was carried out in the syntheses of CCcyclo, HCcyclo, HClinear, 
ICcyclo, IC linear, TCcyclo and TClinear.  
Cleavage of the peptides from the resin was achieved using a slight modidication of reagent K 
[67] for 3 hrs at RT. The elution profiles of the crude products were of good purity with regard 
to the main product. Depending on the sequence that was constructed several deletion 
sequences were also detected. In several syntheses (e.g. DCcyclo, ECcyclo, QCcyclo, 
CClinear, HClinear) the main product (reduced form) co-eluted with a by-product missing 
100 mass units (as was determined by MALDI-MS). Upon air oxidation (as described under 
5.1.1) of the crude material the two products were resovled (the main product shifted to longer 
retention times, where the by-product eluted at the initial retention time). This 
chromatographic behaviour in combination with the mass difference detected by the MALDI-
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MS suggested that the missing residue was a cysteine (most probably Cys1). In other 
syntheses (such as BCcyclo, [Dap17]hCt, TCcyclo, TClinear) the missing cysteine residue was 
also a problem and additionally a second by-product that corresponded to a peptide missing 
57 mass units was detected (probably Gly2). This indicated that the couplings in this region of 
the polypeptide were difficult as compared to the other residues in the sequence. RP-HPLC 
purification was usually sufficient to isolate the main product in yields between 5-10% with 
regard to the crude peptide. Characterization was performed by MALDI-MS and retention 
times in RP-HPLC.  
In Figure 17, the RP-HPLC profile of crude CCcyclo (reduced form, peak at 22.5 min) after 
cleavage and lyophilization is shown. In Figure 18, the RP-HPLC trace of CCcyclo (oxidized 
form, peak at 24.0 min) is shown. 
Both chemistries (Fmoc- and Boc-) proved to be reliable methods for the solid phase 
synthesis of the analogues. Fmoc-chemistry was preferred since it is easier by this method to 
remove peptide / and side-chain protecting groups than by Boc-chemistry. In Figure 19 an 
analytical run of RP-HPLC purified CCcyclo synthesized by Boc-chemistry is shown. In 
Figure 20 an analytical run of the same peptide synthesized by Fmoc-chemistry is shown.  
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Table 23. Peptides synthesized by Fmoc-chemistry (in their oxidized form) and their mass (as 
determined by MALDI-MS).  
 
Short Name                          Sequence [M+H]
+ 
expected: 
[M+H]+ 
found: 
analog 1 cyclo17,21-[Asp17, Lys21]hCt 3428,9      3437,2 
CCcyclo cyclo17,21-[Asp17, Orn21]hCt 3414,9      3413,7 
DCcyclo cyclo17,21-[Asp17, Dab21]hCt 3400,9      3399,2 
FCcyclo cyclo17,21-[Asp17, Dap21]hCt 3386,9      3388,1 
GCcyclo cyclo17,21-[Glu17, Dab21]hCt 3414,9      3434,4# 
CClinear [Asp17, Orn21]hCt 3432,9      3431,2 
ACcyclo cyclo17,21-[Asp17, D-Phe19, Lys21]hCt 3428,9      3448,2§ 
BCcyclo cyclo17,21-[Asp17, Aib18, Lys21]hCt 3386,9      3386,5 
ECcyclo cyclo17,21-[Asp17, D-Lys18, Lys21]hCt 3428,9      3449,3§ 
OClinear [D-Phe19]hCt 3418,9      3418,9 
NClinear [D-Lys18]hCt 3418,9      3417,9 
HCcyclo cyclo17,21-[Asp17, Pro18, Ser19, Orn21]hCt 3323,9      3322,2 
HClinear [Asp17, Pro18, Ser19, Orn21]hCt 3341,9      3339,7 
ICcyclo cyclo17,21-[Asp17, Pro18, Orn21]hCt 3383,9      3382,9 
IClinear [Asp17, Pro18, Orn21]hCt 3401,9      3405,3 
QCcyclo cyclo17,21-[Asp17, (N-Me) Phe19, Orn21]hCt 3429,9      3433,9 
QClinear  [Asp17, (N-Me) Phe19, Orn21]hCt 3447,9      3445,6 
βeta-CClinear [βeta-Asp17, Orn21]hCt 3432,9      3438,1 
βeta-QClinear [βeta-Asp17, (N-Me) Phe19, Orn21]hCt 3447,9      3446,5 
Dap17 linear [Dap17]hCt 3389,9      3389,4 
Dab17 linear [Dab17]hCt 3403,9      3403,5 
TCcyclo cyclo17,21-[Nle8, Leu12,16,19, Asp17, Orn21]hCt 3294,9      3297,7 
TClinear [Nle8, Leu12,16,19, Asp17, Orn21]hCt 3312,9      3316,9 
 
#: [M+Na]+ adduct 3436,9  
§: [M+Na]+ adduct 3450,9 
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Figure 17. RP-HPLC analysis of crude CCcyclo (in reduced form) using gradient 1 on a C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 0.9 mg crude peptide in 1 
ml aqueous 10% AcOH solution (the peak at 14.8 min is due to scavenger phenol form the 
cleavage mixture). 
 
 
Figure 18. RP-HPLC analysis of crude CCcyclo (in oxidized form) using gradient 1 on a C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 1 mg crude peptide in 1 ml 
1.5 M Gdn HCl in aqueous 0.1 M NH4HCO3 solution (the peak at 15.2 min is due to 
scavenger phenol form the cleavage mixture). 
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Figure 19. Analytical run of HPLC purified and oxidized CCcyclo (synthesized by Boc-
chemistry) using gradient 1 on a C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 30 µg pure peptide in 300 µl aqueous 10% AcOH solution. 
 
 
Figure 20. Analytical run of HPLC purified and oxidized CCcyclo (synthesized by Fmoc-
chemistry) using gradient 1 on a C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 30 µg pure peptide in 300 µl aqueous 10% AcOH solution. 
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5.1.3 Binding to the calcitonin receptor  
 
Several of the biological activities of the Cts are thought to be mediated via binding to a 
receptor that belongs to the family of G-protein coupled receptors [79]. Ct-receptors are 
localized in bone and kidney as well as in the central nervous system, i.e. the brain. High 
affinity receptors for Cts exist in some cell lines including the human breast cancer cell line 
T47D. Peptide receptor binding affinities were assayed in the T47D cell line and compared to 
the affinity of sCt which is the strongest known naturally occurring ligand and hCt which is a 
weak ligand. The assay was based on the competitive inhibition of 125I-sCt (15 nM) by the 
analogues. All analogues were assayed in the range 0.01-100 nM in at least two independent 
experiments and in each experiment each concentration was assayed in duplicate. The specific 
binding of the peptides was the difference between total binding (radioligand alone) and non-
specific binding. The latter was determined as the binding of 10 nM sCt and was assessed 
from 13 independent experiments to be 12.94% (± 3.59). 
Receptor binding affinities were calculated as IC50 values (concentration of Ct analogue that 
displaces 50% of bound radioligand from the receptor). Binding of the analogues was 
compared to sCt-binding (IC50 = 0.8 nM) and hCt-binding (IC50 = 4.46 nM), which showed an 
affinity that was six-fold lower than the sCt affinity. As shown in Figure 21, analog 1 with an 
IC50 = 2.45 nM and CCcyclo with an IC50 = 1.73 nM had three-fold and two-fold respectively 
lower binding affinities than sCt. However, both peptides bound better to the receptor as hCt. 
The 18-membered ring containing analogue DCcyclo (IC50 = 9.57 nM) bound weaker than 
hCt, while the 17-membered ring containing analogue FCcyclo nearly did not bind at all. 
These results indicated that further constraining the lactam bridge than in CCcyclo had a 
negative effect on the binding affinity of the peptides. CClinear did not bind at all. This result 
indicated that the exchanging of residues Asn17 and Thr21 by Asp17 and Orn21 results in a 
complete abolishment of receptor binding. On the other hand the introduction of a lactam 
bridge between the side chains of these residues (in CCcyclo) leads to a strongly enhanced 
binding. Of interest, the peptide GCcyclo (IC50 = 2.18 nM) was as potent as CCcyclo. Since 
both peptides had the same ring size (19-membered ring) but different residues constituted the 
lactam bridge (Glu17 / Dab21 instead of Asp17 / Orn21), this result suggested that these 
substitutions are compatible with receptor binding affinity. 
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Figure 21. Human Ct receptor binding of hCt, sCt and bridged analogues of group 1 to T47D 
cells assessed via displacement of bound 125I-labelled sCt. Specific radioligand binding is 
plotted vs. the concentration of competing hCt, sCt and analogues as indicated. Binding 
isotherms are mean ± SD for two to three independent experiments (each of them performed 
in duplicate) and the data for sCt and hCt are the mean of 14, respectively, 13 experiments. 
 
The second group of peptides consisted of bridged and non-bridged substitution analogues of 
analog 1. The aims of the receptor binding studies with these analogues was to identify the 
topologically important features of residues in region 18 to 20 of the Ct sequence, including 
the role of chirality of residues 18 and 19, for bioactivity. According to the obtained results 
(Figure 22), peptides ACcyclo (IC50 = 3.46 nM), BCcyclo (IC50 = 3.31 nM) and ECcyclo 
(IC50 = 4.67 nM) had slightly lower binding affinities as compared to analog 1 (IC50 = 2.45 
nM). The significance of the chirality for L-Lys18 for receptor binding was further confirmed 
by the comparison of the binding activities of the non-bridged analogues OClinear and 
NClinear. Those analogues had one substitution as compared to hCt. OClinear (IC50 = 17.78 
nM) had significantly less binding affinity than hCt, while NClinear showed nearly no 
binding. These data indicated that the D-Phe19 substitution for L-Phe19 (in OClinear) was only 
partially compatible with hCt activity whereas the D-Lys18 substitution for L-Lys18 (in 
NClinear) strongly affected receptor binding affinity.  
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Figure 22. Human Ct receptor binding of hCt, sCt and analogues of group 2 to T47D cells 
assessed via displacement of bound 125I-labelled sCt. Specific radioligand binding is plotted 
vs. the concentration of competing hCt, sCt and analogues as indicated. Binding isotherms are 
mean ± SD for two to three independent experiments (each of them performed in duplicate) 
and the data for sCt and hCt are the mean of 14, respectively, 13 experiments. 
 
The third group of peptides consisted of substitution analogues of CCcyclo and CClinear and 
provided additional insight in the structural features of bioactivity of the agonist CCcyclo. 
These peptides had one substitution (Pro18 for Lys18 in ICcyclo / IClinear) or two substitutions 
(Pro18 for Lys18 and Ser19 for Phe19 in HCcyclo / HClinear) as compared to CCcyclo. With the 
exception of ICcyclo (IC50 = 64.56 nM), which showed an extremely weak binding behaviour, 
the other three peptides showed almost no binding (Figure 23). The results showed that 
exchanging of Lys18 and Phe19 by the ‘Asx-turn’ compatible residues Pro18 and Ser19, strongly 
affected the binding affinity of CCcyclo. 
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Figure 23. Human Ct receptor binding of hCt, sCt, CCcyclo, CClinear and analogues of 
group 3 to T47D cells assessed via displacement of bound 125I-labelled sCt. Specific 
radioligand binding is plotted vs. the concentration of competing hCt, sCt and analogues as 
indicated. Binding isotherms are mean ± SD for two to three independent experiments (each 
of them performed in duplicate) and the data for sCt and hCt are the mean of 14, respectively, 
13 experiments. 
 
Next, the binding affinities of peptides QCcyclo and QClinear (group 4) were studied and 
compared with the ones of CCcyclo and CClinear (Figure 24). Both QCcyclo and QClinear 
showed nearly no binding. The results suggested that the Nα-H of Phe19 is very important for 
receptor binding and/or that the presence of the methyl group was not compatible with 
receptor binding. The group of βeta-peptides (group 5), βeta-CCcyclo / βeta-CClinear and 
βeta-QCcyclo / βeta-QClinear was then studied and compared to CCcyclo / CClinear (Figure 
25). In this group, the backbone of the peptides was distorted by the extra methylene group 
present and the bridge between the side-chains in the cyclo analogues was also shorter by one 
methylene (-CH2-) than in the previous normal peptides. Again, all βeta-peptides showed no 
binding, which indicated a very important role for the region [17-21] in receptor binding. 
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Figure 24. Human Ct receptor binding of hCt, sCt, CCcyclo, CClinear and analogues of 
group 4 to T47D cells assessed via displacement of bound 125I-labelled sCt. Specific 
radioligand binding is plotted vs. the concentration of competing hCt, sCt and analogues as 
indicated. Binding isotherms are mean ± SD for two to three independent experiments (each 
of them performed in duplicate) and the data for sCt and hCt are the mean of 14, respectively, 
13 experiments. 
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Figure 25. Human Ct receptor binding of hCt, sCt, CCcyclo, CClinear and analogues of 
group 5 to T47D cells assessed via displacement of bound 125I-labelled sCt. Specific 
radioligand binding is plotted vs. the concentration of competing hCt, sCt and analogues as 
indicated. Binding isotherms are mean ± SD for two to three independent experiments (each 
of them performed in duplicate) and the data for sCt and hCt are the mean of 14, respectively, 
13 experiments.  
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Next, receptor binding of the non-bridged hCt analogues Dap17 and Dab17 (group 6) was 
determined in order to study the importance of the carbonyl group at position 17 (Figure 26). 
Thereby, peptide [Dab17]hCt had almost no receptor binding, while [Dap17]hCt showed a 
weak (IC50 = 39.8 nM) binding to the receptor. These results indicated that: a) the CO 
function of the side-chain of residue Asn17 is very important for binding and b) also the amino 
group of the side-chain of residue 17 and its topology may play a role in binding.  
Peptides TCcyclo and TClinear (group 7) were designed to study the collective effect of the 
lactam bridge of CCcyclo and the exchange of aromatic residues Tyr12, Phe16, Phe19 by Leu, 
which are the residues present at these positions in the sCt sequence. TCcyclo (IC50 = 2.63 
nM) exhibited a somewhat reduced affinity as compared to CCcyclo. Similarly, TClinear 
(IC50 = 6.76 nM) was slightly less potent than hCt (Figure 27). 
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Figure 26. Human Ct receptor binding of hCt, sCt, and analogues of group 6 to T47D cells 
assessed via displacement of bound 125I-labelled sCt. Specific radioligand binding is plotted 
vs. the concentration of competing hCt, sCt and analogues as indicated. Binding isotherms are 
mean ± SD for two to three independent experiments (each of them performed in duplicate) 
and the data for sCt and hCt are the mean of 14, respectively, 13 experiments. 
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Figure 27. Human Ct receptor binding of hCt, sCt, CCcyclo, CClinear and analogues of 
group 7 to T47D cells assessed via displacement of bound 125I-labelled sCt. Specific 
radioligand binding is plotted vs. the concentration of competing hCt, sCt and analogues as 
indicated. Binding isotherms are mean ± SD for two to three independent experiments (each 
of them performed in duplicate) and the data for sCt and hCt are the mean of 14, respectively, 
13 experiments. 
 
5.1.4 Activation of the adenylate cyclase (AC) 
 
hCt binding to receptors of T47D cells results in activation of the adenylate cyclase (AC) [80]. 
Thus the initial event following binding of Cts to their T47D cell receptors is the increase in 
intracellular cAMP levels. cAMP acts as a signal transducer (second messenger) by 
modifying the rates of various enzyme-catalyzed reactions [81]. The increase in the level of 
cAMP is due to an activation of the adenylate cyclase. The ability of a receptor ligand to 
regulate adenylate cyclase and increase cAMP production is closely associated with its 
receptor agonist potential [82]. Therefore, the synthetic analogues were next tested with regard 
to the activation of AC. 
The EIA assay that was applied selectively measures intracellular cAMP levels following 
peptide binding to the membrane receptors. The assay is based on the competition between 
unlabelled cAMP and a fixed quantity of peroxidase-labelled cAMP for a limited number of 
binding sites of a cAMP specific antibody which is coated on the ELISA plates (Scheme 9). 
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The studies aimed at determining the concentration of peptides that caused the half maximal 
elevation of cAMP (EC50) as compared to the maximal activation, which would be a measure 
of agonist potency of the synthesized analogues. Thereby, the weakest agonist was expected 
to cause only a weak increase in the cAMP levels resulting in more bound peroxidase-labelled 
cAMP. This, in turn, would upon treatment with the TMB substrate give blue colour and 
enhanced absorbance at 450 nm. The basal concentration of cAMP was estimated by 
treatment of the cells in cell assay medium without peptide. The maximum level of cAMP 
was determined by treatment with 100 nM hCt. The percentage of maximum adenylate 
cyclase (AC) activation was estimated using the formula: 
 
% maximum AC activation = [(Absample – Abbasal) / ( Ab100 nM hCt - Abbasal)] x 100  
 
All analogues were tested in a concentration range between 0.01 and 100 nM in two 
independent experiments (each time in duplicate), with the exception for the standards sCt 
and hCt which were tested three times. 
 
Scheme 9. EIA assay based on the competition between unlabelled cAMP (induced by 
peptide treatment) and a fixed quantity of peroxidase-labelled cAMP for a limited number of 
binding sites of a cAMP specific antibody [83]. 
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All analogues were compared to sCt which was the most potent ligand (EC50 = 0.03 nM) and 
hCt which had two-fold lower potency than sCt (EC50 = 0.072 nM). In the first group of 
peptides (Figure 28), the most active was CCcyclo (EC50 = 0.048 nM) followed by the other 
analogues in the order of: hCt = analog 1 (EC50 = 0.075 nM) > GCcyclo (EC50 = 0.154 nM) ≥ 
DCcyclo (EC50 = 0.177 nM) >>> FCcyclo (EC50 = 7.07 nM) >> CClinear (EC50 = 37.32 nM). 
Interestingly, CCcyclo was three times more potent than GCcyclo, though both peptides had 
19-membered ring size. CClinear only weakly activated AC, which suggested that the lactam 
bridge is very important for both binding of the peptide to the receptor and the subsequent 
activation of the AC. 
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Figure 28. Activation of adenylate cyclase in T47D cells by analogues of group 1. Adenylyl 
cyclase activation above basal levels is plotted as a function of peptide concentration (on a log 
scale). Each point is the mean ± SD of two independent assays (performed in duplicate). 
 
All analogues of the second group were less potent than analog 1 and native hCt (Figure 29). 
The order of the potencies was the following: hCt (EC50 = 0.072 nM) = analog 1 (EC50 = 
0.075 nM) ≥ ACcyclo (EC50 = 0.095 nM) ≥ ECcyclo (EC50 = 0.177 nM) ≥ BCcyclo (EC50 = 
0.234 nM) > OClinear (EC50 = 0.478 nM) >>> NClinear (EC50 = 10 nM). Thus, the presence 
of D-residues in the analogues affected the activation of the AC with the substitution D-Phe19 
for L-Phe19 being better tolerated than the substitution of D-Lys18 for L-Lys18. The non-
bridged analogues OClinear and NClinear only weakly induced AC activation.  
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Figure 29. Activation of adenylate cyclase in T47D cells by analogues of group 2. Adenylyl 
cyclase activation above basal levels is plotted as a function of peptide concentration (on a log 
scale). Each point is the mean ± SD of two independent assays (performed in duplicate). 
 
The third group of peptides with ‘Asx-turn’ compatible residues at positions 18, 19 (Pro18, 
Ser19), exhibited extremely low potencies. Moreover, only the cyclo analogues: ICcyclo (EC50 
= 3.71 nM) and HCcyclo (EC50 = 27.5 nM) activated AC, whereas the linear anlogues were 
completely devoid of activity (Figure 30). This was in agreement with the previously found 
lack of receptor binding (see 5.1.3). 
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Figure 30. Activation of adenylate cyclase in T47D cells by analogues of group 3. Adenylyl 
cyclase activation above basal levels is plotted as a function of peptide concentration (on a log 
scale). Each point is the mean ± SD of two independent assays (performed in duplicate). 
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In the fourth group of peptides, only QCcyclo (EC50 = 1.73 nM) showed AC activation 
potency. By contrast, QClinear was extremely (as CClinear) low in activity (Figure 31). In 
QCcyclo the presence of (N-Me) Phe19 residue, which is postulated to destroy a potential 
hydrogen bond between residues 17 and 19, was the main cause for the reduced activity 
compared to CCcyclo (see 5.1.3). 
 
The same low potency was observed for analogues of the fifth group of peptides. In this group 
all the βeta-peptides (cyclo / linear analogues) exhibited low AC potencies (Figure 32). These 
results indicated that the extra methylene group (-CH2-) in the backbone of these analogues 
was related to their extremely low potency. 
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Figure 31. Activation of adenylate cyclase in T47D cells by analogues of group 4. Adenylyl 
cyclase activation above basal levels is plotted as a function of peptide concentration (on a log 
scale). Each point is the mean ± SD of two independent assays (performed in duplicate).  
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Figure 32. Activation of adenylate cyclase in T47D cells by analogues of group 5. Adenylyl 
cyclase activation above basal levels is plotted as a function of peptide concentration (on a log 
scale). Each point is the mean ± SD of two independent assays (performed in duplicate).  
 
Next, the hCt analogues with the substitution Dap17 / Dab17 for Asn17 (group 6) were tested 
and found to exhibit significantly lower AC activation potency than hCt (Figure 33). Peptide 
[Dap17]hCt (EC50 = 0.512 nM) was seven-fold less potent than hCt, where [Dab17]hCt (EC50 = 
19 nM) was thirty seven times less potent than [Dap17]hCt. The results confirmed again that: 
a) the CO function of the side-chain of residue 17 is very important for AC activation and b) 
also the amino group of the side-chain of residue 17 and its topology play a role in AC 
activation. 
 
The two peptides of group 7 bearing hydrophobic substitutions (Leu12,16,19) for the aromatic 
amino acids and Tyr22 for Phe22 and Nle8 for Met8 were then examined (Figure 34). TCcyclo 
(EC50 = 0.038 nM) was almost as active as sCt, whereas the unbridged TClinear (EC50 = 
0.275 nM) was seven times less active than sCt and almost four times less active than hCt. 
However, TClinear was hundred thirty five times more active than CClinear. The findings 
showed that: a) the decreased receptor binding affinity of TCcyclo as compared to sCt did not 
affect its AC activation and b) the hydrophobic residues and Tyr22 were important for the AC 
activation. 
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Figure 33. Activation of adenylate cyclase in T47D cells by analogues of group 6. Adenylyl 
cyclase activation above basal levels is plotted as a function of peptide concentration (on a log 
scale). Each point is the mean ± SD of two independent assays (performed in duplicate).  
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Figure 34. Activation of adenylate cyclase in T47D cells by analogues of group 7. Adenylyl 
cyclase activation above basal levels is plotted as a function of peptide concentration (on a log 
scale). Each point is the mean ± SD of two independent assays (performed in duplicate). 
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5.2 Design of IAPP analogues 
 
To date there is yet no experimental structural model of amyloid fibrils of complete sequence 
IAPP available. IAPP [20-29] or SNNFGAILSS is a partial IAPP fragment that is able to 
form amyloid fibrils. This partial IAPP sequence has been broadly applied as a model IAPP 
sequence to identify the molecular determinants of IAPP amyloidogenicity at the level of 
primary and secondary structure [84].  
According to studies by Griffiths and Lansbury [85], IAPP [20-29] fibrils have a highly pleated 
β-sheet structure between Gly24 and Ile26. According to this model (Scheme 10), the β-sheet 
core of the amyloid fibrils consists of two antiparallel β-sheet strands each of them containing 
residues IAPP [23-27]. The β-sheet places the side chains of Gly24, Ile26 and Ser28 on one face 
of the sheet and the side chains of Phe23, Ala25, Leu27 and Ser29 on the other side. This model 
has been confirmed by studies of Tenidis et al. [86], who showed that the short fragment IAPP 
[23-27] or FGAIL is able to form amyloid fibrils.  
 
 
 
Scheme 10. (A) Proposed model of the Asn22-Ser28 region of the intermolecular, antiparallel 
β-sheet of the amyloid core. The arrows on the left indicate the direction of the β-strands. (B) 
Hypothetical mechanism of inhibition of the lateral extension of the β-sheet model in (A) via 
selective N-methylation of Gly24 and Ile26 [87].  
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Based on the above model of IAPP fibril, FGAIL and other short amyloid forming fragments 
of IAPP were N-methylated at Gly24 and Ile26 [87]. The approach aimed at transforming these 
β-sheet prone, amyloidogenic and cytotoxic sequences into non-amyloidogenic and non-
cytotoxic ones. In fact, the selective N-methylation of residues Gly24 and Ile26 in the short 
amyloid core IAPP sequences resulted in a complete abolishment of β-sheet, amyloid forming 
and cytotoxic properties of the native sequences.  
Based on these results, the strategy of selective N-methylation of amide bonds was next 
applied to full sequence IAPP (in this work IAPP refers to hIAPP sequence) (Scheme 11). 
From the synthetic point of view, however, incorporation of N-methyl residues in peptide 
sequences has proven often to be a very difficult test due to insufficient coupling yields [88], or 
cleavage of amide bonds [89]. In addition, as the N-methyl residues were to be incorporated 
into amyloid core sequences, it was expected that the synthetic problems would increase. 
Therefore, a detailed study of the synthesis of 5 novel N-methylated IAPP analogues was 
undertaken. The N-methyl residues were designed to ‘occupy’ the one side of the potential β-
strand of the IAPP [23-27] amyloid core sequence in analogues: [(N-Me) Phe23, (N-Me) 
Ala25] IAPP [1], [(N-Me) Gly24, (N-Me) Ile26] IAPP [2], and [(N-Me) Ala25, (N-Me) Leu27] 
IAPP [3]. In analogue [(N-Me) Ile26, (N-Me) Leu27] IAPP [4] it was attempted to introduce 
two consequent and in analogue [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [5] three 
consequent N-methyl residues. Full sequence IAPP which is due to its exceptionally high 
amyloid-forming potential a very difficult synthetic task was also synthesized. In addition, an 
IAPP mutant S20G-IAPP [6] that has been associated with the early appearance of Type II 
diabetes in Japanese and has been reported to have even stronger amyloidogenic properties 
than IAPP [90] was synthesized. The structures of the synthesized analogues are shown in 
Scheme 11.  
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Scheme 11. Primary structures of IAPP, the N-methylated IAPP analogues [1] – [5] that were 
synthesized in this work, and analogue [6] with the S20G mutation. IAPP has a C-terminal 
amide which is not shown. The introduced substituents are shown in bold and the (N-Me) 
amino acids are shown using the three letter code.  
 
             10                        20                       30 
KCNTATCATQ RLANFLVHSS NNFGAILSST NVGSNTY     
 IAPP 
 
                                                             23                 25 
KCNTATCATQRLANFLVHSSNN(NMe)PheG(NMe)AlaILSSTNVGSNTY     
   [(N-Me) Phe23, (N-Me) Ala25] IAPP [1] 
 
                                                               24                26 
KCNTATCATQRLANFLVHSSNNF(NMe)GlyA(NMe)IleLSSTNVGSNTY     
     [(N-Me) Gly24, (N-Me) Ile26] IAPP [2] 
 
                                                                 25                 27 
KCNTATCATQRLANFLVHSSNNFG(NMe)AlaI(NMe)LeuSSTNVGSNTY     
   [(N-Me) Ala25, (N-Me) Leu27] IAPP [3] 
 
                                                                    26              27 
KCNTATCATQRLANFLVHSSNNFGA(NMe)Ile(NMe)LeuSSTNVGSNTY     
    [(N-Me) Ile26, (N-Me) Leu27] IAPP [4] 
 
                                                                  25             26              27 
KCNTATCATQRLANFLVHSSNNFG(NMe)Ala(NMe)Ile(NMe)LeuSSTNVGSNTY     
   [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [5] 
 
             10                            20                       30                   
KCNTATCATQ RLANFLVHSGly NNFGAILSST NVGSNTY                    
                                                                             S20G-IAPP [6] 
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5.2.1 Synthesis of IAPP  
 
As IAPP contains a C-terminal amide function, the synthesis was performed on Rink Amide 
MBHA resin (substitution level: 0.28 mmole / gr with regard to the C-terminal amino acid 
Tyr). The intended ‘dilution’ of the resin (0.2-0.3 mmole total amino groups) was achieved 
during the loading of the C-terminal Tyr. The synthesis was performed manually using DMF 
for washings and couplings, whereas a 25% solution of piperidine in DMF was used for the 
deprotection of the Fmoc-group. All couplings were performed twice, with an in situ 
activation protocol: briefly, Fmoc-amino acid (4-fold excess with regard to the mmoles of C-
terminal Tyr) and TBTU (4-fold excess) were dissolved in DMF followed by the addition of 
DIEA (6-fold excess) in this activation mixture. The mixture was then added to the Nα-
deprotected resin. Each coupling cycle was 60-90 min and completeness of the couplings was 
checked by the Kaiser test (for residues in the region IAPP [17-37]). The C-terminal ten 
residues IAPP [28-37] or SSTNVGSNTY were coupled without any difficulty and the 
identity of the correct decapeptide on the resin was confirmed by cleavage of a small amount 
of the peptide resin and characterization of the product by RP-HPLC (retention time) and 
MALDI-MS. Cys2 and Cys7 were coupled by the HOBt-ester coupling method as described 
for the Ct sequences. Accordingly, AA activation was performed by HOBt / DIC (in 
equimolar amounts to the amino acid) at 4 °C for 45 min as described. The activation mixture 
was added to the Nα-deprotected peptide resin and left to react for 90 min, followed by a 
second coupling using the same method. No acetylations were performed throughout the 
synthesis. 
The progress of the synthesis was evaluated by cleavage at position 19. After incorporation of 
residue Ser19, a small sample of peptide resin was subjected first to Fmoc-cleavage and then 
to a mixture of TFA / H2O (95/5 v/v) (2 hrs, RT). Following filtration of the resin, the 
solution was subjected to RP-HPLC analysis (Figure 35). MALDI-MS showed that the peak 
at 16.9 min had the expected mass for IAPP [19-37] (Figure 36): ([M+H]+ expected: 1933.1, 
found: 1935.2). The RP-HPLC profile of IAPP [19-37] also indicated that the synthesis 
proceded in good yields up to residue 19.  
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Figure 35. RP-HPLC analysis of crude IAPP [19-37] using gradient 2 on C18 column, flow 
rate 2 ml / min and detection at 214 nm. Injection of 0.2 mg crude peptide in 100 µl aqueous 
10% TFA solution. 
 
  
Figure 36. MALDI-MS of HPLC-purified peak at 16.9 min (see Figure 35) from crude IAPP 
[19-37]. 
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Residues 18 to1 were coupled using the same protocol as above. There was no Kaiser test 
after the coupling / deprotection step; only before and after the coupling of the Cys2 and Cys7 
a Kaiser test was performed. At the end of the synthesis aliquots of dry peptide resin were 
treated with reagent K (3 hrs, RT). Following evaporation of TFA the crude peptide was 
suspended in 10% AcOH, washed with Et2O three times and the aqueous phase lyophilised 
overnight and analysed by RP-HPLC. Crude IAPP was not soluble in 10% AcOH, (even at 
0.3 mg / ml), probably due to aggregation. Crude IAPP was however good soluble in aqueous 
8 M urea. The chromatographic separation was however difficult (Figure 37). The profile of 
the crude material (dissolved in aqueous 8 M urea solution) indicated either the presence of 
several by-products of the synthesis or that the peptide aggregated on the column. The peak at 
23.7 min corresponded according to MALDI-MS to the reduced product IAPP ([M+H]+ 
expected 3906.4, found 3905.0). The reduced form of the peptide was collected by preparative 
RP-HPLC, lyophilised and subjected to air oxidation for the formation of the intramolecular 
disulfide bond between the two cysteines. The oxidation (1 mg / ml) was performed in 6 M 
Gdn HCl in aqueous 0.1 M NH4HCO3 (in the dark) and required ~ 4 hrs for completion. 
Oxidized products were separated by HPLC retention time (Figure 38). A deletion sequence 
was identified during the purification of the peptide, which coeluted with reduced IAPP. The 
mass of the deletion product (peak at 23.7 min) was found to be 3156 and could correspond to 
fragment IAPP [9-37] ([M+K]+ expected: 3151.5), due to incomplete coupling at this region 
(incomplete coupling of Ala8 to Thr9 ). The peak at 24.8 min corresponded according to 
MALDI-MS to the oxidized product IAPP (Figure 39) ([M+H]+ expected 3904.4, found 
3901.7). An analytical RP-HPLC of pure, oxidized IAPP is shown in Figure 40. The overall 
yield of oxidized peptide with regard to the crude peptide was 3%.  
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Figure 37. RP-HPLC analysis of crude IAPP (in reduced form) using gradient 1 on C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 1 mg crude peptide in 1 ml 
aqueous 8 M urea solution. 
 
 
 
Figure 38. RP-HPLC analysis of crude IAPP (in oxidized form) using gradient 1 on C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 100 µg crude peptide in 
250 µl in aqueous 0.1 M NH4HCO3 solution containing 6 M Gdn HCl. 
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Figure 39. MALDI-MS of HPLC purified peak at 24.8 min (see Figure 38) from crude IAPP 
(oxidized form). 
 
 
Figure 40. RP-HPLC analysis of pure IAPP (in oxidized form) using gradient 2 on C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 10 µg pure peptide in 100 
µl aqueous 100 mM HCl. 
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5.2.2 Synthesis of [(N-Me) Phe23, (N-Me) Ala25] IAPP [1] 
 
Synthesis was performed manually by the Fmoc-strategy on Rink MBHA resin (substitution 
level: 0.25 mmole / gr with regard to C-terminal Tyr residue). Amino acids were coupled 
twice using 4-fold excess (with regard to Tyr) of the Fmoc-protected AA and TBTU in DMF 
and 6-fold excess DIEA for the activation mixture. The synthesis was performed as described 
for IAPP (see 5.2.1). A different coupling procedure was used for region [19-25]: (N-Me) 
Ala25 was coupled twice using 5-fold excess (2 x 90 min), and the next residue Gly24 was 
coupled also twice using 5-fold excess (1 x 75 min, 1 x 15 hrs). Following cleavage of a small 
amount of [(N-Me) Ala25] IAPP [24-37] resin and subsequent RP-HPLC purification (Figure 
41), the main peak at 15.1 min was identified as the expected product [(N-Me) Ala25] IAPP 
[24-37] ([M+H]+ expected: 1398.5, found: 1397.0). The Fmoc-protected peptide resin [(N-
Me) Ala25] IAPP [24-37] was then acetylated before proceeding with the couplings.  
The couplings of the next two residues were more difficult: in the case of (N-Me) Phe23 a 6-
fold excess of amino acid was used and a solvent mixture of DCM / DMF / NMP (1:1:1 v/v/v) 
was applied (1 x 90 min, 1 x 15 hrs). Before proceeding with the next residue, the peptide 
resin Fmoc-[(N-Me) Phe23, (N-Me) Ala25] IAPP [23-37] was acetylated. The coupling of 
Asn22 to (N-Me) Phe23 required three attempts: two with 6-fold excess (2 x 90 min) and a 
third one with 10-fold excess (1 x 14 hrs). In addition the above mentioned solvent mixture 
(equal volumes of DCM / DMF / NMP) was applied for the couplings. Cleavage of a small 
amount of [(N-Me) Phe23, (N-Me) Ala25] IAPP [22-37] resin (before acetylation of non-
reacted groups of (N-Me) Phe23) and subsequent RP-HPLC purification (Figure 42) showed 
that the peak at 18.0 min was the expected product [(N-Me) Phe23, (N-Me) Ala25] IAPP [22-
37] ([M+H]+ expected: 1674.8, found: 1674.2) according to MALDI-MS (Figure 43). The 
shoulder at 17.4 min was [(N-Me) Phe23, (N-Me) Ala25] IAPP [23-37] ([M+H]+ expected: 
1560.7, found: 1559.2) and indicated that the coupling of Asn22 to (N-Me) Phe23 was 60 to 
70% complete. The peptide resin Fmoc-[(N-Me) Phe23, (N-Me) Ala25] IAPP [22-37] was 
acetylated, where the next residue Asn21 was coupled twice: one with 6-fold excess (1 x 145 
min) and a second one with 10-fold excess (1 x 16 hrs). The Fmoc-protected peptide resin 
[(N-Me) Phe23, (N-Me) Ala25] IAPP [21-37] was acetylated.  
Taken together, in the region [21-25] couplings were found to be more difficult than the 
previous ones, as evaluated by small cleavages of resin and RP-HPLC profiling, which might 
has been due to the presence of bulky side chains protecting groups (Trt) in combination with 
the N-methyl groups of Ala25 and Phe23. Therefore, to enhance the coupling efficiencies we 
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increased the amount of the reagents (up to 10-fold excess), the time of the reactions (up to 16 
hrs) and utilized a mixture of solvents as detailed above. The next two residues (Ser20 and 
Ser19) were coupled twice using 6-fold excess of amino acid (2 x 60 min). At this point, a 
small cleavage of peptide resin and RP-HPLC separation of the mixture (Figure 44) showed 
the presence of two products: one peak at 15.3 min with a mass of 1397, corresponding to 
[(N-Me) Ala25] IAPP [24-37] ([M+H]+ expected: 1398.5) and the main fraction at 17.1 min 
with the correct mass for [(N-Me) Phe23, (N-Me) Ala25] IAPP [19-37] ([M+Na]+ expected: 
1985.1, found: 1982.2) (Figure 45). The formation of the product at 15.3 min could be 
explained as follows: incomplete coupling of Asn22 on (N-Me) Phe23 (see Figure 42) and the 
subsequent acetylation of the peptide resin. The truncated peptide Ac-[(N-Me) Phe23, (N-Me) 
Ala25] IAPP [23-37] would have been then still attached to the resin during the subsequent 
synthetic steps. However, during the TFA cleavage of the [(N-Me) Phe23, (N-Me) Ala25] IAPP 
[19-37] peptide resin, the peptide bond between Ac-(N-Me) Phe23 and Gly24 might have been 
cleaved leading to the formation of the partial fragment [(N-Me) Ala25] IAPP [24-37] which 
was eluting at 15.3 min (Figure 44). This mechanism could be in accordance with the 
mechanism of acidic hydrolysis of N-alkylated peptides during TFA deprotection conditions 
proposed by Urban et al. [15] (see also 3.1.2, Figure 4). 
 
 
Figure 41. RP-HPLC analysis of crude [(N-Me) Ala25] IAPP [24-37] using gradient 2 on C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 40 µg of crude peptide in 
100 µl aqueous 10% TFA solution. 
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Figure 42. RP-HPLC analysis of crude [(N-Me) Phe23, (N-Me) Ala25] IAPP [22-37] using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 50 µg of 
crude peptide in 100 µl aqueous 10% TFA solution. 
 
 
 
Figure 43. MALDI-MS of HPLC purified peak at 18.0 min (see Figure 42) from crude [(N-
Me) Phe23, (N-Me) Ala25] IAPP [22-37]. 
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Figure 44. RP-HPLC analysis of crude [(N-Me) Phe23, (N-Me) Ala25] IAPP [19-37] using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 60 µg of 
crude peptide in 100 µl aqueous 10% TFA solution. 
 
 
 
Figure 45. MALDI-MS of HPLC purified peak at 17.1 min (see Figure 44) from crude [(N-
Me) Phe23, (N-Me) Ala25] IAPP [19-37]. 
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The remaining eighteen residues (His18 till Lys1) were coupled twice, using 4-fold excess for 
the amino acids and TBTU and 6-fold excess for DIEA. Each coupling cycle was about 60 to 
80 min, with a Kaiser test done after the couplings of His18, Val17, Leu16, Thr9, and Cys7. Cys7 
and Cys2 were doubly coupled using the HOBt-ester coupling method as described (see 5.2.1) 
(1 x 80 min, 1 x 75 min). No acetylations were performed in the region [1-18].  
At the end of the synthesis, the peptide resin was cleaved with reagent K (3 hrs, RT). Crude 
product was dissolved in 10% AcOH, followed by Et2O washes (3 times) and lyophilised 
overnight. The crude lyophilised peptide was then dissolved in 50% AcOH, a small amount of 
dithiothreitol (DTT) was added and the solution (after warming at 45 °C for 45 min) was 
analysed by RP-HPLC (Figure 46). The main peak at 22.5 min was identified by MALDI-MS 
to correspond to the expected product [(N-Me) Phe23, (N-Me) Ala25] IAPP ([M+H]+ expected: 
3936.4, found: 3934.3), where the adjacent peaks were deletion products of the synthesis: the 
peak at 22.0 min had a mass of 3833.4 and corresponded to a deletion peptide missing one 
Cys residue ([M+H]+ expected: 3833.3), and the peak at 23.5 min most probably 
corresponded to [(N-Me) Phe23, (N-Me) Ala25] IAPP [8-37] as was indicated by MALDI-MS.  
During the air oxidation of the crude peptide (1 mg / ml) in aqueous 0.1 M NH4HCO3 
containing 3 M Gdn HCl (Figure 47), the main peak was shifted one minute later (at 23.6 
min) overlapping with one of the two deletion products. Therefore, it was necessary to search 
for alternative chromatographic conditions to purify the crude product. This was achieved by 
changing the gradient of buffer B in A from 35% to 55% in 27 min (gradient 3). The 
oxidation procedure (in the dark) required at least four hours and at these chromatographic 
conditions (Figure 48), the peak eluting at 19.1 min corresponded according to MALDI-MS to 
[(N-Me) Phe23, (N-Me) Ala25] IAPP (Figure 49) ([M+H]+ expected: 3934.4, found: 3931.9), 
where the peak eluting at 18.4 min corresponded according to MALDI-MS to the truncated 
peptide [(N-Me) Phe23, (N-Me) Ala25] IAPP [8-37] due to incomplete coupling of Cys7 to 
Ala8 ([M+K]+ expected: 3252.7, found: 3251.2) (Figure 50). 
An analytical RP-HPLC of pure, oxidized [(N-Me) Phe23, (N-Me) Ala25] IAPP is shown in 
Figure 51. The overall yield of oxidized peptide with regard to the crude peptide was 3%.  
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Figure 46. RP-HPLC analysis of crude [(N-Me) Phe23, (N-Me) Ala25] IAPP (in reduced form) 
using gradient 1 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 200 
µg of crude peptide in 300 µl aqueous 50% AcOH solution (the peak at 15.3 min is due to 
scavenger phenol from the cleavage mixture). 
 
Figure 47. RP-HPLC analysis of crude [(N-Me) Phe23, (N-Me) Ala25] IAPP (in oxidized 
form) using gradient 1 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection 
of 200 µg of crude peptide in 400 µl 3 M Gdn HCl in aqueous 0.1 M NH4HCO3 solution (the 
peak at 16.0 min is due to scavenger phenol from the cleavage mixture). 
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Figure 48. RP-HPLC analysis of crude [(N-Me) Phe23, (N-Me) Ala25] IAPP (in oxidized 
form) using gradient 3 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection 
of 1 mg crude peptide in 1 ml 3 M Gdn HCl in aqueous 0.1 M NH4HCO3 solution (the peak at 
13.5 min is due to scavenger phenol from the cleavage mixture). 
 
 
 
Figure 49. MALDI-MS of oxidized, HPLC purified peak at 19.1 min (see Figure 48) 
corresponding to [(N-Me) Phe23, (N-Me) Ala25] IAPP.  
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Figure 50. MALDI-MS of HPLC purified peak at 18.4 min (see Figure 48) most probably 
corresponding to [(N-Me) Phe23, (N-Me) Ala25] IAPP [8-37]. 
 
 
 
Figure 51. RP-HPLC analysis of pure [(N-Me) Phe23, (N-Me) Ala25] IAPP (in oxidized form) 
using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 12 
µg pure peptide in 100 µl aqueous 100 mM HCl. 
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5.2.3 Synthesis of [(N-Me) Gly24, (N-Me) Ile26] IAPP [2] 
 
The standard Fmoc-protocol was applied on Rink MBHA resin (substitution level: 0.21 
mmole Tyr / gr). Each residue was coupled twice (4-fold excess) with TBTU (4-fold excess) 
and DIEA (6-fold excess) (2 x 90 min). (N-Me) Ile26 was coupled three times (4-fold excess, 
2 x 90 min, 1 x 110 min). However, the cleavage of a small amount of resin and subsequent 
RP-HPLC analysis indicated that the coupling of (N-Me) Ile26 to Leu27 had proceded almost 
to 70-80% completion. The peptide resin Fmoc-[(N-Me) Ile26] IAPP [26-37] was acetylated 
before proceeding with the synthesis. The next amino acid Ala25 required two couplings with 
4-fold excess (2 x 90 min) and three with 6-fold excess (2 x 90 min, 1 x 150 min in NMP) to 
achieve an overall coupling yield close to 60-70% according to HPLC analysis of the 
coupling. Acetylation was performed again before coupling (N-Me) Gly24 (4-fold excess (1 x 
90 min, 1 x 135 min)), which was followed by acetylation of the Fmoc-protected [(N-Me) 
Gly24, (N-Me) Ile26] IAPP [24-37] peptide resin. For the coupling of Phe23, the amount of 
amino acid was slightly increased (5-fold excess, (1 x 90 min, 1 x 150 min, 1 x 120 min)) and 
the peptide resin Fmoc-[(N-Me) Gly24, (N-Me) Ile26] IAPP [23-37] was acetylated after the 
coupling. The RP-HPLC trace (Figure 52) of the cleavage mixture at this point (before 
acetylation of non-reacted groups of (N-Me) Gly24) revealed a main peak at 16.9 min which 
corresponded to [(N-Me) Gly24, (N-Me) Ile26] IAPP [23-37] according to MALDI-MS 
([M+H]+ expected: 1560.7, found: 1560.0). The following amino acids were then double 
coupled as follows: Asn22 (5-fold excess, (2 x 100 min)), Asn21 (5-fold excess, (1 x 90 min, 1 
x 120 min)), Ser20 (4-fold excess, (1 x 80 min, 1 x 60 min)) and Ser19 (4-fold excess, (1 x 90 
min, 1 x 80 min)). HPLC analysis following cleavage from the resin at the stage of [(N-Me) 
Gly24, (N-Me) Ile26] IAPP [19-37] (Figure 53) and MALDI-MS (Figure 54) showed that the 
main fraction at 16.1 min corresponded to the expected product [(N-Me) Gly24, (N-Me) Ile26 
IAPP [19-37] ([M+H]+ expected: 1963.1, found: 1963.7). 
Residues 18 to 1 were coupled twice using 4-fold excess for the amino acid each time, TBTU 
(4-fold excess) and DIEA (6-fold excess) for more than an hour. Acetylation was performed 
after the couplings of residues Val18, Thr9, Cys7 and Cys2. At the end of the synthesis, the 
resin was cleaved with reagent K (3 hrs, RT). The crude peptide was dissolved in 10% AcOH 
and analysed by HPLC. According to the RP-HPLC separation (Figure 55), the fraction at 
22.8 min was identified as the expected reduced product [(N-Me) Gly24, (N-Me) Ile26] IAPP. 
Oxidation (in the dark) of the crude material (1 mg / ml) was performed in 3 M Gdn HCl in 
aqueous 0.1M NH4HCO3 for 120 min. RP-HPLC purification (Figure 56) and MALDI-MS 
Results 94 
(Figure 57) showed that the peak at 23.9 min was the oxidized form of the peptide ([M+H]+ 
expected: 3934.4, found: 3933.0). The other fraction resolved by RP-HPLC (at 24.5 min) had 
according to MALDI-MS a mass of 3855.6, most probably a deletion sequence with a missing 
Ala residue (possibly Ala8 or Ala5) (expected: 3863.3, found: 3855.6).  
An analytical RP-HPLC of pure, oxidized [(N-Me) Gly24, (N-Me) Ile26] IAPP is shown in 
Figure 58. The overall yield of oxidized peptide with regard to the crude peptide was 5%.  
 
 
 
 
 
Figure 52. RP-HPLC analysis of crude [(N-Me) Gly24, (N-Me) Ile26] IAPP [23-37] using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 40 µg 
crude peptide in 100 µl aqueous 10% TFA solution. 
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Figure 53. RP-HPLC analysis of crude [(N-Me) Gly24, (N-Me) Ile26] IAPP [19-37] using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 40 µg 
crude peptide in 100 µl aqueous 10% TFA solution. 
 
 
 
Figure 54. MALDI-MS of HPLC purified peak at 16.1 min (see Figure 53) from crude [(N-
Me) Gly24, (N-Me) Ile26] IAPP [19-37]. 
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Figure 55. RP-HPLC analysis of crude [(N-Me) Gly24, (N-Me) Ile26] IAPP (in reduced form) 
using gradient 1 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 300 
µg crude peptide in 500 µl aqueous 10% AcOH solution.  
 
 
Figure 56. RP-HPLC analysis of crude [(N-Me) Gly24, (N-Me) Ile26] IAPP (in oxidized form) 
using gradient 1 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 600 
µg crude peptide in 600 µl 3 M Gdn HCl in aqueous 0.1 M NH4HCO3. 
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Figure 57. MALDI-MS of HPLC purified peak at 23.9 min (see Figure 56) from oxidized 
crude [(N-Me) Gly24, (N-Me) Ile26] IAPP. 
 
 
 
Figure 58. RP-HPLC of pure [(N-Me) Gly24, (N-Me) Ile26] IAPP (in oxidized form) using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 10 µg 
pure peptide in 100 µl aqueous 100 mM HCl. 
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5.2.4 Synthesis of [(N-Me) Ala25, (N-Me) Leu27] IAPP [3] 
 
The Fmoc-strategy was followed also for this synthesis on Rink Amide MBHA resin 
(substitution level: 0.5 mmole Tyr / gr) and coupling protocols were as described (see 5.2.1-
5.2.3). The following residues were coupled by variation of these protocols: (N-Me) Leu27 
was coupled once in DMF (2-fold excess, 1 x 90 min). Kaiser test indicated that the coupling 
proceded to completion. Ile26 was coupled twice (2-fold excess, 2 x 75 min) followed by 
acetylation of the Fmoc-[(N-Me) Leu27] IAPP [26-37] peptide resin. (N-Me) Ala25 was 
coupled once (2-fold excess, 1 x 110 min). No acetylation was performed only Kaiser test 
which was negative. The following residue Gly24 was double coupled (2-fold excess, 1 x 80 
min, 1 x 95 min). A small amount of [(N-Me) Ala25, (N-Me) Leu27] IAPP [24-37] resin was 
used for cleavage with a mixture of TFA / water (95/5) (2 hrs, RT). The cleavage mixture was 
analysed by RP-HPLC (Figure 59) that showed two main products: one at 11.3 min which 
according to MALDI-MS had a mass of 1029.8 and a second at 15.5 min with a mass of 
1412.8, that corresponded to [(N-Me) Ala25, (N-Me) Leu27] IAPP [24-37] ([M+H]+ expected: 
1413.5, found: 1412.8). The product with a mass of 1029.8 corresponded to fragment IAPP 
[28-37], as confirmed also by amino acid analysis: Asn (2) 1.9, Thr (2) 1.8, Ser (3) 2.3, Gly 
(1) 1.0, Val (1) 1.0 and Tyr (1) 1.0. The resin was acetylated after the coupling of Gly24 to (N-
Me) Ala25 and the following amino acids were coupled twice (2-fold excess each time): Phe23 
(2 x 60 min), Asn22 (1 x 80, 1 x 90 min), Asn21 (1 x 75, 1 x 80 min), Ser20 (2 x 60 min) and 
Ser19 (1 x 70, 1 x 80 min). No acetylations were performed in the region [19-24]. A small 
amount of [(N-Me) Ala25, (N-Me) Leu27] IAPP [19-37] resin was treated by a mixture of TFA 
/ water (95/5) (2 hrs, RT) and subjected to RP-HPLC analysis. The RP-HPLC profile (Figure 
60) revealed three main fractions: one at 11.4 min which according to MALDI-MS had a 
mass of 1029.2 corresponding to IAPP [28-37] (see above), one at 15.6 min with a mass of 
1412.8 corresponding to [(N-Me) Ala25, (N-Me) Leu27] IAPP [24-37] and one at 17.1 min 
with a mass of 1995.3, corresponding to the expected product [(N-Me) Ala25, (N-Me) Leu27] 
IAPP [19-37] ([M+Na]+ expected: 1985.1, found: 1995.3) (Figure 61). These results indicated 
that elongation of the fragment [24-37] was only partially possible (70 to 80% with regard to 
amino groups of Gly24) under the applied coupling conditions.  
Due to the low yield with regard to the expected product the synthesis was repeated. For the 
second attempt, double couplings (4-fold excess) were employed for the residues in the region 
[24-27]: (N-Me) Leu27 (1 x 70, 1 x 75 min), Ile26 (1 x 75, 1 x 85 min), (N-Me) Ala25 (1 x 70, 1 
x 60 min) and Gly24 (1 x 70, 1 x 80 min). The second coupling was performed in NMP and 
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after each coupling the peptide resin was acetylated. A small cleavage of [(N-Me) Ala25, (N-
Me) Leu27] IAPP [24-37] resin yielded the same RP-HPLC profile as in the first attempt. The 
synthesis was continued with the following residues (double couplings, 4-fold excess): Phe23 
(1 x 70, 1 x 60 min), Asn22 (1 x 100, 1 x 75 min), Asn21 (1 x 70, 1 x 60 min), Ser20 (1 x 65, 1 
x 75 min) and Ser19 (1 x 65, 1 x 80 min). Kaiser test after each coupling was negative. At this 
point cleavage of [(N-Me) Ala25, (N-Me) Leu27] IAPP [19-37] resin and RP-HPLC analysis 
(Figure 62) showed that the same three major fractions were present: one at 11.5 min, another 
at 15.6 min and a last one at 17.1 min, which was the expected product [(N-Me) Ala25, (N-
Me) Leu27] IAPP [19-37]. The question that needed to be addressed was why IAPP [28-37] 
formed during the synthesis. The possible explanations were that:  
a) an incomplete coupling of (N-Me) Leu27 to Ser28 occurred, although the Kaiser test after 
the coupling was negative. However, in this case the peptide IAPP [28-37] should be 
acetylated, which is not what is found b) the coupling of Ile26 to (N-Me) Leu27 was incomplete 
since the coupling was not checked by Kaiser test due to the (N-Me) amino acid. Since the 
peptide resin was then acetylated we suspected that an amide bond cleavage between Ac-(N-
Me) Leu27 and Ser28 might have occurred during the TFA cleavage of the peptide from the 
resin.  
The synthesis was therefore repeated to investigate this issue: (N-Me) Leu27 was coupled 
twice (4-fold excess, 1 x 70, 1 x 75 min) and the coupling was complete as judged by 
cleavage and RP-HPLC analysis of a small aliquot of peptide resin (Figure 63). The main 
peak at 12.7 min corresponded to the expected peptide [(N-Me) Leu27] IAPP [27-37], as 
shown by MALDI-MS ([M+H]+ expected: 1157.2, found: 1161.5). However, coupling of 
Fmoc-Ile26 to (N-Me) Leu27 proved to be extremely difficult even after three consecutive 
couplings (4-fold excess), two of them performed in DMF (1 x 75, 1 x 85 min) and the third 
one in NMP (1 x 85 min). The RP-HPLC trace of the crude product (Figure 64) revealed the 
presence of two main products: one at 12.7 min corresponding to [(N-Me) Leu27] IAPP [27-
37] ([M+H]+ expected: 1157.2, found: 1156.6), and a second one at 15.4 min with a mass of 
1271.6, corresponding to [(N-Me) Leu27] IAPP [26-37] ([M+H]+ expected: 1270.4). The 
conclusions that were drawn from the results of this synthetic attempt as compared to the 
previous two ones were the following: a) incorporation of (N-Me) Leu27 was complete and b) 
the coupling of Ile26 to (N-Me) Leu27 was a very difficult one (30 to 40% completion) and 
could not be completed by the coupling methods applied in this work.  
In an additional experiment (N-Me) Leu27 was coupled twice (4-fold excess, 2 x 60 min) and 
the coupling was close to completion as judged by cleavage and RP-HPLC analysis of a small 
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aliquot of peptide resin (Figure 65): the main peak at 13.3 min was the expected peptide [(N-
Me) Leu27] IAPP [27-37] ([M+H]+ expected: 1157.2, found: 1156.0). The peptide resin after 
deprotection of the Fmoc-group of (N-Me) Leu27 was acetylated, practically leading to 
peptide chain termination at this point. A small amount of Ac-[(N-Me) Leu27] IAPP [27-37] 
resin was treated by a mixture of TFA / water (95/5) (2 hrs, RT) and subjected to RP-HPLC 
analysis. The RP-HPLC (Figure 66) showed that the main peak was eluting at 11.8 min and 
corresponded to IAPP [28-37] ([M+H]+ expected: 1029.0, found: 1028.9). This finding 
indicated that the acetylated form of the peptide [(N-Me) Leu27] IAPP [27-37] was indeed 
unstable and that during TFA deprotection conditions the peptide bond between Ac-(N-Me) 
Leu27 and Ser28 was cleaved. This result was in agreement with the previous finding of 
peptide bond cleavage of Ac-(N-Me) Phe23 and Gly24 in analogue IAPP [1] (see 5.2.2) and 
previous literature report [15]. 
The peptide resins [(N-Me) Ala25, (N-Me) Leu27] IAPP [19-37] from the first two synthetic 
attempts, were used for the coupling of the remaining residues till Lys1. Residues 18 to 1 were 
coupled twice (4-fold excess, 2 x 60-75 min) with Kaiser test done after the couplings of 
His18, Phe15, Thr9, Thr5. Again, for the couplings of Cys7 and Cys2 instead of activation with 
TBTU / DIEA, the HOBt-ester protocol was used (AA in 6-fold excess, 2 x 90 min) (see 
5.2.1-5.2.3). At the end of the synthesis, the peptide resins were treated with reagent K (3 hrs, 
RT). The crude peptide was subjected to RP-HPLC analysis. The analytical profile of the 
reduced form of the crude peptide (Figure 67) with one main peak at 23.7 min ([M+H]+ 
expected: 3936.4, found: 3934.9) indicated that the peptide was obtained in good purity 
although the yield due to the low coupling efficiency of Ile26 to (N-Me) Leu27 was low. The 
peptide was purified following oxidation (in the dark) that was performed by dissolving crude 
material (1 mg /ml) in aqueous 0.1 M NH4HCO3 containing 3 M Gdn HCl. The oxidation 
(Figure 68) required almost two hours for completion and the peak at 24.9 min was the 
expected product [(N-Me) Ala25, (N-Me) Leu27] IAPP ([M+H]+ expected: 3932.4, found: 
3934.1) (Figure 69). 
An analytical RP-HPLC of pure, oxidized [(N-Me) Ala25, (N-Me) Leu27] IAPP is shown in 
Figure 70. The overall yield of the oxidized peptide with regard to the crude peptide was 5%. 
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Figure 59. RP-HPLC analysis of crude [(N-Me) Ala25, (N-Me) Leu27] IAPP [24-37] (1st 
synthesis) using gradient 2 on C18 column, flow rate 2 ml /min and detection at 214 nm. 
Injection of 100 µg crude peptide in 100 µl aqueous 10% TFA solution. 
 
 
Figure 60. RP-HPLC analysis of crude [(N-Me) Ala25, (N-Me) Leu27] IAPP [19-37] (1st 
synthesis) using gradient 2 on C18 column, flow rate 2 ml /min and detection at 214 nm. 
Injection of 800 µg crude peptide in 1 ml aqueous solution. 
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Figure 61. MALDI-MS of HPLC purified peak at 17.1 min (see Figure 60) from crude [(N-
Me) Ala25, (N-Me) Leu27] IAPP [19-37].  
 
 
 
Figure 62. RP-HPLC analysis of crude [(N-Me) Ala25, (N-Me) Leu27] IAPP [19-37] (2nd 
synthesis) using gradient 2 on C18 column, flow rate 2 ml /min and detection at 214 nm. 
Injection of 50 µg crude peptide in 50 µl aqueous 10% AcOH solution. 
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Figure 63. RP-HPLC analysis of crude [(N-Me) Leu27] IAPP [27-37] (3rd synthesis) using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 100 µg 
crude peptide in 150 µl aqueous 10% TFA solution. 
 
Figure 64. RP-HPLC analysis of crude [(N-Me) Leu27] IAPP [26-37] (3rd synthesis) using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 50 µg 
crude peptide in 150 µl aqueous 10% TFA solution. 
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Figure 65. RP-HPLC analysis of crude [(N-Me) Leu27] IAPP [27-37] (4th synthesis) using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 250 µg 
crude peptide in 400 µl water. 
 
Figure 66. RP-HPLC analysis of crude Ac-[(N-Me) Leu27] IAPP [27-37] (4th synthesis) using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 200 µg 
crude peptide in 200 µl water. 
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Figure 67. RP-HPLC analysis of crude [(N-Me) Ala25, (N-Me) Leu27] IAPP (in reduced form) 
using gradient 1 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 150 
µg crude peptide in 100 µl aqueous 10% TFA solution (the peak at 15.7 min is due to 
scavenger phenol from the cleavage mixture). 
 
Figure 68. RP-HPLC analysis of crude oxidized [(N-Me) Ala25, (N-Me) Leu27] IAPP (in 
oxidized form) using gradient 1 on C18 column, flow rate 2 ml /min and detection at 214 nm. 
Injection of 2 mg crude peptide in 2 ml 3 M Gdn HCl in aqueous 0.1 M NH4HCO3 solution 
(the peak at 15.5 min is due to scavenger phenol from the cleavage mixture). 
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Figure 69. MALDI-MS of HPLC purified peak at 24.9 min (see Figure 68) from crude [(N-
Me) Ala25, (N-Me) Leu27] IAPP.  
 
 
Figure 70. RP-HPLC of pure [(N-Me) Ala25, (N-Me) Leu27] IAPP (in oxidized form) using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 10 µg 
pure peptide in 100 µl aqueous 100 mM HCl. 
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5.2.5 Synthesis of [(N-Me) Ile26, (N-Me) Leu27] IAPP [4] 
 
The first synthetic attempt on Rink Amide MBHA resin (substitution level: 0.21 mmole Tyr / 
gr) aimed to study synthetic difficulties up to Ser19. The synthesis up to residue Ser28 was 
performed as described before (see 5.2.1). (N-Me) Leu27 was coupled twice (4-fold excess) 
with TBTU (4-fold excess) and DIEA (6-fold excess) (2 x 75 min). Kaiser test indicated 
complete coupling. For the coupling of (N-Me) Ile26 6-fold excess was used and longer 
coupling times were applied: the first coupling was 17 hrs at RT and the second coupling for 4 
hrs at 50 °C then left for 17 hrs at RT. The coupling efficiency of (N-Me) Ile26 on (N-Me) 
Leu27 was 60 to 70% as estimated by cleavage and RP-HPLC analysis. The peptide resin 
Fmoc-[(N-Me) Ile26, (N-Me) Leu27] IAPP [26-37] was acetylated before proceeding. For the 
coupling of Ala25 5-fold excess was used: first coupling for 6 hrs and the second coupling for 
18 hrs at RT. A small aliquot of [(N-Me) Ile26, (N-Me) Leu27] IAPP [25-37] resin was cleaved 
with TFA / water (95/5) (2 hrs, RT) and the cleavage mixture was analysed by RP-HPLC. The 
RP-HPLC analysis (Figure 71) showed the presence of a peak at 11.3 min, corresponding to 
IAPP [28-37] and a broad peak at 15.2-15.6 min (the intended product was eluting at 15.6 min 
but the separation from the peptide without Ala at 15.2 min was difficult). In order to increase 
the coupling yield of Ala25 on (N-Me) Ile26 a third coupling of Ala (5-fold excess, 1 x 150 
min) was performed followed by acetylation of the Fmoc-[(N-Me) Ile26, (N-Me) Leu27] IAPP 
[25-37] resin. Coupling of Gly24 (5-fold excess, 1 x 100, 1 x 180 min) was followed by Phe23 
(5-fold excess, 1 x 100min, 1 x 11 hrs and 1 x 18 hrs). A small aliquot of [(N-Me) Ile26, (N-
Me) Leu27] IAPP [23-37] resin was cleaved and analysed by RP-HPLC. According to the RP-
HPLC analysis (Figure 72) three main products were formed: peak at 11.5 min, peak at 12.9 
min and a broad peak at 17.4-17.7 min. The product at 12.9 min corresponding to [(N-Me) 
Leu27] IAPP [27-37] was formed from bond cleavage during TFA deprotection between Ac-
(N-Me) Ile26 and (N-Me) Leu27 . The peptide resin Fmoc-[(N-Me) Ile26, (N-Me) Leu27] IAPP 
[23-37] was acetylated before coupling the remaining amino acids: Asn22 (5-fold excess, 1 x 
120 min, 1 x 140 min), Asn21 (5-fold excess, 1 x 120 min, 1 x 18 hours), Ser20 (5-fold excess, 
1 x 70 min, 1 x 80 min) and finally Ser19 (5-fold excess, 1 x 70 min, 1 x 80 min). Cleavage of 
peptide resin and RP-HPLC analysis (Figure 73) showed that the expected product [(N-Me) 
Ile26, (N-Me) Leu27] IAPP [19-37] had a retention time of 16.5 min ([M+H]+ expected: 
1963.1, found: 1963.9) (Figure 74). The peak at 11.1 min corresponded to IAPP [28-37] 
([M+H]+ expected: 1029.0, found: 1031.0) and the peak at 12.5 min corresponded to [(N-Me) 
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Leu27] IAPP [27-37] ([M+H]+ expected: 1157.2, found: 1159.7). The synthesis was stopped 
due to the low yield with regard to [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-37].  
 
 
 
 
Figure 71. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP [25-37] (1st 
synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 30 µg crude peptide in 100 µl aqueous 10% TFA solution. 
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Figure 72. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP [23-37] (1st 
synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 30 µg crude peptide in 100 µl aqueous 10% TFA solution. 
 
Figure 73. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-37] (1st 
synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 2 mg crude peptide in 2 ml aqueous 10% AcOH solution. 
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Figure 74. MALDI-MS of HPLC purified peak at 16.5 min (see Figure 73) from crude [(N-
Me) Ile26, (N-Me) Leu27] IAPP [19-37] (1st synthesis). 
 
Next, a second synthetic attempt was carried out on Rink amide MBHA resin (substitution 
level: 0.25 mmole Tyr /gr). Coupling of (N-Me) Leu27 was performed twice (4-fold excess, 1 
x 95 min, 1 x 150 min). The next residue (N-Me) Ile26 was coupled four times to improve 
coupling yields: in the first three times 5-fold excess was applied (1 x 100 min, 1 x 16 hrs, 1 x 
3 hrs respectively), whereas the fourth coupling 7-fold excess and performed with for 16 hrs 
at RT, followed by heating for 4 hrs at 40 °C and 20 hrs at RT. RP-HPLC analysis (Figure 75) 
of an aliquot showed: the peak at 15.0 min corresponded to the expected product [(N-Me) 
Ile26, (N-Me) Leu27] IAPP [26-37] and as indicated by the RP-HPLC profile the extended 
coupling of (N-Me) Ile26 on (N-Me) Leu27 lead to a coupling yield 80 to 90%. The peptide 
resin Fmoc-[(N-Me) Ile26, (N-Me) Leu27] IAPP [26-37] was acetylated and the next amino 
acid Ala25 was coupled twice: first coupling (6-fold excess) for 2 hrs at 40 °C and 23 hrs at 
RT and the second coupling (6-fold excess) for 3 hrs at 40 °C and 19 hrs at RT. RP-HPLC 
analysis (Figure 76) showed at least three main products: two of them were newly formed 
(peaks at 11.0 and 12.1 min, respectively), whereas the peak at 15.3 min had according to 
MALDI-MS a mass of 1286.3 corresponding to [(N-Me) Ile26, (N-Me) Leu27] IAPP [26-37] 
([M+H]+ expected: 1285.4) indicating that the Ala25 coupling to (N-Me) Ile26 did not work. 
Ala25 (6-fold excess) was recoupled for a third time. Conditions were: 3 hrs at 40 °C and 14 
Results 111 
hrs at RT, followed by acetylation of the Fmoc-[(N-Me) Ile26, (N-Me) Leu27] IAPP [25-37] 
resin. The remaining residues till Ser19 were coupled twice using 5-fold excess amino acid for 
90 min each coupling cycle. RP-HPLC analysis (Figure 77) of crude [(N-Me) Ile26, (N-Me) 
Leu27] IAPP [19-37] showed the same three products as in the first synthesis, with the 
expected product [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-37] eluting at 16.5 min. 
The peptide resin [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-37] from the second synthesis was 
used for further elongation. Residues from His18 till Lys1 were coupled twice (4-fold excess) 
with TBTU (4-fold excess) and DIEA (6-fold excess) for a coupling time of about 90 min 
except for Cys7 and Cys2 residues that were coupled twice with HOBt (4-fold excess) and 
DIC (4-fold excess) in DMF for 90 min. The peptide resin was cleaved in small amounts 
using reagent K (3 hrs, RT). The crude peptide after lyophilisation overnight was dissolved in 
10% AcOH and analysed by RP- HPLC. According to the RP-HPLC analysis (Figure 78) the 
peak at 19.1 min was the expected product ([M+H]+ expected: 3936.4, found: 3935.9), 
whereas the earlier eluting peaks at 11.3 min and 12.6 min were (as mentioned above) IAPP 
[28-37] and [(N-Me) Leu27] IAPP [27-37] respectively. Air oxidation (in the dark) was 
accomplished by dissolving crude peptide in aqueous 0.1 M NH4HCO3 containing 3 M Gdn 
HCl and after 2 hrs the solution was purified by RP-HPLC. The eluting peak at 19.3 min 
(Figure 79) was identified by MALDI-MS (Figure 80) to correspond to the expected product 
[(N-Me) Ile26, (N-Me) Leu27] IAPP ([M+H]+ expected: 3934.4, found: 3933.1). 
An analytical RP-HPLC of pure, oxidized [(N-Me) Ile26, (N-Me) Leu27] IAPP is shown in 
Figure 81. The overall yield of the oxidized peptide with regard to the crude peptide was 5%. 
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Figure 75. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP [26-37] (2nd 
synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 40 µg crude peptide in 150 µl aqueous 10% TFA solution. 
 
 
Figure 76. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP [25-37] (2nd 
synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 30 µg crude peptide in 150 µl aqueous 10% TFA solution. 
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Figure 77. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-37] (2nd 
synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 30 µg crude peptide in 150 µl aqueous 10% TFA solution. 
 
Figure 78. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP (2nd synthesis) (in 
reduced form) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 125 µg crude peptide in 50 µl aqueous 10% AcOH solution. 
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Figure 79. RP-HPLC analysis of crude oxidized [(N-Me) Ile26, (N-Me) Leu27] IAPP (2nd 
synthesis) (in oxidized form) using gradient 2 on C18 column, flow rate 2 ml / min and 
detection at 214 nm. Injection of 300 µg crude peptide in 300 µl 3 M Gdn HCl in aqueous 0.1 
M NH4HCO3 solution. 
 
 
Figure 80. MALDI-MS of HPLC purified peak at 19.3 min (see Figure 79) from crude [(N-
Me) Ile26, (N-Me) Leu27] IAPP. 
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Figure 81. RP-HPLC of pure [(N-Me) Ile26, (N-Me) Leu27] IAPP (in oxidized form) using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 7 µg pure 
peptide in 100 µl aqueous 100 mM HCl.  
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5.2.6 Synthesis of [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [5] 
 
The synthesis of an IAPP analogue with three consecutive N-methyl residues was a big 
challenge. In the first attempt, (N-Me) Leu27 (6-fold excess, 2 x 75 min) was successfully 
coupled on Ser28, as was judged by the RP-HPLC profile after cleavage of a small aliquot of 
peptide resin. As shown in Figure 82, the peak at 12.7 min was the peptide [(N-Me) Leu27] 
IAPP [27-37]. For the coupling of (N-Me) Ile26 8-fold excess was used twice; the first 
coupling was performed for 17 hrs at RT, while the second one for 4 hrs at 50 °C and for 17 
hours at RT. However, the RP-HPLC trace (Figure 83) indicated that the coupling of (N-Me) 
Ile26 on (N-Me) Leu27 was 60 to 70% complete. The peak at 15.2 min was the product [(N-
Me) Ile26, (N- Me) Leu27] IAPP [26-37], whereas the peak at 12.7 min was [(N- Me) Leu27] 
IAPP [27-37]. The peptide resin Fmoc-[(N-Me) Ile26, (N- Me) Leu27] IAPP [26-37] was 
acetylated and the synthesis was continued with one sixth of the peptide resin which was used 
for coupling (N-Me) Ala25. This coupling (10-fold excess of AA) with 10-fold excess of 
TBTU was performed in a mixture of DMF / DCM / NMP (1:1:1), without adding DIEA for 
24 hrs. Cleavage of an aliquot of [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [25-37] 
resin and subsequent RP-HPLC separation (Figure 84) revealed that two main products were 
formed: one at 11.2 min corresponding to IAPP [28-37] due to incomplete coupling of (N-
Me) Ile26 to (N-Me) Leu27 and cleavage of the amide bond between Ac-(N-Me) Leu27 and 
Ser28 during TFA deprotection (see 5.2.4), and one peak at 15.2 min corresponding to (N-Me) 
Ile26, (N-Me) Leu27] IAPP [26-37]. The peak at 15.2 min according to MALDI-MS had a 
mass of 1283.5 and indicated that the coupling of (N-Me) Ala25 to (N-Me) Ile26 without DIEA 
in the coupling mixture did not work at all. 
In a second synthetic attempt, (N-Me) Leu27 was coupled twice (4-fold excess, 1 x 70 min, 1 x 
90 min). (N-Me) Ile26 was coupled four times: two couplings were performed using 4-fold 
excess (1 x 80min, 1 x 85 min), a third coupling was performed using 8-fold excess for 7 hrs 
at 50 °C and for 15 hrs at RT, and the fourth one (4-fold excess) for 4 hrs at 60 °C. Cleavage 
of [(N-Me) Ile26, (N-Me) Leu27] IAPP [26-37] resin and RP-HPLC separation (Figure 85) 
showed that two main products were present: one peak at 12.5 min, corresponding to [(N-Me) 
Leu27] IAPP [27-37], and one at 15. 1 min with a mass of 1284.6, corresponding to [(N-Me) 
Ile26 , (N-Me) Leu27] IAPP [26-37] ([M+H]+ expected:1285.4, found: 1284.6). Again, the 
coupling of (N-Me) Ile26 on (N-Me) Leu27 was 60 to 70% complete as judged by the RP-
HPLC trace (Figure 85). The Fmoc-[(N-Me) Ile26, (N- Me) Leu27] IAPP [26-37] resin was 
acetylated before proceeding. (N-Me) Ala25 was coupled twice (using the standard protocol 
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with TBTU / DIEA): the first coupling (8-fold excess) was performed for 90 min at 50 °C and 
for 5 hrs at RT, and the second coupling (4-fold excess) for 18 hrs at RT. Again, an aliquot of 
[(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [25-37] resin was cleaved and analysed by 
RP-HPLC. As shown in Figure 86, the peak at 11.3 min, corresponding to IAPP [28-37] was 
again present in great amount, whereas the broad peak at 15.2-15.6 min contained both the 
peptide without (N-Me) Ala25 (peak at 15.2 min) as identified by MALDI-MS ([M+H]+ 
expected: 1285.4, found: 1285.4) (Figure 87) and the intended peptide [(N-Me) Ala25, (N-Me) 
Ile26, (N- Me) Leu27] IAPP [25-37] (shoulder at 15.6 min) as confirmed by MALDI-MS 
([M+H]+ expected: 1371.5, found: 1368.0) (Figure 88). 
Both synthetic attempts were aborted at this point due to the low yields of expected product.  
The data again confirmed that the formation of the truncated peptide IAPP [28-37] was taken 
place during the TFA / water cleavage of the acetylated peptide resin (see also 5.2.4). During 
the cleavage reaction (the acetylated fragment Ac-(N-Me) Leu27 IAPP [27-37] which is 
already present on the resin due to incomplete coupling of (N-Me) Ile26 to (N-Me) Leu27 and 
subsequent acetylation) the peptide bond between (N-Me) Leu27 and Ser28 breaks off with the 
release of Ac-(N-Me) Leu27-OH (not detectable under the chromatographic conditions 
employed) and IAPP [28-37]. Additionally, the coupling of (N-Me) Ala25 on (N-Me) Ile26 was 
practically not possible (very low coupling yield) under the coupling conditions employed. 
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Figure 82. RP-HPLC analysis of crude [(N-Me) Leu27] IAPP [27-37] (1st synthesis) using 
gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. Injection of 40 µg 
crude peptide in 100 µl aqueous 10% TFA solution. 
 
Figure 83. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP [26-37] (1st 
synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 40 µg crude peptide in 100 µl aqueous 10% TFA solution. 
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Figure 84. RP-HPLC analysis of crude [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP 
[25-37] (1st synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 
214 nm. Injection of 40 µg crude peptide in 100 µl aqueous 10% TFA solution. 
 
Figure 85. RP-HPLC analysis of crude [(N-Me) Ile26, (N-Me) Leu27] IAPP [26-37] (2nd 
synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 214 nm. 
Injection of 40 µg crude peptide in 100 µl aqueous 10% TFA solution. 
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Figure 86. RP-HPLC analysis of crude [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP 
[25-37] (2nd synthesis) using gradient 2 on C18 column, flow rate 2 ml / min and detection at 
214 nm. Injection of 50 µg crude peptide in 100 µl aqueous 10% TFA solution. 
 
 
Figure 87. MALDI-MS of HPLC peak at 15.2 min (see Figure 86) from crude [(N-Me) Ala25, 
(N-Me) Ile26, (N-Me) Leu27] IAPP [25-37]. 
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Figure 88. MALDI-MS of HPLC shoulder at ~15.6 min (see Figure 86) from crude [(N-Me) 
Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [25-37]. 
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5.2.7 Synthesis of S20G-IAPP [6] 
 
A large scale synthesis was to be performed and optimized at each step. Standard Fmoc-chemistry 
was applied and the resin used was Rink amide MBHA (2 gr, substitution level: 0.33 mmole Tyr / 
gr). Double couplings for each residue were applied following attachment of Tyr37 to the resin. 
Couplings (4-fold excess) were performed by activation with TBTU (4-fold excess), neutralization 
with DIEA (6-fold excess) in DMF and coupling time 45 min each time. This protocol was 
followed till residue Leu27, whereas in the difficult region Ile26 to Gly24 the second coupling was 
accomplished by activation using the more reactive coupling reagent 2-(1H-9 azabenzotriazole-1-
yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (4-fold excess, 1 x 45 min). 
Moreover, for residues Ala25 and Gly24 the first coupling (with TBTU) was performed with 8-fold 
excess for 1 hr. Peptide resin was always acetylated after the couplings (as part of the protocol) in 
the region Ile26 till Lys1. The coupling of Asn22 also proved to be very difficult: even after two 
couplings (4-fold excess, TBTU) free amino groups were detected by the Kaiser test. Therefore, 
the coupling was repeated two more times (4-fold excess TBTU, 2 x 1 hr). The next residue Asn21 
was also coupled twice: the first coupling was performed with TBTU (4-fold excess, 1 x 45 min) 
and the second coupling with HATU (4-fold excess, 1 x 55 min). At this point, a small aliquot of 
IAPP [21-37] resin was cleaved and analysed by RP-HPLC according to our standard procedure. 
The peak eluting at 17.0 min (Figure 89) was identified by FAB-MS as the expected product IAPP 
[21-37] ([M+H]+ expected: 1758.9, found: 1757.8). 
Residues from Gly20 till Leu12 were coupled twice with TBTU (4-fold excess), followed by 
acetylation at each step. For residues Arg11, Gln10 and Thr9 the second coupling was performed 
with HATU (4-fold excess), as, based on the experience from the previous syntheses, these 
residues were difficult to couple. Cys7 and Cys2 residues were coupled three times: the first two 
couplings with DIC (3-fold excess, 1 x 60 min, 1 x 45 min), whereas the third coupling with 
HATU / DIEA (1.5-fold excess each, 1 x 45 min), followed by acetylation of the resin. At the end 
of the synthesis the resin was cleaved in small amounts with reagent K (3 hrs, RT). The crude 
peptide was dissolved in 10% AcOH and was analysed by RP-HPLC. The peak at 23.8 min (Figure 
90) was the expected peptide according to MALDI-MS. Air oxidation (in the dark) was performed 
in 6 M Gdn HCl in aqueous 0.1 M NH4HCO3 using the crude peptide. Oxidation usually required 2 
hrs and the peptide was purified directly after oxidation to avoid aggegration according to our 
standard procedure. The peak at 24.2 min (Figure 91) which was identified by MALDI-MS (Figure 
92) to be the intended peptide S20G-IAPP ([M+H]+ expected: 3874.3, found: 3873.6) was 
collected, whereas the peak at 22.9 min was a deletion peptide corresponding according to 
Results 123 
MALDI-MS to acetylated S20G IAPP [10-37] ([M+H]+ expected: 3024.3, found: 3025.5) that may 
have formed due to incomplete coupling of Thr9 to Gln10 and subsequent acetylation. An analytical 
HPLC of pure S20G-IAPP is shown in Figure 93. The yield of the oxidation / purification 
procedures with regard to the crude material was 6%. 
 
 
 
Figure 89. RP-HPLC analysis of crude IAPP [21-37] using gradient 2 on C18 column, flow rate 2 
ml / min and detection at 214 nm. Injection of 400 µg crude peptide in 500 µl aqueous 10% TFA 
solution. 
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Figure 90. RP-HPLC analysis of crude S20G-IAPP (in reduced form) using gradient 1 on C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 500 µg crude peptide in 1 ml 
aqueous 10% AcOH solution (the peak at 15.0 min is due to scavenger phenol from the cleavage 
mixture). 
 
 
Figure 91. RP-HPLC analysis of crude S20G-IAPP (in oxidized form) using gradient 1 on C18 
column, flow rate 2 ml / min and detection at 214 nm. Injection of 500 µg crude peptide in 500 µl 6 
M Gdn HCl in aqueous 0.1 M NH4HCO3 solution after 4 hrs oxidation (the peak at 14.7 min is due 
to scavenger phenol from the cleavage mixture). 
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Figure 92. MALDI-MS of oxidized and HPLC purified peak at 24.2 min (see Figure 91) from 
crude S20G-IAPP.  
 
 
Figure 93. RP-HPLC of pure S20G-IAPP (in oxidized form) using gradient 1 on C18 column, flow 
rate 2 ml / min and detection at 214 nm. Injection of 60 µg pure peptide in 50 µl aqueous 6 M Gdn 
HCl. 
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5.2.8 FT-IR and cytotoxicity studies of IAPP and the IAPP analogue [2] 
 
IAPP amyloid aggregates contain the peptide chains in a β-sheet conformation and have been 
found to be cytotoxic to a variety of cells [91]. To begin to investigate the effect of selective N-
methylation on the β-sheet, amyloid formation and cytotoxicity potential of IAPP FT-IR 
spectroscopy was first performed. IAPP and analogue [2] were incubated under strong 
amyloidogenic conditions (high concentration of peptide) and FT-IR spectra were recorded.  
In Figure 94 the FT-IR spectra of the two peptides are shown: the native IAPP had a broad 
absorbance maximum at 1630 cm-1, which is often assigned to β-sheet structure [92]. In contrast, in 
the spectrum of [2] the absorbance maximum was shifted at about 1660 cm-1, indicating the 
presence of significant amounts of non-β structures. The differences in β-sheet forming potential 
between the two peptides strongly indicates that the N-methylation of the two residues Gly24 and 
Ile26 inhibited the β-sheet forming potential of IAPP and may thus have affected amyloidogenicity. 
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Figure 94. Effect of N-methylation on the secondary structure / β-sheet formation potential of the 
native IAPP sequence versus the IAPP analogue [2] as assessed by FT-IR of aged solutions. IAPP 
and [2] were incubated under strong amyloidogenic conditions as follows: IAPP or [2] was 
incubated at a concentration of 2.14 mM in 10% AcOH at RT for 4 days. Following neutralization 
with 10% NH4OH peptide solutions were applied to a CaF2 plate, air-dried and the spectra were 
recorded as described [86].  
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Cytotoxic effects of IAPP versus [2] were tested on the HTB14 human glioblastoma /astrocytoma 
cell line 24 hrs following application of the peptide onto the cells. The cytotoxic potential of aged 
IAPP was then compared to the one of aged [2] by using the MTT reduction assay [93]. 
Peptide cytotoxicities were tested at concentrations of 50 and 5 nM. The results of the cytotoxicity 
assay suggested (Figure 95) that the methylated IAPP analogue [2] was not cytotoxic, whereas 
IAPP was strongly cytotoxic.  
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Figure 95. Cytotoxicity assay of IAPP and [2]. Data are percentages of control values (vehicle 
alone) and are the mean (± SD) of five determinations. Camptothecin (Cam 10 µg / ml) was used 
as a cell death inducing agent (positive control) [94]. HFIP (0.01% and 0.001%) was used as a 
control (vehicle alone) for the IAPP and analogue [2] concentrations of 50 and 5 nM, respectively 
[95]. 
 
Together, the results of the IR and cytotoxicity studies strongly suggested that N-methylation at 
Gly24 and Ile26 strongly affected the β-sheet formation potential of IAPP and inhibited its 
cytotoxicity. 
 
Discussion 128 
6 Discussion 
 
6.1 Discussion of the results of the bioactivity studies on the calcitonin analogues 
 
In this work a number of hCt analogues were designed and synthesized to study the effect of 
conformational restriction of region [17-21] on receptor binding and activation using side 
chain lactam bridge. In these studies, covalently linking the side-chains of Asp17 and Lys21 or 
Asp17 and Orn21 was found to enhance the receptor binding affinities of these peptides 
compared to native hCt up to three times for receptor sites in T47D cells. These constrained 
analogues (analog 1 and CCcyclo) bound tightly to the receptors, suggesting that the 
constraints introduced into their structures might have stabilized their solution conformations 
prior to the receptor binding step. The enhanced binding affinities of these analogues were 
accompanied by equal or slightly enhanced increases of the adenylate cyclase activity, as 
expected for a direct ligand-receptor interaction [96]. Analogues that contained shorter ring size 
(DCcyclo and FCcyclo) than analog 1 and CCcyclo showed reduced receptor binding 
affinities and also their potencies to stimulate the production of cAMP were lowered. The 19-
membered ring-containing analogues CCcyclo and GCcyclo were found thus to be the 
strongest Ct-receptor ligands, whereas the Glu17 / Dab21 lactam bridge of GCcyclo resulted in 
two-fold and three-fold reduced adenylate activation potency, compared to native hCt and 
CCcyclo, respectively. The biological importance of constraining the conformation via the 
lactam-bridge was highlighted in the case of CClinear where the complete absence of the 
bridge resulted in an extremely low ability to bind to the receptor and activate AC. 
The topological features of region [17-21] for Ct bioactivity were further explored by 
studying the importance of the chirality of residues 18 and 19 (analogues of group 2). A β-
turn conformation strongly depends on the nature and chirality of the amino acids at its corner 
positions and small changes can affect the type and stability of the turn. Inversement of 
chirality of residue Phe19 by D-Phe19 was expected to stabilize a type II β-turn conformation, 
whereas substituting Lys18 by D-Lys18 was expected to stabilize a type II’ β-turn [24]. The 
substitution Aib18 for Lys18 might retain the postulated type I β-turn [97]. The study of the non-
bridged analogues [D-Phe19]hCt (OClinear) and [D-Lys18]hCt (NClinear) provided 
information about the effect of the substituents alone on hCt bioactivity. Although all 
analogues of group 2 had similar binding affinities to hCt, their ability to induce adenylate 
cyclase activation was up to three times less than hCt. The order of AC activation potency 
was: ACcyclo>ECcyclo>BCcyclo. This indicated that inversement of chirality of residues at 
positions 18 and 19 strongly affects the bioactivity of hCt. The non-bridged analogues 
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(OClinear and NClinear ) showed lower receptor binding affinities and AC activation 
potencies than hCt. Together, it may be concluded that residues Lys18, Phe19 are important for 
the biological activity of hCt, and that the incorporation of the lactam bridge can partly 
compensate for the loss of bioactivity observed during the inversement of chirality at residues 
18 and 19. 
Next, the effect of introducing ‘Asx-turn’ inducing residues such as Pro / Ser at positions 18 
and 19 was studied (analogues of group 3). From the analogues of this group only ICcyclo 
retained some binding affinity for the receptor, whereas the other analogues showed no 
receptor binding. This finding suggested that in ICcyclo the elimination of the side chain of 
Lys18 might in small extent be tolerated, whereas in HCcyclo the elimination of the side 
chains of both Lys18 and Phe19 resulted in abolishment of receptor binding. The AC activation 
potencies were extremely low in accordance with the lack of receptor binding affinities for 
these peptides. From the results with cyclic and linear analogues it was supported that 
residues 18 and 19 are very important for bioactivity. 
The importance of a putative H-bond between the carbonyl group at position 17 (Asp17) was 
studied next using analogues with (Nα-methyl) at Phe19 (group 4) and a series of βeta peptides 
(group 5). The carbonyl group of the side chain of Asp17 was postulated to participate in a 
hydrogen bond with the NH group of the Phe19 residue [71]. Introduction of the N-methylated 
amino acid at the NH of Phe19 position was expected to disrupt the putative H-bonding. In 
fact, both analogues QCcyclo and QClinear exhibited extremely weak binding affinities and 
AC activation potencies. In the βeta peptides, the distorted backbone had the same overall 
effect: no binding to receptor and no stimulation of the adenylate cyclase system.  
Next, the functional role of the side-chain carbonyl group of Asn17 was studied (group 6). In 
the non-bridged analogues [Dap17]hCt and [Dab17]hCt, the carbonyl group was eliminated 
while the rest of the molecule retained the same sequence as hCt. Both analogues showed 
weak binding affinities and AC activation potencies compared to native hCt, with the former 
analogue ([Dap17]hCt) being more active than the latter ([Dab17]hCt). Thus, the deletion of the 
carbonyl group of the side chain of Asn17 resulted in reduced biological properties. It is 
interesting to note that the longer side chain of Dab17 has a strong negative effect on 
bioactivity. This suggests that bioactivity may also be related to the exact position (topology) 
of the NH2 group of the side chain of Asn17. 
The role of the proposed amphiphilic α-helical region [8-22] of Ct and its amino acid 
composition was evaluated in the peptides TCcyclo and TClinear (group 7). In these 
analogues the aromatic residues Tyr12 and Phe16,19 of the hydrophobic face of the potential 
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helix of hCt, were substituted by Leu12,16,19 that are present in the sCt sequence [38]. In 
addition, Phe22 was replaced by Tyr [98]. In all analogues, the incorporation of the lactam 
bridge resulted in increased receptor binding affinities and enhanced potencies in AC 
activation. Surprisingly, analogue TCcyclo exhibited a somewhat reduced binding affinity as 
compared to sCt and CCcyclo. However, its ability to activate AC was similar to sCt. The 
unbribged TClinear, bound to the receptor as strong as hCt and had a four times reduced AC 
activation potency as compared to hCt.  
The results of the bicyclic analogues confirmed and strongly supported the working 
hypothesis suggested by Kapurniotu et al. [22] that a type I β turn/antiparallel β sheet centered 
around residues 18 and 19 play a crucial role in hCt bioactivity. Moreover, the importance of 
the side chain carbonyl at Asp17 was significant as it was suggested for stabilizing the 
potential β turn/β sheet by hydrogen bonding to the NH group of Phe19. The importance of β 
turn conformations has often been attributed to the resulting surface exposure and clustering 
of side chains, which might be important pharmacophores and/or to the nucleation of folding 
into bioactive conformation [99]. However, the stabilization of the β turn/β sheet conformation 
alone may not be the only factor for hCt bioactivity, which depends on additional factors such 
as overall conformational flexibility, and the topology of the side chains of certain residues in 
the [17-21] region. 
Overall the results suggested that the receptor binding affinity and the agonist potency of hCt 
may have determinants that are different from those of sCt. For sCt, it has been suggested that 
the binding of the central amphiphilic α-helical segment to the extracellular N-terminal 
receptor domain may be the major determinant of affinity to the hCt receptor [100]. Binding of 
an α-helical state may be less important for hCt since the underlying sequence shows a lesser 
propensity for helix formation [101]. Instead, the affinity of hCt for receptors may be 
determined by additional interactions involving the peptide sequences that was constrained by 
the bridge and/or the C-terminal segment that may be correctly oriented by the bridge for 
optimal receptor interaction.  
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6.2 Discussion of the syntheses and studies of the IAPP analogues 
 
The SPPS of IAPP belongs to the difficult syntheses. This is due to the fact that IAPP is an 
amyloid forming peptide and has the potential of β-sheet formation and aggregation during 
synthesis [102]. In fact, the synthesis of IAPP proved to be a very difficult one. The HPLC 
profile indicated many by-products, the chromatographic purification was extensive and the 
final yield with regard to pure peptide was not satisfactory. 
Since S20G-IAPP was reported to be more aggregation prone than IAPP its synthesis was 
expected to be more difficult than the IAPP one. Therefore an optimised protocol was applied: 
a) by utilization of HATU for the second coupling of residues Gly24, Ala25, Ile26, Asn 21, 
Arg11, Gln10, and Thr9 that were expected, based on the experience with IAPP, to be difficult 
to reach completeness and b) acetylation was performed after all (double) couplings in region 
between residues 26 and 2. In fact, the results showed that this synthetic protocol worked 
much better than the IAPP one. However, difficult couplings in the IAPP region [8-10] as 
well as with the Cys residues were still encountered. 
The incorporation of (N-Me) residues into the β-sheet core IAPP region [20-29] was expected 
to cause even more synthetic difficulties The reason for this are sequence-related 
(hydrophobic amino acids in region [20-29]) and the steric hindrance caused by the (N-Me) 
residues [103]. N-methylation has been reported to allow formation of left-handed α-helical 
structures, to promote cis-trans isomerization of the peptide bond, to disrupt hydrogen 
bonding of the amide nitrogen, and to increase the hydrophobicity of the peptide [104]. On the 
other hand, the incorporation of (N-Me) moieties in crucial for β-sheet formation amide bonds 
was expected to suppress synthetic problems related to internal β-sheet formation and 
aggregation.  
Peptide bond formation is generally not difficult when only the acid component of the 
coupling pair is N-methylated, and these reactions proceed well under standard coupling 
conditions, although one must be aware of the potential for racemization and diketopiperazine 
formation [105]. On the other hand, serious problems with coupling rates arise when the amine 
component or when both the amine and the acid components are N-methylated [106]. Low 
coupling rates in these cases can lead to extended reaction times, undesired side reactions, 
racemization or incomplete couplings that give rise to deletion sequences [107]. 
In the synthesis of [(N-Me) Phe23, (N-Me) Ala25] IAPP [19-37] (part of analogue [1]), (N-Me) 
Ala25 as well as Gly24 were coupled without any difficulties. The second N-methylated 
residue (N-Me) Phe23 was also coupled without significant difficulty, whereas the coupling of 
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Asn22 to (N-Me) Phe23 could not reach completion (60 to 70% completion according to HPLC 
analysis). To avoid formation of deletion sequences the peptide resin was acetylated after the 
couplings of AA 24 to 21. Cleavage and RP-HPLC analysis of [(N-Me) Phe23, (N-Me) Ala25] 
IAPP [19-37] resin showed two main products: the intended peptide [(N-Me) Phe23, (N-Me) 
Ala25] IAPP [19-37] and the deletion sequence [(N-Me) Ala25] IAPP [24-37]. Detailed HPLC 
and mass spectroscopic analysis of the synthesis products between residues 25-22 suggested 
that the truncated peptide formed due to peptide bond cleavage between (N-Me) Phe23 and 
Gly24 in the acetylated truncated peptide sequence Ac-[(N-Me) Phe23 , (N-Me) Ala25] IAPP 
[23-37]. This latter peptide sequence corresponded to about 35% of the total product and 
formed due to the incomplete coupling of Asn22 to (N-Me) Phe23 and the subsequent capping 
of the non-reacted amino groups of (N-Me) Phe23 with Ac2O. This finding was in accordance 
to previous findings that suggested that the presence of a N-methylated residue makes the 
amide bond C-terminal to this residue susceptible to TFA-mediated hydrolysis [15]. In this 
latter work, resin-bound Ac-(N-Me) PheSerLeuGly has been found to get readily hydrolysed 
during treatment of the peptide resin with TFA yielding the two products Ac-(N-Me) Phe and 
Ser-Leu-Gly (yield of hydrolysis: 76%).  
During the synthesis of [(N-Me) Gly24, (N-Me) Ile26] IAPP [19-37] (part of analogue [2]) the 
coupling of (N-Me) Ile26 to Leu27 could not reach completion (70 to 80% completion). In 
addition, the coupling of Ala25 to (N-Me) Ile26 was even more difficult and, although it was 
repeated five-times, it could not reach completion (60 to 70% completion). Acetylations were 
thus performed after the couplings of the above residues to avoid formation of deletion 
sequences. The second N-methyl residue (N-Me) Gly24, however, was coupled without any 
difficulties and this was the case for the remaining residues until residue 19. Overall, the 
peptide resin was acetylated after the couplings of (N-Me) Ile26, Ala25, (N-Me) Gly24 and 
Phe23. It was concluded that the major difficulties of the synthesis of [(N-Me) Gly24, (N-Me) 
Ile26] IAPP [19-37] were due to the couplings of residues (N-Me) Ile26 and Ala25. The yield in 
main product [(N-Me) Gly24, (N-Me) Ile26] IAPP [19-37] was 50 to 55% with regard to the 
total functional groups of the resin. The truncated acetylated sequences represented 40 to45% 
of the total product and it was observed that the acetylated sequence Ac-[(N-Me) Ile26 IAPP 
[26-37] was also hydrolysed to a small extent during TFA treatment yielding the dipeptide 
Ac-(N-Me) Ile26-Leu27-OH and IAPP [28-37].  
In the synthesis of [(N-Me) Ala25, (N-Me) Leu27] IAPP [19-37] (part of analogue [3], the (N-
Me) Leu27 coupled efficiently. In contrast, the coupling of Ile26 was difficult and could not 
reach completion (30 to 40% completion). This low coupling efficiency of Ile26 to (N-Me) 
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Leu27 could also be partly attributed to the relative “high loading” of the resin (0.5 mmole / 
gr) used for this synthesis as compared to the “low loading” resins (0.2-0.3 mmole / gr) used 
for the syntheses of the other N-methylated analogues in which the coupling efficiency was 
normally double (60 to 70% completion). The coupling of (N-Me) Ala25 and Gly24 proceded 
without difficulty. The peptide resin was acetylated after the couplings of (N-Me) Leu27, Ile26, 
(N-Me) Ala25 and Gly24. However, cleavage and RP-HPLC analysis of the [(N-Me) Ala25, (N-
Me) Leu27] IAPP [24-37] resin showed two main products were formed: the intended peptide 
[(N-Me) Ala25, (N-Me) Leu27] IAPP [24-37] and the deletion sequence IAPP [28-37]. The 
finding that IAPP [28-37] was not acetylated, although the coupling of (N-Me) Leu27 on [28-
37] resin was followed by acetylation of free amine groups on the resin, indicated that IAPP 
[28-37] might have formed during TFA cleavage of the peptide from the resin. To investigate 
that issue the following study was done: Fmoc-(N-Me) Leu27 was coupled to [28-37] resin 
and the resin was then subjected to Fmoc cleavage conditions. The H2N-[27-37] resin was 
then acetylated with Ac2O. The cleavage of the Ac-(N-Me) Leu27 IAPP [27-37] resin with 
TFA / H2O that was performed thereafter yielded only the peptide [28-37] and not Ac-(N-Me) 
Leu27 IAPP [27-37]. This result clearly demonstrated that the amide bond between Ac-(N-Me) 
Leu27 and Ser28 in Ac-[(N-Me) Leu27] IAPP [27-37] resin is susceptible to cleavage by TFA / 
H2O (95/5) and suggested that this was the side reaction that was observed during the 
synthesis.  
Further in the synthesis of [3], the coupling of Phe23 to Gly24 could not reach completion (70 
to 80% completion) although the Kaiser test was negative. The resin was not acetylated. The 
couplings of the following residues Asn22, Asn21, Ser20 and Ser19 did not cause any 
difficulties. Cleavage and RP-HPLC analysis of [(N-Me) Ala25, (N-Me) Leu27] IAPP [19-37] 
resin showed three main products: the intended peptide [(N-Me) Ala25, (N-Me) Leu27] IAPP 
[19-37] and the deletion sequences IAPP [28-37] (formed as mentioned above) and [(N-Me) 
Ala25, (N-Me) Leu27] IAPP [24-37] that formed due to incomplete coupling of Phe23 to Gly24. 
The yield of the main product [(N-Me) Ala25, (N-Me) Leu27] IAPP [19-37] was 25 to 30% 
with regard to the total functional groups of the resin, whereas the truncated sequences IAPP 
[28-37] and [(N-Me) Ala25, (N-Me) Leu27] IAPP [24-37] represented 60-65 and 10%, 
respectively, of the total functional groups of the resin. 
In the 1st synthesis of [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-37] (part of analogue [4]), (N-
Me) Leu27 coupled efficiently. The coupling of (N-Me) Ile26 to (N-Me) Leu27 could not reach 
completion (60 to 70% completion). The peptide resin was, therefore, acetylated after the 
coupling of (N-Me) Ile26. Coupling of Ala25 was also very difficult. Cleavage and RP-HPLC 
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analysis of [(N-Me) Ile26, (N-Me) Leu27] IAPP [25-37] resin showed three products: the 
intended peptide [(N-Me) Ile26, (N-Me) Leu27] IAPP [25-37], the peptide [(N-Me) Ile26, (N-
Me) Leu27] IAPP [26-37] that formed due to the incomplete coupling of Ala25 to (N-Me) Ile26 
(50 to 60% completion) and the deletion sequence IAPP [28-37] that formed by the peptide 
bond cleavage between Ac-(N-Me) Leu27 and Ser28. The peptide resin was acetylated after the 
coupling of Ala25. Coupling of residues Gly24, Phe23, Asn22, Asn21, Ser20 and Ser19 proceded 
without difficulties. Cleavage and RP-HPLC analysis of [(N-Me) Ile26, (N-Me) Leu27] IAPP 
(19-37) resin showed three products: the intended peptide [(N-Me) Ile26, (N-Me) Leu27] IAPP 
[19-37], and the truncated sequences IAPP [28-37] and [(N-Me) Leu27] IAPP [27-37] formed 
by peptide bond cleavage of Ac-(N-Me) Leu27 and Ser28 and Ac-(N-Me) Ile26 and (N-Me) 
Leu27, respectively. The yield of the intended product [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-
37] was 40% with regard to the total functional groups of the resin, whereas the truncated 
sequences represented the remaining 60%.  
The synthesis of [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-37] was repeated. Following 
coupling of (N-Me) Leu27 the coupling (N-Me) Ile26 was performed several times using longer 
reaction times and increased temperatures. In this way the coupling of (N-Me) Ile26 to (N-Me) 
Leu27 was almost complete (80 to 90% completion). The peptide resin was acetylated after 
this coupling. The coupling of Ala25 to (N-Me) Ile26 was very difficult. Cleavage and RP-
HPLC analysis of [(N-Me) Ile26, (N-Me) Leu27] IAPP [25-37] resin (before acetylation of 
non-reacted groups of (N-Me) Ile26) showed four products: the intended peptide [(N-Me) Ile26, 
(N-Me) Leu27] IAPP [25-37], the peptide [(N-Me) Ile26, (N-Me) Leu27] IAPP [26-37] that 
formed due to the incomplete coupling of Ala  to (N-Me) Ile , and the deletion sequences 
IAPP [28-37] and [(N-Me) Leu ] IAPP [27-37]. The latter two deletion sequences could have 
formed via a partial cleavage from the resin of the dipeptide (N-Me) Ile - (N-Me) Leu  
(possible formation of a diketopiperazine) and via break up of the peptide bond between (N-
Me) Ile  and (N-Me) Leu . The peptide resin was acetylated after the coupling of Ala . 
Coupling of residues Gly , Phe , Asn , Asn , Ser  and Ser  proceded without difficulties. 
Similarly to the results obtained by the 1  synthesis, cleavage and RP-HPLC analysis of [(N-
Me) Ile , (N-Me) Leu ] IAPP [19-37] resin showed three products: the intended peptide [(N-
Me) Ile , (N-Me) Leu ] IAPP [19-37], and the deletion sequences IAPP [28-37] and (N-Me) 
Leu ] IAPP [27-37]. These results suggested that the incomplete coupling of Ala  to (N-Me) 
Ile  and the presence of consequtive N-methylated residues caused the observed side 
reactions. Moreover, the presence of the two consecutive N-methyl residues resulted in 
incomplete couplings and break up of peptide bonds C-terminal to the N-methylated residues. 
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The yield in the intended product [(N-Me) Ile26, (N-Me) Leu27] IAPP [19-37] was 30% with 
regard to the total functional groups of the resin, whereas the truncated sequences represented 
the remaining 70%. 
In the synthesis of [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [25-37], (analogue [5]) 
(N-Me) Leu27 coupled efficiently. The coupling of the (N-Me) Ile26, however, was as 
expected a difficult one and could not reach completion (60 to 70% completion). Accordingly, 
the peptide resin Fmoc-[(N-Me) Ile , (N-Me) Leu26 27] IAPP [26-37] was acetylated after this 
coupling. Coupling of the following N-methyl residue (N-Me) Ala25 was even more difficult. 
Cleavage and RP-HPLC analysis of [(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [25-
37] resin showed, as expected, three products: the intended peptide [(N-Me) Ala25, (N-Me) 
Ile26, (N-Me) Leu27] IAPP [25-37], and the deletion sequences [(N-Me) Ile26, (N-Me) Leu27] 
IAPP [26-37], that formed due to incomplete coupling of (N-Me) Ala25 to (N-Me) Ile26 and 
IAPP [28-37] that formed by peptide bond cleavage between and Ac-(N-Me) Leu27 and Ser28. 
Two synthetic attempts were undertaken and both gave the main product only in very low 
yield (20-30% with regard to the total functional groups of the resin). Therefore, this synthesis 
was not continued any further. 
Taken together, the results of the syntheses indicated that the peptide bond breaking observed 
during the TFA / H2O mediated cleavage was primarily affected by the nature of the N-
methylated residue and secondly by the exact position of the N-methyl residue in the 
sequence. (N-Me) Leu27 exhibited the greatest destabilizing effect on the peptide backbone. 
Although the coupling of this residue to Ser28 was complete in all cases, the presence of (N-
Me) Leu27 resulted in poor couplings for the next two residues Ile26 and/or (N-Me) Ile26 and 
Ala25 or (N-Me) Ala25. Acetylations performed in this region resulted in end capping of 
incomplete couplings but at the same time they rendered the peptide bond between the N-
methylated and the following C-terminal residue acid labile leading thus to enhanced 
susceptibility towards acid hydrolysis. The same was true for (N-Me) Ile26 as well as for (N-
Me) Phe23 whereas Ac-(N-Me) Ala25 or Ac-(N-Me) Gly24 did not cause any destabilization of 
the peptide bond C-terminal to them. In the latter cases, the smaller alkyl side-chain of Ala or 
the complete absence of side-chain in Gly as compared to the larger alkyl side-chains of Leu 
or Ile or the aromatic ring of Phe could account for the absence of any destabilizing effect on 
peptide bonds. These findings were in accordance with the findings of Urban et. al.[15] that the 
steric interactions of the alkyl side chains (larger versus smaller) and the inductive effect of 
the methyl group might be related to the stabilization of the proposed oxazolone intermediate 
of the peptide bond cleavage reaction, accounting thus for the differences in peptide bond 
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labilities between peptides containing (N-Me) Gly (this and Urban’s work), (N-Me) Ala (this 
and Urban’s work), (N-Me) Phe (this and Urban’s work), (N-Me) Leu (this work), and (N-
Me) Ile (this work). Thus, the nature of the residue on the N-terminal side of the N-
methylated peptide strongly affects peptide bond lability.  
In the N-methylated analogues [1]-[4], residues 1 to 18 did not cause any difficulties with the 
exception of residues in the IAPP region [7-10]. Difficulties with the coupling of these latter 
residues were also encountered during the synthesis of the native IAPP sequence. The main 
products of the synthesis of the N-methylated analogues were obtained in a quite good purity 
degree, which facilitated the oxidation and purification procedures. The overall yield for the 
pure N-methylated peptide in oxidized form was thus between 5 to 10% with regard to the 
initial substitution level of the resin.  
N-methyl amino acids are present in several naturally occurring peptides exhibiting important 
biological properties, such as cyclosporines or dolastatins. It has been also established that the 
metabolic stability of biologically active peptides can be altered or enhanced by the 
introduction of N-methylated amino acid residues, which has become an important 
modification in peptide chemistry [108]. The difficulties with the couplings involving N-methyl 
amino acids have been addressed by several groups, and a number of specialized reagents and 
methods are now available to facilitate the coupling of N-methyl amino acids. As mentioned 
above, cyclosporine, an immunosuppressive cycloundecapeptide with seven N-methyl 
residues, is a formidable synthetic challenge and different groups have reported different 
methods of achieving this. In 1995, the first synthesis of a cyclosporin derivative by solid-
phase methods, as compared to standard solution synthesis of the peptide, was reported [109]. 
The linear undecapeptide precursor was synthesized under SPPS conditions by use of the 
azabenzotriazole-based coupling reagents HATU and HOAt, which were effective for the 
coupling of the sterically hindered, N-methylated amino acids. It was shown that the synthesis 
of the peptide utilizing HOAt/DIC resulted in higher couplings yields compared to HATU-
mediated couplings. In the year 2000, the synthesis of cyclosporin O (both in solution and 
solid-phase) using novel thiazolium-, immonium- and pyridinium-type coupling reagents was 
reported [110]. In this study, the peptide was successfully synthesized in 20-23% overall yield 
using the novel coupling reagents 2-bromo-3-ethyl-4-methyl thiazolium tetrafluoroborate 
(BEMT) and 2-bromo-1-ethyl pyridinium tetrafluoroborate (BEP) which were used for the 
fast coupling of the N-methylated amino acids with low epimerization and excellent coupling 
yields. Recently, the use of triphosgene as highly efficient reagent for the solid-phase 
synthesis of peptides containing N-alkylated amino acids has been reported [11, 111]. In one of 
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these reports the total SPPS of cyclosporin O was described. Synthesis was achieved in high 
purity and an overall yield of 15% utilizing trisphosgene as the activating agent for the 
coupling of the N-methylated amino acids. In addition, a comparative evaluation study of four 
different coupling methods showed that the better coupling yields were obtained with 
triphosgene (bis[trichloromethyl] carbonate, BTC), as compared to HOAt/DIC, or 
symmetrical anhydride method using DCC or tetramethylfluorformamidinium 
hexafluorophosphate (TFFH) method. The study concluded that in contrast to the liquid-phase 
synthesis of the cyclosporin analogue with all the intermediate purification steps, the approach 
on solid-phase synthesis utilizing the inexpensive activating reagent BTC was time- and cost- 
efficient for obtaining the peptide analogue in good yields and purity. 
Finally, the findings that contrary to IAPP the N-methylated IAPP analogue [2] has reduced 
β-sheet forming potential and no cytotoxic properties suggested that N-methylation of 
selective residues in the amyloid core of IAPP (FGAIL) is, in principle, a suitable strategy to 
reduced or completely inhibit the amyloidogenic and cytotoxic potential of IAPP. N-
methylation of protein contact sides is a well-known approach to inhibit protein self-
association and has been also shown to inhibit Aβ(25-35) amyloid formation [112]. Kapurniotu 
et al. [93] have also shown that the short N-methylated IAPP sequences F(N-Me)GA(N-Me)IL, 
NF(N-Me)GA(N-Me)IL, SNNF(N-Me)GA(N-Me)IL, and SNNF(N-Me)GA(N-Me)ILSS 
were, contrary to their precursor sequences, highly soluble, unable to aggregate into β-sheet 
and amyloid fibrils and devoid of cytotoxicity. Together with these reports the results 
presented in this thesis on the IAPP analogue [2] also suggest that the rational N-methylation 
strategy [93] may be applicable to various amyloidogenic sequences as a general strategy to 
convert amyloidogenic and cytotoxic peptide sequences in non-amyloidogenic and non-
cytotoxic ones with potential diagnostic or therapeutic applications.  
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7 Zusammenfassung 
 
Konformationell eingeschränkte Analoga von nativ-vorkommenden bioaktiven Polypeptiden 
sind wichtige Werkzeuge, welche der Aufklärung von Strukturaktivitäts-Beziehungen dienen 
und beim Design und der Entwicklung von Leitstrukturen mit therapeutischen und 
diagnostischen Anwendungen Einsatz finden können. 
In der hier vorgelegten Doktorarbeit wurden Konformationsrestriktionen auf zwei Polypeptide 
aus der Calcitonin-Gen-Peptid-Familie, das Calcium- und Knochenstoffwechsel-regulierende 
Hormon Calcitonin (Ct) und das Kohlenhydratmetabolismus-regulierende Hormon Islet 
Amyloid Polypeptid (IAPP) angwendet. Diese zwei, aus 32 bzw. 37 Aminosäure bestehenden, 
Polypeptide haben eine gemeinsame genetische Herkunft und weisen zum Teil eine 
Primärstrukturhomologie sowie überlappende Bioaktivitäten und Rezeptorkreuzreaktivitäten 
auf. 
Das Peptidhormon Ct wird seit mehreren Jahren therapeutisch zur Behandlung von 
Osteoporose eingesetzt. Die niedrige Bioaktivität der beim Menschen vorkommenden Ct-
Sequenz (hCt) führte jedoch dazu, dass hCt eine nur geringe medizinische Anwendung 
gefunden hat. Aufgrund seiner hohen Bioaktivität wird heutzutage hauptsächlich 
synthetisches Calcitonin aus Lachs (sCt) therapeutisch eingesetzt. Vor kurzem wurde gezeigt, 
dass die Einführung von i, i+4-Seitenkette-zu-Seitenkette-Lactamverbrückungen zwischen 
den Resten 17 und 21 von hCt zu Analoga mit stark erhöhter hypocalcämischer Aktivität in 
vivo führen kann (Kapurniotu et al., Eur. J. Biochem. (1999)). Diese Arbeiten haben zur 
Entdeckung des hCt-Analogs cyclo17,21-[Asp17, Orn21]hCt geführt, welches bis dato das 
potenteste bekannte hCt-Analog im Bezug auf die hypocalcämische Aktivität im Tiermodell 
in vivo ist. Es wurde darüber hinaus vorgeschlagen, dass die Bioaktivität vo hCt mit dem 
Vorhandensein bzw. der Stabilisierung eines β-Faltblatt-/β-Haarnadelschleifen-enthaltenden 
konformeren Zustands zwischen den Resten 17 und 21 zusammenhängen könnte. 
Das Ziel des ersten Teils der hier vorgelegten Arbeit war es, eine detaillierte Auskunft über 
die Wirkung von Konformationsrestriktionen in der Region 17-21 von hCt auf die 
Rezeptorbindungsaffinität und die Aktivierung der Adenylatcyclase (AC) zu bekommen und 
dadurch möglicherweise strukturelle Eigenschaften identifizieren zu können, welche mit der 
Bioaktivität in Zusammenhang stehen könnten. Die spezifischen Fragestellungen, welchen 
nachgegangen wurde sind: 
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- der Effekt der Ringgröße der Lactambrücke und der verschiedenen Arten an β-
Haarnadelschleifen-stabilisierenden Resten an den Positionen 18 und 19 auf 
Rezeptorbindungsaffinität und Adenylatcyclaseaktivierung, 
- die Rolle einer potentiellen „Asx- Haarnadelschleifen“-Konformation in der Region 17-
21, 
- die H-Brückenbindungsfähigkeit der Aminogruppe von Phe19 und der Seitenkette von 
Aminosäurerest 17 bei der Rezeptorbindungsaffinität und Adenylatcyclaseaktivierung, 
- und letzlich der Effekt der Einführung bestimmter hydrophober Aminosäurereste aus der 
α-helikalen Region der sCt-Sequenz in die entsprechende Region des potenten hCt-
Analogs cyclo17,21-[Asp17, Orn21]hCt auf die Bioaktivität. 
Im Hinblick auf diese Ziele wurden fünfundzwanzig hCt-Analoga designt, welche eine 
cyclische Konformationsrestriktion und/oder verschiedene Substituenten für Aminosäurereste 
in der Region 17 bis 20 enthalten, die aufgrund der Literatur für die Bioaktivität potenziell für 
wichtig gehalten werden konnten. Die Analoga wurden in guten Ausbeuten und guter 
Reinheit durch Festphasenpeptidsynthese (SPPS) mittels der Boc- und/oder der Fmoc-
Strategie in Kombination mit speziellen Seitenkettenschutzstrategien für die Seitenkette-zu-
Seitenketten-Cyclisierung am Harz hergestellt. Nach RP-HPLC-Reinigung und 
Charakterisierung mittels Massenspektometrie wurden die Ct-Rezeptorbindungsaffinitäten 
und Adenylatcyclaseaktivierungspotenziale der Analoga an der Brustcarcinom-Zelllinie T47D 
untersucht. 
Die Untersuchungen mit den „Ringgröße“-Analoga zeigten, dass die 19-gliedrigen Analoga 
cyclo17,21-[Asp17, Orn21]hCt und cyclo17,21-[Glu17, Dab21]hCt zusammen mit dem 20-
gliedrigen Analog cyclo17,21-[Asp17, Lys21]hCt die höchsten Rezeptorbindungsaffinitäten 
verglichen zu den anderen Analoga aufweisen. Der Adenylatcyclaseaktivierungs-Assay 
zeigte, dass cyclo17,21-[Asp17, Orn21]hCt der stärkste hCt-Agonist ist, während cyclo17,21-
[Asp17, Lys21]hCt ein zu hCt Ähnliches AC-Aktivierungspotenzial aufweist und cyclo17,21-
[Glu17, Dab21]hCt ein schwächeres AC-Aktivierungspotenzial als hCt zeigt. Die 
Rezeptorbindungsaffinitäten und AC-Aktivierungspotenziale waren jedoch signifikant 
reduziert beim 18-gliedrigen cyclo17,21-[Asp17, Dab21]hCt und sehr schwach beim 17-
gliedrigen Analog cyclo17,21-[Asp17, Dap21]hCt. Interessanterweise wies [Asp17, Orn21]hCt 
keine Rezeptorbindungsaffinität und ein nur sehr schwaches AC-Aktivierungspotenzial auf. 
Dies deutete darauf hin, dass die durch die Asp17- zu Orn21-Verbrückung induzierte 
Konformationsrestriktion in cyclo17,21-[Asp17, Orn21]hCt mit seiner erhöhten 
Rezeptorbindungsaffinität und dem verstärkten AC-Aktivierungspotenzial zusammenhängt. 
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Die Untersuchungen mit verschiedenen Substitutionsanaloga von cyclo17,21-[Asp17, Lys21]hCt 
und den entsprechenden linearen Kontrollpeptiden zeigten, dass das Umkehren der Chiralität 
der Aminosäurereste in den Positionen 18 und 19 oder das Ersetzen von Lys18 durch einen 
Typ I-β-Haarnadelschleifen-stabilisierenden Rest (Aib) mit den Anforderungen an das 
cyclische Analog bzgl. seiner Rezeptorbindung kompatibel ist, während diese Substitutionen 
zu einer Reduktion des AC-Aktivierungspotenzials führten. In der hCt-Sequenz führten diese 
Substitutionen zu einer starken Abnahme von Rezeptorbindingsaffinität und AC-
Aktivierungspotenzial. 
Darüber hinaus zeigten die Untersuchungen mit verschiedenen Substitutionsanaloga von 
cyclo17,21-[Asp17, Orn21]hCt, bei welchen die Reste 18 und 19 durch die "Asx-turn"-
induzierenden Reste Pro und Ser ersetzt wurden, dass Lys18 und Phe19 sehr wichtig für die 
Rezeptorbindung und die AC-Aktivierung sind. Es stellte sich nämlich heraus, dass die 
obigen Substitutionen zu Analoga mit stark reduzierter Rezeptorbindung und stark 
reduziertem AC-Aktivierungspotenzial führen. 
Die Untersuchungen mit den N-methylierten Phe19-Analoga von cyclo17,21-[Asp17, Orn21]hCt 
deuten darauf hin, dass ein intaktes H-Brückenbildungspotenzial dieser Aminosäure für 
Rezeptorbindung und AC-Aktivierung sehr wichtig ist. Darüber hinaus, haben die 
Untersuchungen mit den beta-Analoga von cyclo17,21-[Asp17, Orn21]hCt gezeigt, dass die 
Integrität des Peptidrückgrades zwischen den Resten 17 und 21 für die Rezeptorbindung und 
die AC-Aktivierung notwendig ist. Die Ergebnisse der Untersuchungen mit den hCt-Analoga, 
welche Dab oder Dap an der Stelle von Asn17 hatten, weisen darauf hin, dass die Carbonyl- 
und auch die Aminofunktion der Asn-Seitenkette mit der Rezeptorbindung und der AC-
Aktivierung stark zusammenhängen. Letzlich weisen die Untersuchungen zum Effekt der 
Einführung von hydrophoben Resten aus der helikalen Region von sCt in cyclo17,21-[Asp17, 
Orn21]hCt oder [Asp17, Orn21]hCt darauf hin, dass die Anwesenheit von Nle8, Leu12,16,19 und 
Tyr22 zu einer starken Erhöhung des AC-Aktivierungspotenzials führt. Diese Substituenten 
allein führten auch zu einer starken Zunahme der Rezeptorbindungsaffinität von [Asp17, 
Orn21]hCt und hatten keinen Einfluss auf die Affinität von cyclo17,21-[Asp17, Orn21]hCt.  
Zusammenfassend haben die Ergebnisse der Untersuchungen mit allen hCt-Analoga gezeigt, 
dass die Region 17 bis 21 von hCt eine sehr wichtige Rolle für die biologische Aktivität 
dieses Hormons spielt, und dass kleine strukturelle Veränderungen in dieser Region die 
Rezeptorbindungsaffinität und das AC-Aktivierungspotenzial stark beeinflussen können. Dies 
deutet darauf hin, dass rational eingeführte strukturelle Veränderungen in der Region 17 bis 
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21 von hCt möglicherweise zu hochpotenten und somit therapeutisch interessanten hCt-
Agonisten führen könnten. 
Das zweite Mitglied der Calcitonin-Gen-Peptid-Familie, das Hormon IAPP, spielt eine 
wichtige Rolle bei der Pathogenese des Typ II Diabetes mellitus. Dies wird hauptsächlich auf 
Befunde zurückgeführt, wonach in den Bauchspeicheldrüsen von mehr als 95% der Typ II 
Diabetes-Patienten Amyloidaggregate bestehend aus IAPP gebildet werden, und dass solche 
Aggregate zelltoxische Eigenschaften aufweisen. Die Aufklärung des molekularen 
Mechanismus, der der β-Faltblattbildung von IAPP und den damit assoziierten 
Amyloidbildungs- und Zelltoxizitätspotenzialen dieses Moleküls zugrundeliegt, ist die 
Grundvoraussetzung für das Verständnis der molekularen Grundlagen dieser Krankheit und 
die Entwicklung von therapeutischen Strategien. Es wurde kürzlich vorgeschlagen, dass die 
Strategie der Konformationsrestriktion von kurzen β-Faltblatt-bildenden, amyloidogenen und 
zytotoxischen Peptidsequenzen mittels der strukturbasierten Einführung von N-Methylresten 
in bestimmte ausgewählte Amidbindungen eine geeignete Strategie für das Aufklären von 
Struktur-Amyloidogenese-Zytotoxizitäs-Beziehungen solcher Sequenzen und für die 
Umwandlung von amyloidogenen Peptidsequenzen in nicht-amyloidogene und nicht-
zytotoxische Sequenzen ist. 
Der zweite Teil dieser Doktorarbeit beschreibt detailliert die Festphasenpeptidsynthesen der 
(humanen) IAPP-Peptidsequenz, welche aufgrund der amyloidogenen Moleküleigenschaften 
mehr als komplex sind. Auch die hoch-amyloidogene IAPP-Mutante S20G-IAPP, für die 
pathophysiologische Relevanz vermutet wird, sowie fünf, mittels N-Methylierung von 
Amidbindungen, konformationell-eingeschränkte IAPP-Analoga wurden in dieser Arbeit 
synthetisiert und dargestellt. Darüber hinaus umfasst dieser Teil der Arbeit die Ergebnisse 
erster Untersuchungen an einem der N-methylierten Analog zum Effekt der N-Methylierung 
auf das β-Faltblattbildungspotenzial und die Zelltoxizität von IAPP. 
Die SPPS von IAPP, S20G-IAPP, und der N-methylierten IAPP-Analoga stellte sich als eine 
sehr schwierige Aufgabe heraus. Dies war auf die Anwesenheit verschiedenener sterisch 
gehinderter und zur Aggregation neigender Aminosäurereste in der IAPP-Sequenz sowie auch 
auf Synthese-inhärente Probleme, welche mit der sterischen Hinderung von Kupplungen und 
der Labilität von Peptidbindungen in N-methylierten Sequenzen zusammenhängen, 
zurückzuführen. Da die SPPS von IAPP das Produkt in niedriger Ausbeute lieferte, wurde für 
die Synthese der Mutante S20G-IAPP ein entsprechend optimiertes synthetisches Protokoll 
verwendet. Letzteres führte in guter Ausbeute zu einem –nach RP-HPLC-Reinugung- reinen 
S20G-IAPP. Während der Synthese der N-methylierten Analoga [(N-Me) Phe23, (N-Me) 
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Ala25] IAPP [1], [(N-Me) Gly24, (N-Me) Ile26] IAPP [2], [(N-Me)Ala25, (N-Me) Leu27] IAPP 
[3] und [(N-Me) Ile26, (N-Me) Leu27] IAPP [4] erwiesen sich jedoch verschiedene 
Kupplungen, bei welchen N-Methyl-Reste involviert waren, als unvollständig. Die nicht-
gekoppelten Aminofunktionen der N-Methyl-Reste wurden daher anschließend mittels 
Acetylierung gecapped. Es stellte sich jedoch heraus, dass die Acetylierungen einiger N-
methylierten Reste zu einer Anzahl an TFA-vermittelten Amidbindungsspaltungen geführt 
hatten. Die beobachteten Amidbindungsspaltungen lagen dabei zwischen Ac-(N-Me) Ile und 
Leu oder (N-Me) Leu, zwischen Ac-(N-Me) Phe und Gly und zwischen Ac-(N-Me) Leu und 
Ser. Die Nebenprodukte der obigen Synthesen wurden komplett charakterisiert und die 
auftretenden Nebenreaktionen somit komplett aufgeklärt. Die Untersuchungen zeigten auch, 
dass die obigen Peptidbindungen eine TFA-Labilität (unter den Bedingungen der TFA-
mediierten Abspaltung des Peptids vom Anker) aufweisen, und zwar nur, wenn die N-
methylierten Reste in acetylierter Form vorliegen. Somit fand diese Nebenreaktion bei den 
acetylierten Rumpfsequenzen bei der finalen TFA-Abspaltungsstufe am Ende der Synthese 
statt, wobei sich die gewünschten Volllängen-Peptiddsequenzen per se unter den 
Bedingungen der Fmoc-Synthesestrategie als stabil erwiesen. Die Synthese des fünften IAPP 
Analogs ([(N-Me) Ala25, (N-Me) Ile26, (N-Me) Leu27] IAPP [5]), welches drei 
aufeinanderfolgende, N-methylierte Reste enthalten sollte, wurde aufgrund der niedrigen 
Kupplungsausbeute von (N-Me) Ala25 on (N-Me) Ile26 nur bis zu diesem Schritt durchgeführt. 
Aus den Ergebnissen der Synthesen der IAPP-Analoga [1] – [4] lässt sich zusammenfassend 
schließen, dass die Ausbeuten der Synthesen aufgrund der unvollständigen Kupplungen 
niedrig waren, wobei insgesamt weniger Nebenprodukte im Vergleich zur IAPP-Synthese 
auftraten. Letzteres führte zu höheren Ausbeuten der RP-HPLC-Reinigungsprozesse der N-
methylieren Analoga verglichen mit IAPP. 
Letztlich wurde [(N-Me) Gly24, (N-Me) Ile26] IAPP [2] als Analogon ausgewählt, um die 
Wirkung der strukturbasierten N-Methylierung von Amidbindungen auf die β-Faltblatt- und 
Zytotoxizitätspotenziale von IAPP zu untersuchen. Diese Untersuchungen zeigten deutlich, 
dass die zwei N-Methyl-Reste an Gly24 und Ile26 zu einer starken Reduktion des β-
Faltblattbildungspotenzials und zur kompletten Inhibition der Zytotoxizität von IAPP im in 
vitro-Modell der pankreatischen Zelllinie RIN5fm geführt hatten. Diese Ergebnisse wiesen 
darauf hin, dass es einen direkten Zusammenhang der Konformationsrestriktion, welche durch 
die strukturbasierten N-Methylierung von Amidbindungen erzielt wurde, mit dem 
Amyloidbildungspotenzial und der Zytotoxizität von IAPP gibt. 
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Zusammenfassend haben die Ergebnisse dieser Arbeit gezeigt, dass die Restriktion der 
konformationellen Flexibilität von bioaktiven Polypeptiden mittlerer Länge wichtige 
Auskunft über ihre Struktur-Aktivitäts-Beziehungen liefern kann und zum Design von 
potenten Agonisten (wie hCt-Analoga) oder zu Abkömmlingen der nativ vorkommenden 
Polypeptidsequenz mit komplett veränderten biophysikalischen Eigenschaften (wie IAPP-
Analoga) führen kann. Auch lässt sich aus den erzielten Ergebnissen ableiten, dass diese 
Strategie auch auf weitere Polypeptide, wie z.B. weitere amyloidogene Polypeptide oder 
Polypeptide größerer Länge übertragbar sein sollte. Diese Arbeit hat auch gezeigt, dass die 
SPPS von N-methylierten und zur Aggregation neigenden Polypeptidsequenzen noch immer 
ein anspruchsvolles Ziel für den Synthetiker ist, wobei in der vorgelegten Doktorarbeit 
wichtige Ansätze zur Optimierung solcher Synthesen erarbeitet wurden. 
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